var title_f16_8_16512="TB Ghon complex";
var content_f16_8_16512=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F67954&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F67954&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Classic Ghon complex in a child infected with",
"    <em>",
"     Mycobacterium tuberculosis",
"    </em>",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 281px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This radiograph shows a classic Ghon complex in a child infected with Mycobacterium tuberculosis about 6 months previously, based on results of a contact investigation. There is a calcifed parenchymal lesion and calcification of the regional hilar lymph node. Although a Ghon complex contains live organisms, the number is small (as seen in infection rather than disease), so management with isoniazid alone as for latent infection is sufficient.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jeffrey R Starke, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_8_16512=[""].join("\n");
var outline_f16_8_16512=null;
var title_f16_8_16513="Calculator: Creatinine clearance (measured)";
var content_f16_8_16513=[" <div id=\"topicText\">",
"  <div id=\"mc3k\">",
"   <form action=\"\" id=\"CreatinineCl_form\" name=\"CreatinineCl_form\" onkeydown=\"clrResults();\" onkeyup=\"CreatinineCl_fx();\" onsubmit=\"return false;\">",
"    <table cellpadding=\"4\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"100%\">",
"     <tr>",
"      <td bgcolor=\"#eeeeee\" width=\"1%\">",
"       <br/>",
"      </td>",
"      <td align=\"left\" bgcolor=\"#eeeeee\">",
"       <span class=\"medCalcFontTitleBox\">",
"        Calculator: Creatinine clearance (measured)",
"       </span>",
"      </td>",
"     </tr>",
"    </table>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <center>",
"     <div id=\"calc_equation\">",
"      <table cellpadding=\"10\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"       <tr>",
"        <td align=\"left\" bgcolor=\"#6c9a9c\">",
"         <span class=\"medCalcFontFormuli\">",
"          CreatClear = UrineCreat * DaysUrineVolume / SerumCreat / 1440",
"         </span>",
"        </td>",
"       </tr>",
"      </table>",
"      <br/>",
"      &nbsp;",
"      <br/>",
"     </div>",
"    </center>",
"    <div id=\"calc_main\">",
"     <center>",
"      <table cellpadding=\"6\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"95%\">",
"       <tr>",
"        <td align=\"right\" width=\"50%\">",
"         <center>",
"          <span class=\"medCalcFontIO\">",
"           Input:",
"          </span>",
"          <br/>",
"          &nbsp;",
"          <br/>",
"          <table cellpadding=\"3\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"           <tr>",
"            <td align=\"right\" width=\"42%\">",
"             <span class=\"medCalcFontOneBold\">",
"              Urine Creat",
"             </span>",
"            </td>",
"            <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"             &nbsp;",
"             <input name=\"Urine_Creat_param\" onblur=\"CreatinineCl_fx(); minMaxCheck();\" onchange=\"CreatinineCl_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"            </td>",
"            <td align=\"left\" valign=\"top\" width=\"115\">",
"             <select class=\"medCalcFontSelect\" name=\"Urine_Creat_unit\" onchange=\"CreatinineCl_fx();\" style=\"width:105px;\">",
"              <option value=\"0.0113122171945701|0|mcmol/L_Cr\">",
"               mcmol/L",
"              </option>",
"              <option value=\"1|0|mg%_Cr\">",
"               mg%",
"              </option>",
"              <option selected=\"selected\" value=\"1|0|mg/dL_Cr\">",
"               mg/dL",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"right\" width=\"42%\">",
"             <span class=\"medCalcFontOneBold\">",
"              Serum Creat",
"             </span>",
"            </td>",
"            <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"             &nbsp;",
"             <input name=\"Serum_Creat_param\" onblur=\"CreatinineCl_fx(); minMaxCheck();\" onchange=\"CreatinineCl_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"            </td>",
"            <td align=\"left\" valign=\"top\" width=\"115\">",
"             <select class=\"medCalcFontSelect\" name=\"Serum_Creat_unit\" onchange=\"CreatinineCl_fx();\" style=\"width:105px;\">",
"              <option value=\"0.0113122171945701|0|mcmol/L_Cr\">",
"               mcmol/L",
"              </option>",
"              <option value=\"1|0|mg%_Cr\">",
"               mg%",
"              </option>",
"              <option selected=\"selected\" value=\"1|0|mg/dL_Cr\">",
"               mg/dL",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"right\" width=\"42%\">",
"             <span class=\"medCalcFontOneBold\">",
"              Days Urine Volume",
"             </span>",
"            </td>",
"            <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"             &nbsp;",
"             <input name=\"Days_Urine_Volume_param\" onblur=\"CreatinineCl_fx(); minMaxCheck();\" onchange=\"CreatinineCl_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"            </td>",
"            <td align=\"left\" valign=\"top\" width=\"115\">",
"             <select class=\"medCalcFontSelect\" name=\"Days_Urine_Volume_unit\" onchange=\"CreatinineCl_fx();\" style=\"width:105px;\">",
"              <option value=\"1000|0|L\">",
"               L",
"              </option>",
"              <option value=\"1e-12|0|fL\">",
"               fL",
"              </option>",
"              <option selected=\"selected\" value=\"1|0|mL\">",
"               mL",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"          </table>",
"         </center>",
"        </td>",
"        <td align=\"left\" bgcolor=\"#eeeeee\">",
"         <center>",
"          <span class=\"medCalcFontIO\">",
"           Result:",
"          </span>",
"          <br/>",
"          &nbsp;",
"          <br/>",
"          <table bgcolor=\"#eeeeee\" cellspacing=\"4\" summary=\"MedCalc 3000 Table\">",
"           <tr>",
"            <td align=\"right\">",
"             <span class=\"medCalcFontOneBold\">",
"              Creat Clear",
"             </span>",
"            </td>",
"            <td nowrap=\"nowrap\" valign=\"top\">",
"             &nbsp;",
"             <input name=\"Creat_Clear_param\" onfocus=\"blur();\" size=\"6\" type=\"text\"/>",
"            </td>",
"            <td valign=\"top\">",
"             <span class=\"medCalcFontOne\">",
"              <select class=\"medCalcFontSelect\" name=\"Creat_Clear_unit\" onchange=\"CreatinineCl_fx();\" style=\"width:105px;\">",
"               <option value=\"1000|0|L/min\">",
"                L/min",
"               </option>",
"               <option value=\"60000|0|L/sec\">",
"                L/sec",
"               </option>",
"               <option value=\"0.01666666667|0|mL/hr\">",
"                mL/hr",
"               </option>",
"               <option selected=\"selected\" value=\"1|0|mL/min\">",
"                mL/min",
"               </option>",
"               <option value=\"60|0|mL/sec\">",
"                mL/sec",
"               </option>",
"              </select>",
"             </span>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td colspan=\"3\">",
"             &nbsp;",
"             <br/>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"center\" colspan=\"3\">",
"             <span class=\"medCalcFontOneBold\">",
"              Decimal Precision:",
"             </span>",
"             <select class=\"medCalcFontSelect\" name=\"decpts\" onchange=\"CreatinineCl_fx();\">",
"              <option>",
"               0",
"              </option>",
"              <option>",
"               1",
"              </option>",
"              <option selected=\"selected\">",
"               2",
"              </option>",
"              <option>",
"               3",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"          </table>",
"         </center>",
"         <br/>",
"         &nbsp;",
"         <br/>",
"         <center>",
"          <span class=\"medCalcFontOne\">",
"           <input name=\"reset\" type=\"reset\" value=\"Reset form\"/>",
"          </span>",
"         </center>",
"        </td>",
"       </tr>",
"      </table>",
"     </center>",
"    </div>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_hints\">",
"     <span class=\"medCalcFontOne\">",
"      To calculate the creatinine clearance from a 24-hour urine collection, enter your patient's",
"data into the appropriate data fields. The serum creatinine concentration must be stable for",
"this formula to be valid. (See UpToDate topic reviews that discuss calculation of the creatinine clearance, for a review of the factors that limit the accuracy of this test).",
"     </span>",
"    </div>",
"   </form>",
"  </div>",
" </div>",
" <div id=\"topicAgreement\">",
"  Use of UpToDate is subject to the",
"  <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"   Subscription and License Agreement",
"  </a>",
"  .",
" </div>",
" <div id=\"printDisclaimer\">",
"  Information on this page may not appear correctly if printed.",
" </div>",
" <div id=\"disclaimerCalculator\">",
"  <div class=\"medCalcFontTwo\">",
"   <p class=\"header\">",
"    Legal Notices and Disclaimer",
"   </p>",
"   <p>",
"    All information contained in and produced by the MedCalc 3000 system is provided",
"			for educational purposes only. This information should not be used for the diagnosis or treatment",
"			of any health problem or disease.",
"    <b>",
"     THIS INFORMATION IS NOT INTENDED TO REPLACE CLINICAL JUDGMENT OR",
"			GUIDE INDIVIDUAL PATIENT CARE IN ANY MANNER.",
"    </b>",
"    <a class=\"medCalcDisclaimerLink\" href=\"./med-calc-disclaimer\">",
"     Click here for",
"				full notice and disclaimer.",
"    </a>",
"   </p>",
"   <p class=\"copy\">",
"    MedCalc 3000 is Copyright &copy; 1998-2013 Foundation Internet Services",
"   </p>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_8_16513=[" ",
"",
"",
"function log(i){",
"return Math.log(i) * Math.LOG10E;   ",
"}",
"",
"function ln(i){",
"return Math.log(i);",
"}",
"",
"function sq(i){",
"return i * i;",
"}",
"",
"function sqr(i){",
"return Math.sqrt(i);",
"}",
"",
"",
"function power(x,y){",
"return Math.pow(x,y);",
"}",
"",
"function eTo(x){",
"return Math.exp(x);",
"}",
"",
"",
"function fixDP(r, dps) {",
"if (isNaN(r)) return \"NaN\";",
"var msign = '';",
"if (r < 0) msign = '-';",
"x = Math.abs(r);",
"if (x > Math.pow(10, 21)) return msign + x.toString();",
"var m = Math.round(x * Math.pow(10, dps)).toString();",
"if (dps == 0) return msign + m;",
"while (m.length <= dps) m = \"0\" + m;",
"return msign + m.substring(0, m.length - dps) + \".\" + m.substring(m.length - dps);",
"}",
"",
"var currenttimeout;",
"",
"",
"var calctxt = ''; ",
"var xmltxt = ''; ",
"var htmtxt = ''; ",
"",
"",
"",
"function CreatinineCl_fx() {",
"",
"currenttimeout = self.setTimeout('minMaxCheck();', 3000);",
"",
"with(document.CreatinineCl_form){",
"",
"",
"doCalc = true;",
"if (Urine_Creat_param.value.indexOf(',') >= 0){ Urine_Creat_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Urine_Creat_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Urine_Creat_unit.options[Urine_Creat_unit.selectedIndex].value.split('|');",
"Urine_Creat = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"if (Serum_Creat_param.value.indexOf(',') >= 0){ Serum_Creat_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Serum_Creat_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Serum_Creat_unit.options[Serum_Creat_unit.selectedIndex].value.split('|');",
"Serum_Creat = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"if (Days_Urine_Volume_param.value.indexOf(',') >= 0){ Days_Urine_Volume_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Days_Urine_Volume_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Days_Urine_Volume_unit.options[Days_Urine_Volume_unit.selectedIndex].value.split('|');",
"Days_Urine_Volume = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"dp = decpts.options[decpts.selectedIndex].text;",
"Creat_Clear =  Urine_Creat * Days_Urine_Volume / Serum_Creat / 1440;",
"",
"unit_parts = Creat_Clear_unit.options[Creat_Clear_unit.selectedIndex].value.split('|');",
"if (doCalc) Creat_Clear_param.value = fixDP((Creat_Clear - parseFloat(unit_parts[1])) / parseFloat(unit_parts[0]), dp);",
"",
"",
"",
"",
"",
"}",
"",
"}",
"",
"function minMaxCheck(){",
"",
"if (currenttimeout) self.clearTimeout(currenttimeout);",
"",
"with(document.CreatinineCl_form){",
"",
"",
"",
"}",
"",
"}",
"",
"",
"function clrResults(){",
"",
"if (currenttimeout) self.clearTimeout(currenttimeout);",
"",
"with(document.CreatinineCl_form){",
"",
"Creat_Clear_param.value = '';",
"",
"",
"}",
"",
"}",
"",
"",
"",
"",
"",
"",
"",
"",
"",
"",
"",
""].join("\n");
var outline_f16_8_16513=null;
var title_f16_8_16514="Thrombopen drug metabolite";
var content_f16_8_16514=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F65492&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F65492&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Antibody-mediated drug-induced thrombocytopenia. The patient's antibody reacted with normal platelets in the presence of acetaminophen glucuronide, but not with acetaminophen or acetaminophen sulfate",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 428px; height: 458px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Washed platelets (5 x 106) were combined with patient serum in the presence or absence of 0.4 mM acetaminophen or the metabolite indicated in a final volume of 50 microL. After incubation for 1 hour, the platelets were washed in the presence or absence of the indicated drug or metabolite (0.2 mM). Bound human IgG was detected by the addition of FITC goat (Fab')2 anti-human IgG (H+L) (1:200; Jackson Immunoresearch, West Grove, PA). No reaction occurred with normal serum under same conditions. Abscissa indicates mean platelet fluorescence intensity in arbitrary units.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Bougie, DW, Benito, AI, Sanchez-Abarca, LI, et al. Acute thrombocytopenia caused by sensitivity to the glucuronide conjugate of acetaminophen. Blood 2007; 109:3608. Copyright &copy;2007 The American Society of Hematology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_8_16514=[""].join("\n");
var outline_f16_8_16514=null;
var title_f16_8_16515="Laparoscopic cystectomy b";
var content_f16_8_16515=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F73354&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F73354&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 495px\">",
"   <div class=\"ttl\">",
"    Laparoscopic ovarian cystectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 475px; height: 345px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The cyst wall is grasped and blunt dissection used to separate the cyst wall from the ovarian cortex.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of William J Mann, Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_8_16515=[""].join("\n");
var outline_f16_8_16515=null;
var title_f16_8_16516="Epidemiology and genetics of Prader-Willi syndrome";
var content_f16_8_16516=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epidemiology and genetics of Prader-Willi syndrome",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/8/16516/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/8/16516/contributors\">",
"     Ann O Scheimann, MD, MBA",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/8/16516/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/8/16516/contributors\">",
"     William J Klish, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/8/16516/contributors\">",
"     John L Kirkland, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/8/16516/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/8/16516/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?16/8/16516/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 25, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prader-Willi syndrome (PWS) is the most common syndromic form of obesity, and is caused by absence of expression of the paternally active genes in a discrete region on the long arm of chromosome 15, either due to deletions from the paternal chromosome or maternal disomy. The vast majority of cases occur sporadically. In adults and children, the primary clinical features are hyperphagia, usually leading to early-onset obesity, hypogonadism, developmental delay, and characteristic facial features. In infants the most prominent findings are hypotonia and feeding difficulties.",
"   </p>",
"   <p>",
"    The epidemiology and genetics of PWS will be reviewed here. The clinical features, diagnosis, and approaches to treatment of this disorder are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/8/134?source=see_link\">",
"     \"Clinical features, diagnosis, and treatment of Prader-Willi syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 1887, Langdon-Down described the first girl with probable PWS during adolescence manifest by mental impairment, short stature, hypogonadism, and obesity, and he termed the condition polysarcia [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16516/abstract/1\">",
"     1",
"    </a>",
"    ]. Seventy years later, Prader and colleagues reported a series of patients with similar phenotypes [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16516/abstract/2\">",
"     2",
"    </a>",
"    ]. In 1981, Ledbetter et al, identified microdeletions within chromosome 15 as the site for PWS [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16516/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prader-Willi-Labhart Syndrome (PWS) is the most common syndromic form of obesity and affects between 350,000 and 400,000 individuals worldwide. Both sexes are affected equally [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16516/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although prevalence estimates differ among studies, this is likely due to using different methods for case identification, and there is no strong evidence for increased risk in specific countries or gene pools. Within the United States, the rate of prevalence has been reported between 1 in 16,062 [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16516/abstract/5\">",
"     5",
"    </a>",
"    ] to 1 in 25,000 [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16516/abstract/6\">",
"     6",
"    </a>",
"    ]. Outside of the US, reported prevalence rates for PWS range from 1 per 8000 in rural Sweden [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16516/abstract/7\">",
"     7",
"    </a>",
"    ] to 1 per 16,000 in Western Japan [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16516/abstract/8\">",
"     8",
"    </a>",
"    ], and a birth incidence of 1 per 27,000 in Flanders [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16516/abstract/9\">",
"     9",
"    </a>",
"    ]. Within the UK, a lower population prevalence of 1 in 52,000 was estimated, with a proposed true prevalence of 1 in 45,000 [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16516/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     GENETICS AND PATHOGENESIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Genetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prader-Willi syndrome is the first genetic disorder attributed to genomic imprinting, meaning that the expression of the gene depends on the gender of the parent donating the gene. Prader-Willi syndrome arises due to the loss of the paternal copy of 15q11.2-13; loss of the maternal copy of 15q11.2-13 results in Angelman syndrome. The majority of cases of PWS arise sporadically. Monozygotic twins are concordantly affected. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/38/21097?source=see_link\">",
"     \"Basic principles of genetic disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/38/21097?source=see_link&amp;anchor=H1497302#H1497302\">",
"     \"Basic principles of genetic disease\", section on 'Imprinting'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/44/11978?source=see_link&amp;anchor=H8964746#H8964746\">",
"     \"Microdeletion syndromes (chromosomes 12 to 22)\", section on '15q11-13 paternal deletion syndrome (Prader-Willi syndrome)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Approximately 70 percent of cases of PWS arise from deletion of 15q11.2-13, and 28 percent of cases arise from maternal uniparental disomy. Fewer than 1 percent of patients have mutations isolated to the imprinting center. Determining the type of mutation has implications for recurrence risk. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Risk of recurrence in future pregnancies'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    There appears to be some association between the type of genetic defect and the phenotypic features seen in an individual with PWS. Individuals with uniparental disomy generally have less distinct physical features, higher IQs, and milder behavioral problems than individuals with PWS caused by deletions. However, patients with uniparental disomy are also more likely to exhibit autistic-like behaviors and psychosis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16516/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Maternal uniparental disomy of chromosome 14 or microdeletions of the 14q32.2 imprinted region has been associated with a Prader-Willi syndrome-like phenotype, especially during infancy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16516/abstract/12,13\">",
"     12,13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Risk of recurrence in future pregnancies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of PWS in siblings of an affected child depends on the type of molecular defect causing PWS in that individual. Thus, genetic testing is important not only to establish the diagnosis of PWS, but to determine the risk of recurrence in future pregnancies.",
"   </p>",
"   <p>",
"    The recurrence risk is less than one percent if the affected child has a deletion or maternal disomy. The recurrence risk for siblings is up to 50 percent if the affected child has a mutation of the imprinting control center, and up to 25 percent if a parental chromosomal translocation is present (",
"    <a class=\"graphic graphic_table graphicRef61992 \" href=\"UTD.htm?32/16/33035\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16516/abstract/11,14\">",
"     11,14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/8/134?source=see_link&amp;anchor=H10#H10\">",
"     \"Clinical features, diagnosis, and treatment of Prader-Willi syndrome\", section on 'Genetic testing'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Molecular pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several genes have been mapped to the 15q11.2-13 region. Genetic analysis of many different individuals with PWS progressively narrowed the candidate region, and it now appears that the major manifestations of PWS are caused by paternal deficiency for HBII-85 \"small nucleolar RNA\" (snoRNA) cluster [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16516/abstract/15\">",
"     15",
"    </a>",
"    ]. SnoRNAs are non-coding molecules that guide post-transcriptional modification of ribosomal RNA and other small nuclear RNAs. The modifications include methylation, which is the mechanism for sex-specific imprinting. The precise mechanisms through which HBII-85 deletions cause the clinical features of PWS have not been established.",
"   </p>",
"   <p>",
"    HBII-85 and several other snoRNA clusters are located just downstream of the SNURF-SNRPN, NDN (necdin), MAGEL2, and MKRN3 genes, explaining the apparent association of PWS with these candidate genes in previous studies [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16516/abstract/11,14\">",
"     11,14",
"    </a>",
"    ]. These genes, or others in the PWS region may account for some associated features but are unlikely to be primary causes (eg, the P gene encodes for tyrosinase-positive albinism and is likely responsible for the hypopigmentation observed in 30 percent of individuals with PWS).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     MOLECULAR GENETIC TESTING",
"    </span>",
"   </p>",
"   <p>",
"    Molecular testing for PWS is highly sensitive, as standard panels with a methylation analysis will detect over 99 percent of PWS cases [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16516/abstract/11\">",
"     11",
"    </a>",
"    ]. For probands with a strong clinical suspicion of PWS, the testing is done in a sequence that allows identification of all potential genetic defects. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/8/134?source=see_link&amp;anchor=H9#H9\">",
"     \"Clinical features, diagnosis, and treatment of Prader-Willi syndrome\", section on 'Indications for genetic testing'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Diagnostic panel",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A methylation analysis detects abnormal parent-specific methylation imprinting within the PWS critical region on 15q11.2-13. This can be done by the Southern method using a methylation-sensitive probe (SNRPN or PW71B) or by polymerase chain reaction (PCR) using parent-specific primers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Mutation identification",
"    </span>",
"    &nbsp;&mdash;&nbsp;If abnormal methylation is detected, further studies are performed to determine the type of mutation:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Deletion &mdash; (70 percent of PWS cases). Deletions of the PWS-critical region are detected by fluorescence in-situ hybridization (FISH) using the probe SNRPN, or by quantitative PCR. If FISH is positive, then other family members should be evaluated to exclude the possibility of a translocation.",
"     </li>",
"     <li>",
"      Uniparental disomy &mdash; (25 percent of PWS cases). Analysis of microsatellite markers detects uniparental disomy and is conducted on the parents and affected child.",
"     </li>",
"     <li>",
"      Mutation center mutation &mdash; (&lt;1 percent of PWS cases). If microsatellite markers detect no uniparental disomy, then a mutation or deletion in the imprinting center is suspected. Further sequencing diagnostic studies may be required to determine the risk of recurrence in future pregnancies. The majority of imprinting defects are \"epimutations\", in which the imprint, but not the underlying DNA sequence, is abnormal [",
"      <a class=\"abstract\" href=\"UTD.htm?16/8/16516/abstract/11,16\">",
"       11,16",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prader-Willi syndrome is caused by the absence of expression of the paternally active genes in the \"Prader-Willi syndrome-critical\" region of Chromosome 15q11.2-13. This dependence of the phenotype on the gender of the parent of origin is known as \"genomic imprinting\". (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Genetics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The prevalence of Prader-Willi syndrome is approximately 1 in 25,000 live births, and both sexes are affected equally. The vast majority of cases are sporadic rather than familial. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Seventy percent of cases of PWS are caused by deletions within the PWS-critical chromosome region, and 25 to 28 percent are caused by uniparental disomy (in which the paternal copy of the gene is replaced by a second maternal copy). The remaining PWS cases are caused by defects in the imprinting process or chromosomal translocations. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Genetics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The risk of PWS occurring in a sibling of an affected individual is very low unless an imprinting defect is present (imprinting defects represent less than one percent of PWS cases). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Risk of recurrence in future pregnancies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of PWS is made by genetic testing of individuals that exhibit typical clinical features. Genetic testing is highly sensitive and detects PWS in over 99 percent of cases. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Molecular genetic testing'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/8/134?source=see_link\">",
"       \"Clinical features, diagnosis, and treatment of Prader-Willi syndrome\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Down, JL. In: Mental Affections of Childhood and Youth. Churchill Publisher, London 1887:172.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16516/abstract/2\">",
"      Prader, A, Labhart, A, Willi, H. Ein Syndrom von Adipositas, Kleinwuchs, Kryptorchismus, und Oligophrenie Nach Myatonieartigem Zustard in Neugeborenenalter. Schweiz Med Wschr 1956; 86:1260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16516/abstract/3\">",
"      Ledbetter DH, Riccardi VM, Airhart SD, et al. Deletions of chromosome 15 as a cause of the Prader-Willi syndrome. N Engl J Med 1981; 304:325.",
"     </a>",
"    </li>",
"    <li>",
"     Butler, MG, Hanchett, JM, Thompson, T. Clinical Findings and Natural History of Prader-willi Syndrome. In: Management of Prader-willi Syndrome, Butler, MG, Lee, PDK, Whitman, BY (Eds), Springer, New York 2006.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16516/abstract/5\">",
"      Burd L, Vesely B, Martsolf J, Kerbeshian J. Prevalence study of Prader-Willi syndrome in North Dakota. Am J Med Genet 1990; 37:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16516/abstract/6\">",
"      Butler MG. Prader-Willi syndrome: current understanding of cause and diagnosis. Am J Med Genet 1990; 35:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16516/abstract/7\">",
"      Akefeldt A, Gillberg C, Larsson C. Prader-Willi syndrome in a Swedish rural county: epidemiological aspects. Dev Med Child Neurol 1991; 33:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16516/abstract/8\">",
"      Ehara H, Ohno K, Takeshita K. Frequency of the Prader-Willi syndrome in the San-in district, Japan. Brain Dev 1995; 17:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16516/abstract/9\">",
"      Vogels A, Van Den Ende J, Keymolen K, et al. Minimum prevalence, birth incidence and cause of death for Prader-Willi syndrome in Flanders. Eur J Hum Genet 2004; 12:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16516/abstract/10\">",
"      Whittington JE, Holland AJ, Webb T, et al. Population prevalence and estimated birth incidence and mortality rate for people with Prader-Willi syndrome in one UK Health Region. J Med Genet 2001; 38:792.",
"     </a>",
"    </li>",
"    <li>",
"     Cassidy, SB, Schwartz, S. Prader-Willi syndrome. GeneReviews. Available at: www.genetests.org. (Accessed on August 23, 2006).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16516/abstract/12\">",
"      Hosoki K, Kagami M, Tanaka T, et al. Maternal uniparental disomy 14 syndrome demonstrates prader-willi syndrome-like phenotype. J Pediatr 2009; 155:900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16516/abstract/13\">",
"      Mitter D, Buiting K, von Eggeling F, et al. Is there a higher incidence of maternal uniparental disomy 14 [upd(14)mat]? Detection of 10 new patients by methylation-specific PCR. Am J Med Genet A 2006; 140:2039.",
"     </a>",
"    </li>",
"    <li>",
"     Buiting, K, Horsthemke, B. Molecular Genetic Findings in Prader-willi Syndrome in Management of Prader-willi Syndrome, Butler MG, Lee PDK, Whitman BY (Eds), Springer, New York 2006. p.63.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16516/abstract/15\">",
"      Sahoo T, del Gaudio D, German JR, et al. Prader-Willi phenotype caused by paternal deficiency for the HBII-85 C/D box small nucleolar RNA cluster. Nat Genet 2008; 40:719.",
"     </a>",
"    </li>",
"    <li>",
"     Monaghan, KG, Van Dyke, DL. Laboratory Testing for Prader-willi Syndrome. In: Management of Prader-willi Syndrome, Butler, MG, Lee, PDK, Whitman, BY (Eds), Springer, New York 2006. p.79.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5875 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-197.136.42.3-93F80B87AB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_8_16516=[""].join("\n");
var outline_f16_8_16516=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      HISTORY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      GENETICS AND PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Genetics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Risk of recurrence in future pregnancies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Molecular pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      MOLECULAR GENETIC TESTING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Diagnostic panel",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Mutation identification",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5875\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5875|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/16/33035\" title=\"table 1\">",
"      Genetic test panel for PWS",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/38/21097?source=related_link\">",
"      Basic principles of genetic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/8/134?source=related_link\">",
"      Clinical features, diagnosis, and treatment of Prader-Willi syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/44/11978?source=related_link\">",
"      Microdeletion syndromes (chromosomes 12 to 22)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_8_16517="Pralidoxime: Drug information";
var content_f16_8_16517=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Pralidoxime: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?22/31/23027?source=see_link\">",
"    see \"Pralidoxime: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/15/12532?source=see_link\">",
"    see \"Pralidoxime: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F212244\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Protopam&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F212264\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antidote",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F212248\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Use in conjunction with atropine; atropine effects should be established before pralidoxime is administered.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Anticholinesterase poisoning (eg, neostigmine, pyridostigmine):",
"     </b>",
"     I.V.: 1000-2000 mg; followed by increments of 250 mg every 5 minutes as needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Organophosphate poisoning:",
"     </b>",
"     <b>",
"      Note:",
"     </b>",
"     May be given I.M. or SubQ if I.V. administration is not feasible:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: Loading dose: 1000-2000 mg; Maintenance: Repeat bolus of 1000-2000 mg after 1 hour and repeated every 10-12 hours thereafter, as needed. Alternatively, administer a loading dose of 30 mg/kg followed by a maintenance infusion of 8 mg/kg/hour (unlabeled dose; Roberts, 2007).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Mild symptoms:",
"     </i>",
"     600 mg; repeat as needed for persistent mild symptoms every 15 minutes to a maximum total dose of 1800 mg; may administer doses in rapid succession if severe symptoms develop",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Severe symptoms:",
"     </i>",
"     600 mg; repeat twice in rapid succession to deliver a total dose of 1800 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Persistent symptoms:",
"     </i>",
"     May repeat the entire series (1800 mg) beginning ~1 hour after administration of the last injection",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F212258\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/15/12532?source=see_link\">",
"      see \"Pralidoxime: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Organophosphate poisoning:",
"     </b>",
"     <b>",
"      Note:",
"     </b>",
"     Use in conjunction with atropine; atropine effects should be established before pralidoxime is administered.  May be given I.M. or SubQ if I.V. administration is not feasible:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &le;16 years: Loading dose: 20-50 mg/kg (maximum: 2000 mg/dose); Maintenance infusion: 10-20 mg/kg/hour; alternatively, a repeat bolus of 20-50 mg/kg (maximum: 2000 mg/dose) may be administered after 1 hour and repeated every 10-12 hours thereafter, as needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &gt;16 years: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.M.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &lt;40 kg:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Mild symptoms:",
"     </i>",
"     15 mg/kg; repeat as needed for persistent mild symptoms every 15 minutes to a maximum total dose of 45 mg/kg; may administer doses in rapid succession if severe symptoms develop",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Severe symptoms:",
"     </i>",
"     15 mg/kg; repeat twice in rapid succession to deliver a total dose of 45 mg/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Persistent symptoms:",
"     </i>",
"     May repeat the entire series (45 mg/kg) beginning ~1 hour after administration of the last injection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &ge;40 kg: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F212249\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing. Dosing should be cautious, considering possibility of decreased hepatic, renal, or cardiac function.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F212250\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dose should be reduced; no specific recommendations are provided by the manufacturer.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F212224\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution, as chloride:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Protopam&reg;: 1 g",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as chloride: 300 mg/mL (2 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F212210\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F212228\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Loading dose: Infuse as a 10-20 mg/mL solution over 15-30 minutes. Alternatively, if this is not practical or if pulmonary edema is present and/or fluid restriction is necessary, may administer as a 50 mg/mL solution over &ge;5 minutes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Maintenance dose: Administer as a continuous or intermittent infusion at a rate not to exceed 200 mg/minute.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.M., SubQ: May administer I.M. or SubQ if I.V. administration is not feasible.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F212227\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of muscle weakness and/or respiratory depression secondary to poisoning due to organophosphate anticholinesterase pesticides and chemicals (eg, nerve agents); control of overdose of anticholinesterase medications used to treat myasthenia gravis (ambenonium, neostigmine, pyridostigmine)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F212271\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Pralidoxime may be confused with pramoxine, pyridoxine",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Protopam&reg; may be confused with protamine",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F212262\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Cardiac arrest, hypertension, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness, drowsiness, headache, seizure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Nausea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: ALT increased (transient), AST increased (transient)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Pain at injection (I.M. administration)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: CPK increased, fasciculations, muscle rigidity, paralysis, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Accommodation impaired, blurred vision, diplopia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Renal function decreased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Apnea, hyperventilation, laryngospasm",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F212231\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no absolute contraindications listed within the manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F212214\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Carbamate poisoning: Pralidoxime is not indicated for the treatment of carbamate poisoning; acetylcholinesterase is weakly, but not permanently, affected by carbamates.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myasthenia gravis: Use with caution in patients with myasthenia gravis; administration may precipitate a myasthenic crisis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Nonanticholinesterase poisoning: Pralidoxime is not indicated for the treatment of poisoning due to phosphorus, inorganic phosphates, or organophosphates without anticholinesterase activity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; dosage modification required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Clinical symptoms that are consistent with suspected organophosphate poisoning should be treated with antidote immediately; administration should not be delayed for confirmatory laboratory tests. Treatment should include proper evacuation and decontamination procedures as indicated; medical personnel should protect themselves from inadvertent contamination. Antidote administration is intended only for initial management; definitive and more intensive medical care is required following administration. Individuals should not rely solely on antidote for treatment; the concomitant use of atropine will be necessary and other supportive measures (eg, artificial respiration) may still be required.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299930\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F212218\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F212220\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13459587\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted. A case report did not show evidence of adverse events after pralidoxime administration during the second trimester (Kamha, 2005).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F212253\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323722\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Device",
"     </b>",
"     (Pralidoxime Chloride Intramuscular)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     600 mg/2 mL (2 mL): $32.62",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Protopam Chloride Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 g (1): $104.04",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F212222\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Heart rate, respiratory rate, muscle fasciculations and strength, pulse oximetry; cardiac monitor and blood pressure monitor required for I.V. administration",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038776\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Aldopam (IN);",
"     </li>",
"     <li>",
"      Contrathion (AR, BR, FR, GR, IT, TR);",
"     </li>",
"     <li>",
"      PAM (NZ);",
"     </li>",
"     <li>",
"      Pam-A (SG);",
"     </li>",
"     <li>",
"      Pamcl (TW);",
"     </li>",
"     <li>",
"      Pampara (MY, TW);",
"     </li>",
"     <li>",
"      Pamu (KP);",
"     </li>",
"     <li>",
"      Pralidoxime Iodide (AU)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F212213\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reactivates cholinesterase that had been inactivated by phosphorylation due to exposure to organophosphate pesticides and cholinesterase inhibiting nerve agents (eg, terrorism and chemical warfare agents such as sarin) by displacing the enzyme from its receptor sites; removes the phosphoryl group from the active site of the inactivated enzyme",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F212230\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      dss",
"     </sub>",
"     : 0.6-2.7 L/kg; may increase with increasing severity of organophosphate intoxication (~9 L/kg in a severely poisoned pediatric patients; Schexnayder, 1998)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: None",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Apparent: 74-77 minutes; Poisoned patients (I.M., I.V.): 3-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: I.V.: 5-15 minutes; I.M.: ~35 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (~80% as metabolites and unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Agency for Toxic Substances and Disease Registry (ATSDR), &ldquo;Medical Management Guidelines for Nerve Agents: Tabun (GA); Sarin (GB); Soman (GD); and VX,&rdquo; August, 2008. Available at",
"      <a href=\"file://www.atsdr.cdc.gov/mhmi/mmg166.pdf\" target=\"_blank\">",
"       file://www.atsdr.cdc.gov/mhmi/mmg166.pdf",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      de Kort WL, Kiestra SH, and Sangster B, &ldquo;The Use of Atropine and Oximes in Organophosphate Poisoning: A Modified Approach,&rdquo;",
"      <i>",
"       J Toxicol Clin Toxicol",
"      </i>",
"      , 1988, 26(3-4):199-208.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/8/16517/abstract-text/3418775/pubmed\" id=\"3418775\" target=\"_blank\">",
"        3418775",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ekins BR and Geller RJ, &ldquo;Methomyl-Induced Carbamate Poisoning Treated With Pralidoxime Chloride,&rdquo;",
"      <i>",
"       West J Med",
"      </i>",
"      , 1994, 161(1):68-70.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/8/16517/abstract-text/7941519/pubmed\" id=\"7941519\" target=\"_blank\">",
"        7941519",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Farrar HC, Wells TG, and Kearns GL, &ldquo;Use of Continuous Infusion of Pralidoxime for Treatment of Organophosphate Poisoning in Children,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1990, 116(4):658-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/8/16517/abstract-text/2319410/pubmed\" id=\"2319410\" target=\"_blank\">",
"        2319410",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jovanovic D, &ldquo;Pharmacokinetics of Pralidoxime Chloride. A Comparative Study in Healthy Volunteers and in Organophosphorus Poisoning,&rdquo;",
"      <i>",
"       Arch Toxicol",
"      </i>",
"      , 1989, 63(5):416-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/8/16517/abstract-text/2818204/pubmed\" id=\"2818204\" target=\"_blank\">",
"        2818204",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kamha AA, Al Omary IY, Zalabany HA, et al, \"Organophosphate Poisoning in Pregnancy: A Case Report,\"",
"      <i>",
"       Basic Clin Pharmacol Toxicol",
"      </i>",
"      , 2005, 96(5):397-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/8/16517/abstract-text/15853933/pubmed\" id=\"15853933\" target=\"_blank\">",
"        15853933",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kurtz PH, &ldquo;Pralidoxime in the Treatment of Carbamate Intoxication,&rdquo;",
"      <i>",
"       Am J Emerg Med",
"      </i>",
"      , 1990, 8(1):68-70.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/8/16517/abstract-text/2403479/pubmed\" id=\"2403479\" target=\"_blank\">",
"        2403479",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Medical Management Guidelines (MMGs) for Nerve Agents: Tabun (GA); Sarin (GB); Soman (GD); and VX.&rdquo; Available at",
"      <a href=\"file://www.atsdr.cdc.gov/mmg/mmg.asp?id=523&amp;tid=93\" target=\"_blank\">",
"       file://www.atsdr.cdc.gov/mmg/mmg.asp?id=523&amp;tid=93",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Medicis JJ, Stork CM, Hoffman RS, et al, &ldquo;Improved 2-PAM Dosing Regimen in Human Volunteers: A Pharmacokinetic Study,&rdquo;",
"      <i>",
"       Vet Hum Toxicol",
"      </i>",
"      , 1994, 36:377.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mokhlesi B, Leikin JB, Murray P, et al, &ldquo;Adult Toxicology in Critical Care: Part II: Specific Poisonings,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2003, 123(3):897-922.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/8/16517/abstract-text/12628894/pubmed\" id=\"12628894\" target=\"_blank\">",
"        12628894",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Murphy M and Desai H, &ldquo;Pralidoxime-Induced Laryngospasm,&rdquo;",
"      <i>",
"       Vet Hum Toxicol",
"      </i>",
"      , 1994, 36:375.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Roberts DM and Aaron CK, &ldquo;Management of  Acute Organophosphorus Pesticide Poisoning,&rdquo;",
"      <i>",
"       BMJ",
"      </i>",
"      , 2007, 334(7594):629-34.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/8/16517/abstract-text/17379909/pubmed\" id=\"17379909\" target=\"_blank\">",
"        17379909",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rotenberg JS and Newmark J, \"Nerve Agent Attacks on Children: Diagnosis and Management,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2003, 112(3 Pt 1):648-58.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/8/16517/abstract-text/12949297/pubmed\" id=\"12949297\" target=\"_blank\">",
"        12949297",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schexnayder S, James LP, Kearns GL, et al, &ldquo;The Pharmacokinetics of Continuous Infusion Pralidoxime in Children With Organophosphate Poisoning,&rdquo;",
"      <i>",
"       J Toxicol Clin Toxicol",
"      </i>",
"      , 1998, 36(6):549-55.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/8/16517/abstract-text/9776957/pubmed\" id=\"9776957\" target=\"_blank\">",
"        9776957",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9802 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-190.92.87.115-3AD7EB5AF7-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_8_16517=[""].join("\n");
var outline_f16_8_16517=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212244\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212264\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212248\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212258\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212249\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212250\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212224\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212210\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212228\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212227\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212271\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212262\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212231\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212214\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299930\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212218\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212220\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13459587\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212253\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323722\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212222\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038776\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212213\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212230\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9802\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9802|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?22/31/23027?source=related_link\">",
"      Pralidoxime: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/15/12532?source=related_link\">",
"      Pralidoxime: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_8_16518="Resistance to thyrotropin and thyrotropin-releasing hormone";
var content_f16_8_16518=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Resistance to thyrotropin and thyrotropin-releasing hormone",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/8/16518/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/8/16518/contributors\">",
"     Samuel Refetoff, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/8/16518/contributors\">",
"     Roy E Weiss, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/8/16518/contributors\">",
"     Helmut Grasberger, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/8/16518/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/8/16518/contributors\">",
"     David S Cooper, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/8/16518/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/8/16518/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?16/8/16518/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 24, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hormone resistance syndromes can be broadly defined as reduced or absent end-organ responsiveness to a hormone. Several general mechanisms have been identified:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Impaired biologic activity of the hormone &mdash; Impaired activity of the hormone is caused by mutations or post-transcriptional modification that result in production of an abnormal hormone molecule. Since response to the authentic hormone is normal, this circumstance is a \"pseudo-resistance.\"",
"     </li>",
"     <li>",
"      Impaired function of hormone receptor &mdash; Impaired receptor function is caused by mutations in the receptor gene, leading in defective or absent receptor protein. Receptor defects result in impaired or absent ability to bind the hormone, defective transmission of the signal produced by hormone binding, defective targeting to the site of action, or lack of receptor synthesis.",
"     </li>",
"     <li>",
"      Quantitative reduction in receptor in the absence of receptor gene defect &mdash; Reduced quantity of the receptor may be caused by decreased synthesis or accelerated degradation. These can occur in an absence of a defect in the receptor gene or molecule proper but involve substances that control such functions.",
"     </li>",
"     <li>",
"      Postreceptor abnormalities &mdash; Cell-membrane hormone receptors, such as the thyrotropin (TSH) receptor, mediate hormone action by activating second messengers through interaction with guanine nucleotide-binding (Gs or Gq) proteins. Because these second messengers are activated by multiple hormones, some defects in postreceptor signaling pathways can give rise to impaired action of several hormones, as is the case in McCune-Albright syndrome. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/5/19546?source=see_link&amp;anchor=H3989453#H3989453\">",
"       \"Definition, etiology, and evaluation of precocious puberty\", section on 'McCune-Albright syndrome'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The syndromes of resistance to thyrotropin (TSH) and resistance to thyrotropin-releasing hormone (TRH) will be discussed here. Disorders of reduced sensitivity to thyroid hormone, including resistance to thyroid hormone, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/37/1626?source=see_link\">",
"     \"Reduced sensitivity to thyroid hormone\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RESISTANCE TO TSH (RTSH)",
"    </span>",
"    &nbsp;&mdash;&nbsp;RTSH is broadly defined as high serum TSH (hyperthyrotropinemia) of normal biological activity in the absence of goiter. Affected individuals have normal or hypoplastic thyroid glands, high serum TSH concentrations, and normal or low serum T4 and T3 concentrations. They are often identified at birth through neonatal screening for congenital hypothyroidism. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/39/2682?source=see_link\">",
"     \"Clinical features and detection of congenital hypothyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Mechanism of TSH action",
"    </span>",
"    &nbsp;&mdash;&nbsp;TSH is the predominant regulator of thyroid growth and T4 and T3 synthesis and secretion. These actions are mediated through TSH-binding to the TSH receptor located on the plasma membrane of thyroid follicular cells. Activation of the TSH receptor results in activation of G proteins and then of the adenylyl cyclase-cyclic AMP pathway of signal transduction (",
"    <a class=\"graphic graphic_figure graphicRef63929 \" href=\"UTD.htm?9/56/10127\">",
"     figure 1",
"    </a>",
"    ). At higher concentrations of TSH, the phospholipase C-phosphatidylinositol pathway is activated. The result is stimulation of thyroid follicular-cell growth and function [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16518/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The TSH receptor belongs to a superfamily of G protein-coupled receptors that have an extracellular amino-terminal domain, seven transmembrane segments, and a cytoplasmic carboxyl terminus [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16518/abstract/2\">",
"     2",
"    </a>",
"    ]. It has some constitutive activity, so that thyroid function does not cease entirely in the absence of TSH. Expression of the TSH receptor gene is under the control of several factors, including the thyroid transcription factors 1 and 2 and by PAX8 [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16518/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Prevalence and inheritance",
"    </span>",
"    &nbsp;&mdash;&nbsp;The precise prevalence of RTSH is not known. However, partial RTSH must not be uncommon, as one-third of infants born in the state of Illinois with high blood TSH levels",
"    <span class=\"nowrap\">",
"     (&gt;30mU/L)",
"    </span>",
"    maintain normal levels of T4",
"    <span class=\"nowrap\">",
"     (&gt;8mcg/dL)",
"    </span>",
"    when measured two to three weeks later (from the records of the Illinois State Laboratory). RTSH is inherited in either autosomal recessive [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16518/abstract/4\">",
"     4",
"    </a>",
"    ] or dominant manner [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16518/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Pathogenesis of RTSH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three genetic causes of RTSH have been so far identified. They involve two distinct genes and linkage to a gene locus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Inactivating mutations in the TSH receptor gene",
"    </span>",
"    &nbsp;&mdash;&nbsp;This disorder was first described in 1995 [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16518/abstract/7\">",
"     7",
"    </a>",
"    ]. Thirty-seven families harboring 49 mutations have since been identified. The inheritance is recessive, equally split between homozygous and compound heterozygous gene mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16518/abstract/8\">",
"     8",
"    </a>",
"    ]. Decreased action of TSH results in reduced T4 and T3 synthesis and secretion, with compensatory increase in TSH secretion. The absence of goiter and the presence of thyroid hypoplasia in these patients are compatible with the dominant role of TSH on the growth of the thyroid gland [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16518/abstract/9\">",
"     9",
"    </a>",
"    ]. Though not uncommon, TSH receptor gene mutations rarely cause severe congenital hypothyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16518/abstract/10\">",
"     10",
"    </a>",
"    ]. To a certain degree, the magnitude of serum TSH elevation and the thyroid status of the patient vary with the severity of the functional impairment of the mutant TSH receptor.",
"   </p>",
"   <p>",
"    With some of the mutations, heterozygotes may have on the average higher serum TSH values, usually in the upper limit of normal or just above normal [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16518/abstract/11\">",
"     11",
"    </a>",
"    ]. In one series, 20 percent of young subjects with non-autoimmune hyperthyrotropinemia were heterozygotes for inactivating mutations of the TSH receptor [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16518/abstract/8\">",
"     8",
"    </a>",
"    ]. In a sampling of a Japanese population, the frequency of heterozygous mutations of the TSH receptor was approximately 1:172, and the prevalence of homozygotes was approximately 1:118,000 [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16518/abstract/12\">",
"     12",
"    </a>",
"    ]. A complex phenotype of congenital hypothyroidism and pseudohypoparathyroidism has been described in the presence of a combination of inactivating mutations of the TSH receptor and mutations of the downstream G protein (GNAS) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16518/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most loss-of-function mutations in the TSH receptor that have been identified are located in the extracellular domain of the TSH receptor, in contrast to the gain-of-function mutations that cause hyperthyroidism, which are located principally in the transmembrane domains of the receptor [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16518/abstract/14\">",
"     14",
"    </a>",
"    ]. Approximately half of the mutant TSH receptors have partial impairment of function, and in one-third of cases, affected subjects could maintain a euthyroid state by an appropriate increase in serum TSH levels (fully compensated RTSH).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     PAX8 gene mutations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initially associated with thyroid dysgenesis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16518/abstract/15\">",
"     15",
"    </a>",
"    ], PAX8 gene mutations can cause RTSH. Patients often are indistinguishable clinically and by thyroid tests from those with loss-of-function mutations in the TSH receptor gene [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16518/abstract/16\">",
"     16",
"    </a>",
"    ]. Inheritance is autosomal dominant. The impaired association of the mutant PAX8 with other transcription factors regulating the TSH receptor, thyroglobulin, and thyroperoxidase genes appear to be responsible for the RTSH phenotype.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Defect in the long arm of chromosome 15",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients with similar clinical findings have no detectable TSH receptor or PAX8 gene mutations, nor do they have inactivating mutations in G-protein [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16518/abstract/5,17,18\">",
"     5,17,18",
"    </a>",
"    ]. The defect is inherited in an autosomal dominant manner. Although the precise cause of their RTSH is not known, it is linked to a 2.9 Megabase interval on chromosome 15q25.3-26.1 [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16518/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Classification and clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three phenotypes of resistance to TSH have been identified, representing different degrees of resistance to TSH. In subjects with TSH receptor gene defects, the phenotype correlates with the magnitude of functional impairment of the mutant TSH receptor (",
"    <a class=\"graphic graphic_figure graphicRef79922 \" href=\"UTD.htm?12/27/12720\">",
"     figure 2",
"    </a>",
"    ). This does not appear to be the case in RTSH caused by PAX8 gene mutations and those linked to the locus on chromosome 15. In such individuals, wide variations in both TSH and free T4 and T3 are observed in affected individuals with the same mutation and within the same family (",
"    <a class=\"graphic graphic_figure graphicRef79922 \" href=\"UTD.htm?12/27/12720\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16518/abstract/5,16,19\">",
"     5,16,19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Fully compensated defect",
"    </span>",
"    &nbsp;&mdash;&nbsp;The impaired response to TSH is compensated by hypersecretion of TSH; this overcomes the resistance, resulting in euthyroid hyperthyrotropinemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Partially compensated defect",
"    </span>",
"    &nbsp;&mdash;&nbsp;This occurs when the high serum TSH cannot fully compensate for the defect; affected individuals have mild hypothyroidism. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/48/3850?source=see_link\">",
"     \"Subclinical hypothyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Uncompensated defect",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complete lack of TSH receptor function results in severe hypothyroidism. This most often occurs when both alleles carry mutant TSH receptors with complete lack of function [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16518/abstract/9,20,21\">",
"     9,20,21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;RTSH should be suspected in patients, particularly infants, who have high serum TSH concentrations, normal or low serum free T4 and T3 concentrations, and a normally located thyroid gland. The differential diagnosis includes all those conditions that impair thyroid secretion. Because of the important role of TSH in promoting thyroid growth, RTSH is unlikely if the patient has a goiter or ectopically located thyroid tissue. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/39/2682?source=see_link\">",
"     \"Clinical features and detection of congenital hypothyroidism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/47/42744?source=see_link\">",
"     \"Disorders that cause hypothyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Irrespective of the cause, subjects with mild or partially compensated RTSH have normal serum thyroid hormone levels and elevated TSH. Such individuals have, by definition \"subclinical hypothyroidism\" which, in the absence of goiter, is indistinguishable from mild primary thyroid insufficiency. Although thyroperoxidase and thyroglobulin antibodies are present in many subjects with subclinical hypothyroidism, the presence of these antibodies does not rule out RTSH. The presence of other family members expressing the same phenotype and ultimately a defect in the TSH receptor confirms the diagnosis of RTSH. Several studies have examined the role of polymorphisms in the TSH receptor gene, but have been unable to fully explain the wide range of normal TSH concentrations in the \"normal population\". One study has shown that 13 of 166 adults with subclinical hypothyroidism, but without evidence of autoimmune thyroid disease, were heterozygous for TSH receptor gene mutations, most proven to result in loss-of-function [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16518/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individuals with fully compensated RTSH are euthyroid and need no treatment. There is no evidence that in the absence of other risk factors, persistent elevation of serum TSH levels produces pituitary TSHomas or thyroid neoplasia.",
"   </p>",
"   <p>",
"    Individuals with partially compensated or uncompensated RTSH should be treated with L-T4, like any other hypothyroid patient. Because these individuals have normal responsiveness to thyroid hormone, the goal is to normalize their serum TSH concentration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     RESISTANCE TO THYROTROPIN-RELEASING HORMONE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Resistance to thyrotropin-releasing hormone (TRH) is a rare disorder that is transmitted as an autosomal recessive trait. It is due to an inactivating mutation in the TRH receptor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Mechanism of action of TRH",
"    </span>",
"    &nbsp;&mdash;&nbsp;TRH, a tripeptide of hypothalamic origin, acts by binding to TRH receptors located on the cell membranes of the pituitary thyrotroph cells. This results in depolarization, an influx of calcium into the cytosol, and activation of the phospholipase C-phosphatidylinositol pathway that stimulates the synthesis and release of TSH [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16518/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The human TRH gene is located on chromosome 3 and contains six copies of the progenitor sequence [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16518/abstract/24\">",
"     24",
"    </a>",
"    ]. The TRH receptor, a typical G-protein-coupled receptor with seven transmembrane spanning domains, is encoded by a single gene located on chromosome 8 [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16518/abstract/23,25\">",
"     23,25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Resistance to TRH is due to inactivating mutations in the TRH receptor (TRHR) gene. This disorder was first described in 1997 in a child with compound heterozygote mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16518/abstract/26\">",
"     26",
"    </a>",
"    ]. Twelve years passed before a second family with resistance to TRH was reported; affected members were homozygous for a different TRHR mutation [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16518/abstract/27\">",
"     27",
"    </a>",
"    ]. Heterozygotes are normal. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient with resistance to TRH presented with findings of central hypothyroidism: normal serum TSH, low T4 and T3 concentrations, and no serum TSH or prolactin responses to the administration of TRH. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/6/18536?source=see_link\">",
"     \"Central hypothyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Resistance to TSH (RTSH) is broadly defined as high serum TSH (hyperthyrotropinemia) of normal biological activity in the absence of goiter. Affected individuals have normal or hypoplastic thyroid glands, high serum TSH concentrations, and normal or low serum T4 and T3 concentrations. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Resistance to TSH (RTSH)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      RTSH has been associated with inactivating mutations in the TSH receptor gene (autosomal recessive), or PAX 8 gene mutations (autosomal dominant). Other cases in which these mutations are absent have been linked to a region on the long arm of chromosome 15. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Pathogenesis of RTSH'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      RTSH should be suspected in patients, particularly infants, who have high serum TSH concentrations, normal or low serum free T4 and T3 concentrations, and a normally located thyroid gland. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with RTSH who are euthyroid (the impaired response to TSH is fully compensated by hypersecretion of TSH), we suggest NOT treating with thyroid hormone (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Fully compensated defect'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If the high serum TSH cannot fully compensate for the defect (partially compensated or uncompensated defects), the individual is hypothyroid and should be treated with thyroid hormone, like any other hypothyroid patient. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Resistance to thyrotropin-releasing hormone (TRH) is a very rare disorder that is transmitted as an autosomal recessive trait. It is due to an inactivating mutation in the TRH receptor, and manifests as central hypothyroidism. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Resistance to thyrotropin-releasing hormone'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16518/abstract/1\">",
"      Allgeier A, Offermanns S, Van Sande J, et al. The human thyrotropin receptor activates G-proteins Gs and Gq/11. J Biol Chem 1994; 269:13733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16518/abstract/2\">",
"      Laugwitz KL, Allgeier A, Offermanns S, et al. The human thyrotropin receptor: a heptahelical receptor capable of stimulating members of all four G protein families. Proc Natl Acad Sci U S A 1996; 93:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16518/abstract/3\">",
"      Damante G, Di Lauro R. Thyroid-specific gene expression. Biochim Biophys Acta 1994; 1218:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16518/abstract/4\">",
"      Refetoff S. Resistance to thyrotropin. J Endocrinol Invest 2003; 26:770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16518/abstract/5\">",
"      Grasberger H, Mimouni-Bloch A, Vantyghem MC, et al. Autosomal dominant resistance to thyrotropin as a distinct entity in five multigenerational kindreds: clinical characterization and exclusion of candidate loci. J Clin Endocrinol Metab 2005; 90:4025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16518/abstract/6\">",
"      Grasberger H, Ringkananont U, Croxson M, Refetoff S. Resistance to thyroid hormone in a patient with thyroid dysgenesis. Thyroid 2005; 15:730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16518/abstract/7\">",
"      Sunthornthepvarakui T, Gottschalk ME, Hayashi Y, Refetoff S. Brief report: resistance to thyrotropin caused by mutations in the thyrotropin-receptor gene. N Engl J Med 1995; 332:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16518/abstract/8\">",
"      Persani L, Calebiro D, Cordella D, et al. Genetics and phenomics of hypothyroidism due to TSH resistance. Mol Cell Endocrinol 2010; 322:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16518/abstract/9\">",
"      Abramowicz MJ, Duprez L, Parma J, et al. Familial congenital hypothyroidism due to inactivating mutation of the thyrotropin receptor causing profound hypoplasia of the thyroid gland. J Clin Invest 1997; 99:3018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16518/abstract/10\">",
"      Ahlbom BD, Yaqoob M, Larsson A, et al. Genetic and linkage analysis of familial congenital hypothyroidism: exclusion of linkage to the TSH receptor gene. Hum Genet 1997; 99:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16518/abstract/11\">",
"      Alberti L, Proverbio MC, Costagliola S, et al. Germline mutations of TSH receptor gene as cause of nonautoimmune subclinical hypothyroidism. J Clin Endocrinol Metab 2002; 87:2549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16518/abstract/12\">",
"      Narumi S, Muroya K, Abe Y, et al. TSHR mutations as a cause of congenital hypothyroidism in Japan: a population-based genetic epidemiology study. J Clin Endocrinol Metab 2009; 94:1317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16518/abstract/13\">",
"      Lado-Abeal J, Castro-Piedras I, Palos-Paz F, et al. A family with congenital hypothyroidism caused by a combination of loss-of-function mutations in the thyrotropin receptor and adenylate cyclase-stimulating G alpha-protein subunit genes. Thyroid 2011; 21:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16518/abstract/14\">",
"      Van Sande J, Parma J, Tonacchera M, et al. Somatic and germline mutations of the TSH receptor gene in thyroid diseases. J Clin Endocrinol Metab 1995; 80:2577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16518/abstract/15\">",
"      Macchia PE, Lapi P, Krude H, et al. PAX8 mutations associated with congenital hypothyroidism caused by thyroid dysgenesis. Nat Genet 1998; 19:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16518/abstract/16\">",
"      Grasberger H, Ringkananont U, Lefrancois P, et al. Thyroid transcription factor 1 rescues PAX8/p300 synergism impaired by a natural PAX8 paired domain mutation with dominant negative activity. Mol Endocrinol 2005; 19:1779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16518/abstract/17\">",
"      Mimouni M, Mimouni-Bloch A, Schachter J, Shohat M. Familial hypothyroidism with autosomal dominant inheritance. Arch Dis Child 1996; 75:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16518/abstract/18\">",
"      Xie J, Pannain S, Pohlenz J, et al. Resistance to thyrotropin (TSH) in three families is not associated with mutations in the TSH receptor or TSH. J Clin Endocrinol Metab 1997; 82:3933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16518/abstract/19\">",
"      Grasberger H, Vaxillaire M, Pannain S, et al. Identification of a locus for nongoitrous congenital hypothyroidism on chromosome 15q25.3-26.1. Hum Genet 2005; 118:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16518/abstract/20\">",
"      Gagn&eacute; N, Parma J, Deal C, et al. Apparent congenital athyreosis contrasting with normal plasma thyroglobulin levels and associated with inactivating mutations in the thyrotropin receptor gene: are athyreosis and ectopic thyroid distinct entities? J Clin Endocrinol Metab 1998; 83:1771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16518/abstract/21\">",
"      Tiosano D, Pannain S, Vassart G, et al. The hypothyroidism in an inbred kindred with congenital thyroid hormone and glucocorticoid deficiency is due to a mutation producing a truncated thyrotropin receptor. Thyroid 1999; 9:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16518/abstract/22\">",
"      Camilot M, Teofoli F, Gandini A, et al. Thyrotropin receptor gene mutations and TSH resistance: variable expressivity in the heterozygotes. Clin Endocrinol (Oxf) 2005; 63:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16518/abstract/23\">",
"      Gershengorn MC, Osman R. Molecular and cellular biology of thyrotropin-releasing hormone receptors. Physiol Rev 1996; 76:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16518/abstract/24\">",
"      Wilber JF, Feng P, Li QL, Shi ZX. The thyrotropin-releasing hormone gene: differential regulation, expression, and function in hypothalamus and two unexpected extrahypothalamic loci, the heart and testis. Trends Endocrinol Metab 1996; 7:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16518/abstract/25\">",
"      Hinuma S, Hosoya M, Ogi K, et al. Molecular cloning and functional expression of a human thyrotropin-releasing hormone (TRH) receptor gene. Biochim Biophys Acta 1994; 1219:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16518/abstract/26\">",
"      Collu R, Tang J, Castagn&eacute; J, et al. A novel mechanism for isolated central hypothyroidism: inactivating mutations in the thyrotropin-releasing hormone receptor gene. J Clin Endocrinol Metab 1997; 82:1561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16518/abstract/27\">",
"      Bonomi M, Busnelli M, Beck-Peccoz P, et al. A family with complete resistance to thyrotropin-releasing hormone. N Engl J Med 2009; 360:731.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5845 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-190.92.87.115-3AD7EB5AF7-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_8_16518=[""].join("\n");
var outline_f16_8_16518=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RESISTANCE TO TSH (RTSH)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Mechanism of TSH action",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Prevalence and inheritance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Pathogenesis of RTSH",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Inactivating mutations in the TSH receptor gene",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - PAX8 gene mutations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Defect in the long arm of chromosome 15",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Classification and clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Fully compensated defect",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Partially compensated defect",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Uncompensated defect",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      RESISTANCE TO THYROTROPIN-RELEASING HORMONE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Mechanism of action of TRH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5845\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5845|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?9/56/10127\" title=\"figure 1\">",
"      Mechanism of TSH action",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/27/12720\" title=\"figure 2\">",
"      TSH receptor gene mutations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/6/18536?source=related_link\">",
"      Central hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/39/2682?source=related_link\">",
"      Clinical features and detection of congenital hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/5/19546?source=related_link\">",
"      Definition, etiology, and evaluation of precocious puberty",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/47/42744?source=related_link\">",
"      Disorders that cause hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/37/1626?source=related_link\">",
"      Reduced sensitivity to thyroid hormone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/48/3850?source=related_link\">",
"      Subclinical hypothyroidism",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_8_16519="Intermediate anorectal malformation";
var content_f16_8_16519=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F62573%7EPEDS%2F65755&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F62573%7EPEDS%2F65755&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Rectal shelf in a three-month-old girl with an intermediate anorectal anomaly",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 312px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A)&nbsp;The anal opening is excentrically located in pigmented skin of perineum. The opening is not stenotic. B)&nbsp;To demonstrate the posterior shelf, a&nbsp;surgical clamp&nbsp;is inserted&nbsp;into the anal opening, pulling outward on the posterior lip of anorectal canal.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Hendren WH. Pediatric rectal and perineal problems. Pediatr Clin North Am 1998; 45:1353. Copyright &copy;1998 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Nineteen-year-old woman with life-long history of severe constipation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 328px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A) In this 19 year-old woman with a life-long history of constipation, the&nbsp;anus is clearly anteriorly located,&nbsp;with a short perineal body. Normally, the anus should be located in the&nbsp;shiny pigmented skin, which is&nbsp;posterior to anal opening in this patient. B) Barium enema in the same patient. There is&nbsp;marked dilatation of rectum,&nbsp;extending to the anus. This is the typical appearance of so-called \"habit constipation\" or \"psychogenic\" constipation. However, some of these cases are probably caused by unrecognized slight anorectal malformation, as in this case.&nbsp;After anoplasty, this patient&nbsp;developed normal&nbsp;defecation patterns.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Hendren WH. Pediatric rectal and perineal problems. Pediatr Clin North Am 1998; 45:1353. Copyright &copy;1998 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_8_16519=[""].join("\n");
var outline_f16_8_16519=null;
var title_f16_8_16520="Ascariasis";
var content_f16_8_16520=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Ascariasis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/8/16520/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/8/16520/contributors\">",
"     Karin Leder, MBBS, FRACP, PhD, MPH, DTMH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/8/16520/contributors\">",
"     Peter F Weller, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/8/16520/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/8/16520/contributors\">",
"     Edward T Ryan, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/8/16520/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/8/16520/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?16/8/16520/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ascaris lumbricoides is an intestinal nematode (roundworm); it is one of the most common helminthic human infections worldwide [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16520/abstract/1\">",
"     1",
"    </a>",
"    ]. The epidemiology, clinical manifestations, and diagnosis of ascariasis are reviewed here. Issues related to pulmonary infection are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/25/11668?source=see_link\">",
"     \"Pulmonary manifestations of ascariasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The distribution of the organism is worldwide; it is estimated that more than one billion people are infected with A. lumbricoides [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16520/abstract/2\">",
"     2",
"    </a>",
"    ]. The prevalence of ascariasis is highest in tropical countries where warm, wet climates favor year-round transmission of infection. In dry areas, transmission occurs predominantly during the rainy months [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16520/abstract/3\">",
"     3",
"    </a>",
"    ]. The prevalence of infection is greatest in areas where suboptimal sanitation practices lead to increased contamination of soil and water. The majority of individuals with ascariasis live in Asia (73 percent), Africa (12 percent), and South America (8 percent), where some populations have infection rates as high as 95 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16520/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ascariasis occurs among all age groups; it is most common in children 2 to 10 years old, and the prevalence of infection decreases over the age of 15 years. Infections tend to cluster in families, and worm burden correlates with the number of people living in a home [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16520/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the United States, the prevalence of infection decreased dramatically after the introduction of modern sanitation and waste treatment in the early 1900s [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16520/abstract/7\">",
"     7",
"    </a>",
"    ]. It is estimated that the prevalence of A. lumbricoides in the United States is approximately 2 percent, but it may be as high as 30 percent among children between one and five years of age, particularly in southern rural areas [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16520/abstract/2,8\">",
"     2,8",
"    </a>",
"    ]. Ascariasis also occurs among travelers from endemic areas [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16520/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Human immunodeficiency virus (HIV) has not been associated with increased risk for ascariasis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16520/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8718740\">",
"    <span class=\"h2\">",
"     Life cycle",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adult worms inhabit the lumen of the small intestine, usually in the jejunum or ileum (",
"    <a class=\"graphic graphic_picture graphicRef52868 \" href=\"UTD.htm?41/43/42673\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef79015 \" href=\"UTD.htm?14/45/15064\">",
"     figure 1",
"    </a>",
"    ). They have a life span of 10 to 24 months, and are subsequently passed in the stool. When both female and male worms are present in the intestine, each female worm produces approximately 200,000 fertilized eggs per day. In the setting of infection with only female worms, infertile eggs are produced that do not develop into the infectious stage. In the setting of infection with only male worms, no eggs are formed.",
"   </p>",
"   <p>",
"    The eggs are oval, have a thick shell and mamillated outer coat, and measure 45 to 70 microns by 35 to 50 microns (",
"    <a class=\"graphic graphic_picture graphicRef76433 \" href=\"UTD.htm?38/30/39392\">",
"     picture 2",
"    </a>",
"    ). The ova are passed into the stool and prefer warm, shady, moist conditions under which they can survive for up to 10 years [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16520/abstract/1\">",
"     1",
"    </a>",
"    ]. The eggs are resistant to usual methods of chemical water purification but are removed by filtration or by boiling. Within in two to four weeks, fertile eggs embryonate and become infective.",
"   </p>",
"   <p>",
"    When ingested by humans, the ova hatch in the small intestine and release larvae, which penetrate the intestinal wall and migrate hematogenously or via lymphatics to the lungs within four days following ingestion. Occasionally larvae migrate to other sites, including to the kidney or brain.",
"   </p>",
"   <p>",
"    Within the alveoli of the lungs, the larvae mature over a period of approximately 10 days, then ascend the bronchial tree and are swallowed. Once back in the intestine, they mature into adult worms. The majority of worms are found in the jejunum, though worms may be found anywhere in the gastrointestinal tract and occasionally migrate to other ectopic sites. Conditions such as fever, illness, anesthesia, and anthelmintic drugs can stimulate migration of adult worms. After approximately two to three months, gravid females begin to produce ova, which are excreted in stool, completing the cycle.",
"   </p>",
"   <p>",
"    Adult worms do not multiply in the human host; the number of adult worms in an infected individual depends on the degree of exposure to infectious eggs over time. In highly endemic areas, worm burdens of several hundred per individual may be observed; there are case reports of more than 2000 worms in individual children [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16520/abstract/5\">",
"     5",
"    </a>",
"    ]. The number of eggs produced per female worm tends to decrease as the worm burden increases.",
"   </p>",
"   <p>",
"    There is no significant animal reservoir, but A. suum, which infects pigs, is morphologically similar to A. lumbricoides, and the larval forms can occasionally infect humans [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16520/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Transmission",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transmission occurs primarily via ingestion of water or food contaminated with A. lumbricoides eggs. Uncommonly, transmission occurs via airborne ingestion of contaminated dust. Children playing in contaminated soil may acquire the parasite from their hands, and poor hygiene facilitates spread of infection. Transplacental migration of larvae has also occasionally been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16520/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Transmission is enhanced by asymptomatically infected individuals who can continue to shed eggs for years. Prior infection does not confer protective immunity [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16520/abstract/13\">",
"     13",
"    </a>",
"    ]. Coinfection with other parasitic diseases occurs with some regularity because of similar predisposing factors for transmission [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16520/abstract/2,14\">",
"     2,14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most infections with A. lumbricoides are asymptomatic; worldwide the burden of symptomatic disease is relatively high because of the high prevalence of disease. In general, clinical symptoms occur among individuals with high worm loads [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16520/abstract/1\">",
"     1",
"    </a>",
"    ]. Symptoms tend to occur during the larval migration stage or the adult worm intestinal stage. Pathophysiologic mechanisms include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Direct tissue damage",
"     </li>",
"     <li>",
"      The immunologic response of the host to infection with larvae, eggs, or adult worms [",
"      <a class=\"abstract\" href=\"UTD.htm?16/8/16520/abstract/13\">",
"       13",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Obstruction of the gastrointestinal tract by an aggregation of worms",
"     </li>",
"     <li>",
"      Nutritional sequelae of infection [",
"      <a class=\"abstract\" href=\"UTD.htm?16/8/16520/abstract/2\">",
"       2",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The symptoms and complications of infection can be classified into the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Pulmonary and hypersensitivity manifestations",
"     </li>",
"     <li>",
"      Intestinal symptoms",
"     </li>",
"     <li>",
"      Intestinal obstruction",
"     </li>",
"     <li>",
"      Hepatobiliary and pancreatic symptoms",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Pulmonary and hypersensitivity manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transient respiratory symptoms can occur in sensitized individuals during larval migration through the lungs. Symptoms associated with the pneumonitis, known as Loeffler's syndrome, tend to occur one to two weeks after ingestion of eggs. The severity of symptoms correlates with larval burden, although pulmonary symptoms are less common in regions with continuous transmission of A. lumbricoides. Urticaria and other hypersensitivity symptoms usually occur toward the end of the period of migration through the lungs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/25/11668?source=see_link\">",
"     \"Pulmonary manifestations of ascariasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Intestinal symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is uncertain whether nonspecific symptoms, such as abdominal discomfort, anorexia, nausea, and diarrhea, are attributable to ascariasis. Ascariasis has been associated with growth retardation and malnutrition. It has also been proposed that heavy infections may be associated with impaired cognitive development in school children [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16520/abstract/15,16\">",
"     15,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A high burden of infection can lead to impaired absorption of dietary proteins, lactose, and vitamin A and C; steatorrhea may occur. In one review, children treated for ascariasis had better nutritional status in terms of growth, lactose tolerance, vitamins A and C, and albumin levels than children with untreated ascariasis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16520/abstract/17\">",
"     17",
"    </a>",
"    ]. However, it is difficult to discern the true effect of ascariasis on nutritional status given other coexisting nutritional deficiencies in infected children [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16520/abstract/18-25\">",
"     18-25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Intestinal obstruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;In heavy Ascaris infection, a mass of worms can obstruct the bowel lumen, leading to acute intestinal obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16520/abstract/26\">",
"     26",
"    </a>",
"    ]. In one report, the estimated worm burden in individuals presenting with intestinal obstruction was &gt;60 [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16520/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ascariasis is the most common cause of acute abdominal surgical emergencies in certain countries including South Africa and Myanmar [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16520/abstract/5\">",
"     5",
"    </a>",
"    ]. In endemic areas, between 5 and 35 percent of all bowel obstructions are due to ascariasis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16520/abstract/1\">",
"     1",
"    </a>",
"    ]. Approximately 85 percent of obstructions due to ascariasis occur in children between the ages of one and five years. The overall incidence of obstruction associated with ascariasis is approximately 1 in 500 children. In one meta-analysis, intestinal obstruction accounted for 38 to 87 percent of all complications of the infection [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16520/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The obstruction occurs most commonly at the ileocecal valve. Symptoms include colicky abdominal pain, vomiting, and constipation. Emesis may contain worms. In some cases, an abdominal mass that changes in size and location may be appreciated on serial physical examinations [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16520/abstract/2\">",
"     2",
"    </a>",
"    ]. Complications including volvulus, ileocecal intussusception, gangrene, and intestinal perforation occasionally result.",
"   </p>",
"   <p>",
"    Complications associated with A. lumbricoides infections are fatal in about 1 percent of cases. It is estimated that 20,000 deaths from ascariasis occur annually, due to intestinal obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16520/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Hepatobiliary and pancreatic symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Migration of adult worms into the biliary tree can cause abdominal pain, biliary colic, acalculous cholecystitis, ascending cholangitis, obstructive jaundice, or bile duct perforation with peritonitis. Biliary tree strictures may occur; hepatic abscesses can also result [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16520/abstract/30-32\">",
"     30-32",
"    </a>",
"    ]. In addition, retained worm fragments can serve as a nidus for recurrent pyogenic cholangitis.",
"   </p>",
"   <p>",
"    The pancreatic duct may become obstructed, leading to pancreatitis. The appendix may become obstructed, resulting in appendicitis. Occasionally, migrating adult worms emerge from the mouth, nose, lacrimal ducts, umbilicus, or inguinal canal. High fever, diarrhea, spicy foods, anesthesia, and other stresses have all been associated with an increased likelihood of worm migration [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16520/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In India, ascariasis has been associated with up to one-third of biliary and pancreatic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16520/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. In a Syrian study including 300 patients with biliary or pancreatic ascariasis diagnosed by endoscopic retrograde cholangiopancreatography, 98 percent presented with abdominal pain, 16 percent developed ascending cholangitis, 4 percent developed acute pancreatitis, and 1 percent developed obstructive jaundice [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16520/abstract/35\">",
"     35",
"    </a>",
"    ]. A previous cholecystectomy or endoscopic sphincterotomy had been performed in 80 percent of patients. Endoscopic extraction of the worms led to rapid resolution of symptoms in most cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of ascariasis is usually established via stool microscopy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Microscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Characteristic eggs may be seen on direct examination of stool or following concentration techniques (",
"    <a class=\"graphic graphic_picture graphicRef76433 \" href=\"UTD.htm?38/30/39392\">",
"     picture 2",
"    </a>",
"    ). However, eggs do not appear in the stool for at least 40 days after infection; thus, the main drawback of relying on stool microscopy is that an early diagnosis cannot be made, including during the phase of respiratory symptoms. In addition, no eggs will be present in stool if the infection is due to male worms only.",
"   </p>",
"   <p>",
"    Sometimes an adult worm is passed, usually per rectum (",
"    <a class=\"graphic graphic_picture graphicRef52868 \" href=\"UTD.htm?41/43/42673\">",
"     picture 1",
"    </a>",
"    ); adult worms may also be coughed up or passed in urine. A. lumbricoides is the largest human intestinal nematode. Worms mature to become 10 to 30 cm long; the female worms are larger and can measure 40 cm in length and 6 mm in diameter. The worms are white or pink and are tapered at both ends.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Eosinophilia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peripheral eosinophilia may be observed, particularly during the phase of larval migration through the lungs and in some cases at other stages of infection as well [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16520/abstract/36\">",
"     36",
"    </a>",
"    ]. Eosinophil levels are usually 5 to 12 percent but can be as high as 30 to 50 percent. Serum levels of IgG and IgE are also often elevated during early infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;In heavily infected individuals, particularly children, large collections of worms may be detectable on plain radiograph of the abdomen. The mass of worms contrasts against the gas in the bowel, typically producing a \"whirlpool\" effect (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef79228 \" href=\"UTD.htm?17/51/18224\">",
"     image 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16520/abstract/5\">",
"     5",
"    </a>",
"    ]. Radiographic detection of adult worms can also made following",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    swallow, which can demonstrate elongated filling defects of the small bowel. In addition, the worms may ingest barium; in such cases the worm&rsquo;s alimentary canal appears as a white thread bisecting the length of the worm's body (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef76347 \" href=\"UTD.htm?13/47/14065\">",
"     image 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16520/abstract/5\">",
"     5",
"    </a>",
"    ]. Radiographs can also demonstrate associated intestinal obstruction. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Intestinal obstruction'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Ultrasonography can be useful for diagnosis of hepatobiliary or pancreatic ascariasis. Single worms, bundles of worms, or a pseudotumor-like appearance may be seen [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16520/abstract/37\">",
"     37",
"    </a>",
"    ]. Sonographic findings may include echogenic tubular structures, curved strips, or a &lsquo;target&rsquo; sign (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef62196 \" href=\"UTD.htm?17/62/18403\">",
"     image 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16520/abstract/38\">",
"     38",
"    </a>",
"    ]. In some cases, the worms demonstrate curling movements [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16520/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Computed tomographic (CT) scanning or magnetic resonance imaging (MRI) may also be used to identify worm(s) in the liver or bile ducts. Imaging the worm in cross-section demonstrates a \"bull's eye\" appearance (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef62196 \" href=\"UTD.htm?17/62/18403\">",
"     image 3",
"    </a>",
"    ). In the setting of suspected involvement of the biliary tree or pancreatic duct, endoscopic retrograde cholangiopancreatography (ERCP) is the most useful tool to establish the diagnosis and facilitate removal of the worm (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef68876 \" href=\"UTD.htm?21/8/21647\">",
"     image 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16520/abstract/35,40\">",
"     35,40",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/6/42087?source=see_link\">",
"     \"Endoscopic diagnosis and management of biliary parasitosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Serology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infected individuals produce detectable antibodies to A. lumbricoides. However, serology is generally reserved for epidemiologic studies rather than clinical diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16520/abstract/13\">",
"     13",
"    </a>",
"    ]. IgG antibodies do not appear to have protective function against infection [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16520/abstract/41\">",
"     41",
"    </a>",
"    ]. In addition, antibodies to Ascaris frequently cross react with antigens from other helminths.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H881290663\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiplex PCR and probe-based detection for concurrent detection of Ascaris and other intestinal parasites is being developed [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16520/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Selecting therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anthelminthic therapy is warranted for intestinal, biliary and pancreatic disease. In general anthelminthic therapy should not be administered at the time of pulmonary symptoms because inflammation associated with dying organisms may cause more harm than symptoms associated with migration. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/25/11668?source=see_link\">",
"     \"Pulmonary manifestations of ascariasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In general, targeted treatment for individuals with symptomatic infection helps reduce the morbidity of infection but does not have a substantial effect on transmission [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16520/abstract/43-45\">",
"     43-45",
"    </a>",
"    ]. Several agents have activity against A. lumbricoides as discussed in the following sections. These therapies act against the adult worm but not the larvae. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/43/23221?source=see_link\">",
"     \"Anthelminthic therapies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17356140\">",
"    <span class=\"h3\">",
"     First line agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mainstays of treatment for ascariasis are the benzimidazoles,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/6/24678?source=see_link\">",
"     albendazole",
"    </a>",
"    (400 mg orally once), and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/42/12965?source=see_link\">",
"     mebendazole",
"    </a>",
"    (100 mg twice daily for three days or 500 mg as a single dose) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16520/abstract/46\">",
"     46",
"    </a>",
"    ]. A single dose of albendazole is effective in almost 100 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16520/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. Both the three-day mebendazole regimen and the single dose mebendazole regimen are approximately 95 percent effective [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16520/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. A meta-analysis including 20 randomized trials demonstrated high cure rates with single doses of albendazole and mebendazole [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16520/abstract/51\">",
"     51",
"    </a>",
"    ]. Similar results and good tolerability have been described in other studies [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16520/abstract/49,52-54\">",
"     49,52-54",
"    </a>",
"    ]. Adverse effects of the benzimidazoles include transient GI discomfort, headache, and, rarely, leukopenia.",
"   </p>",
"   <p>",
"    For treatment of pregnant women,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/62/4068?source=see_link\">",
"     pyrantel pamoate",
"    </a>",
"    should be used, given possible teratogenic effects due to the benzimidazoles [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16520/abstract/51\">",
"     51",
"    </a>",
"    ]. Pyrantel pamoate (11",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    up to a maximum of 1 g) is administered as a single dose. The efficacy varies with worm load; single dose therapy is approximately 90 percent effective in eradicating adult worms [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16520/abstract/3\">",
"     3",
"    </a>",
"    ]. Adverse effects include gastrointestinal (GI) disturbances, headaches, rash, and fever.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17356148\">",
"    <span class=\"h3\">",
"     Alternative agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alternative agents include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32976?source=see_link\">",
"     ivermectin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/24/5508?source=see_link\">",
"     nitazoxanide",
"    </a>",
"    , piperazine citrate, and levamisole.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32976?source=see_link\">",
"       Ivermectin",
"      </a>",
"      &mdash; Ivermectin causes paralysis of adult worms. In one study comparing ivermectin (200",
"      <span class=\"nowrap\">",
"       mcg/kg)",
"      </span>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/6/24678?source=see_link\">",
"       albendazole",
"      </a>",
"      (400 mg single dose), cure rates were similar (78 versus 70 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?16/8/16520/abstract/55\">",
"       55",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/24/5508?source=see_link\">",
"       Nitazoxanide",
"      </a>",
"      &mdash; Nitazoxanide is a thiazolide antiparasitic agent [",
"      <a class=\"abstract\" href=\"UTD.htm?16/8/16520/abstract/56\">",
"       56",
"      </a>",
"      ]. The efficacy of nitazoxanide varies according to egg burden [",
"      <a class=\"abstract\" href=\"UTD.htm?16/8/16520/abstract/57,58\">",
"       57,58",
"      </a>",
"      ]. In patients with light infection, cure rates of 100 percent have been observed; in patients with heavy egg burdens (&gt;10,000",
"      <span class=\"nowrap\">",
"       eggs/g",
"      </span>",
"      stool), cure rates of only 50 to 80 percent can be achieved [",
"      <a class=\"abstract\" href=\"UTD.htm?16/8/16520/abstract/58\">",
"       58",
"      </a>",
"      ]. In a randomized trial among Peruvian children, comparable cure rates with nitazoxanide (three day course) and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/6/24678?source=see_link\">",
"       albendazole",
"      </a>",
"      (single dose) were observed (89 percent versus 91 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?16/8/16520/abstract/59\">",
"       59",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Piperazine citrate &mdash; Piperazine citrate (50 to 75",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      once daily up to a maximum of 3.5 g for two days) was a frequently used treatment regimen; it has been withdrawn from the market in many regions because other available alternatives are less toxic and more efficacious. However, it may still be useful for cases in which intestinal or biliary obstruction is suspected since the drug paralyzes worms, aiding expulsion.",
"     </li>",
"     <li>",
"      Levamisole &mdash; Levamisole (150 mg for adults and 5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      for children) is effective in 77 to 96 percent of cases of ascariasis [",
"      <a class=\"abstract\" href=\"UTD.htm?16/8/16520/abstract/1\">",
"       1",
"      </a>",
"      ]. The availability of this drug is limited.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Follow-up",
"    </span>",
"    &nbsp;&mdash;&nbsp;The anthelminthic therapies act against the adult worm but not the larvae. Therefore, patients should be reevaluated in two to three months, following therapy with repeat stool microscopy. Detection of eggs suggests inadequate elimination of adult worms or reinfection. In endemic areas reinfection occurs frequently; in some areas more than 80 percent of individuals become reinfected within six months [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16520/abstract/1\">",
"     1",
"    </a>",
"    ]. Given the propensity of infection to cluster in households, evaluation of other household members is also warranted [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16520/abstract/2,12\">",
"     2,12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Endoscopy and surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to anthelminthic therapy, in some cases endoscopic or surgical intervention is also warranted. In the setting of intestinal obstruction, surgical intervention may be required. Patients with hepatobiliary disease may require endoscopic or laparoscopic extraction of worms [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16520/abstract/60,61\">",
"     60,61",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Hepatobiliary and pancreatic symptoms'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In regions where Ascaris worms are abundant in soil, prevention of reinfection is extremely difficult [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16520/abstract/62\">",
"     62",
"    </a>",
"    ]. Soil treatments have been attempted but in general are not practical. Good sanitation to prevent ongoing fecal contamination of soil is required. A study in Sri Lanka demonstrated that, even in congested living conditions with poor sanitary facilities, washing hands before meals and drinking boiled water significantly reduced the risk of Ascaris infection [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16520/abstract/63\">",
"     63",
"    </a>",
"    ]. In areas where human feces are used as fertilizer, educational programs are needed to change this behavior.",
"   </p>",
"   <p>",
"    Mass treatment with single dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/42/12965?source=see_link\">",
"     mebendazole",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/6/24678?source=see_link\">",
"     albendazole",
"    </a>",
"    every three to four months for school-age children has been successful some communities [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16520/abstract/64\">",
"     64",
"    </a>",
"    ]. It is unknown whether routine administration of deworming drugs to children can be correlated with improved cognition or school performance; community deworming does not appear to affect serum hemoglobin levels substantially [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16520/abstract/65\">",
"     65",
"    </a>",
"    ]. In general, mass community therapy has a greater effect on the intensity of infection than on the overall prevalence [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16520/abstract/43,66-68\">",
"     43,66-68",
"    </a>",
"    ]. In a large, randomized trial of school-based deworming performed in Zanzibar, for example, single dose mebendazole given twice or three times a year decreased intensity of A. lumbricoides infection by 63 and 97 percent, respectively, compared to control children who received no mebendazole [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16520/abstract/69\">",
"     69",
"    </a>",
"    ]. Thus, relatively short intervals between treatments have been found to be preferable.",
"   </p>",
"   <p>",
"    In general, targeted treatment for individuals with symptomatic infection helps reduce the morbidity of infection, but does not have a substantial effect on transmission [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16520/abstract/43-45\">",
"     43-45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3293273\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ascaris lumbricoides is an intestinal nematode (roundworm); it is estimated that more than one billion people are infected with A. lumbricoides worldwide. The prevalence of infection is highest in tropical countries where warm, wet climates favor year-round transmission of infection. In addition, the prevalence is high in areas where suboptimal sanitation practices lead to increased contamination of soil and water. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Adult worms inhabit the lumen of the small intestine, usually in the jejunum or ileum (",
"      <a class=\"graphic graphic_figure graphicRef79015 \" href=\"UTD.htm?14/45/15064\">",
"       figure 1",
"      </a>",
"      ). When both female and male worms are present in the intestine, female worms produce fertilized eggs which pass into the stool. The eggs prefer warm, shady, moist conditions under which they can survive for up to 10 years. Within days following oral ingestion of eggs (via contaminated food or water), the eggs hatch in the small intestine and release larvae which migrate hematogenously to the lungs. In the alveoli, the larvae mature over a period of approximately 10 days, then ascend the bronchial tree and are swallowed. Once back in the intestine, they mature into adult worms. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most infections with A. lumbricoides are asymptomatic. When symptoms do develop, they occur during the larval migration stage or the adult worm intestinal stage. Transient respiratory symptoms can occur during larval migration through the lungs. During intestinal infection, a high burden of worms can lead to nutritional deficiencies. In the setting of heavy infection a mass of worms can obstruct the bowel lumen. Migration of adult worms into the biliary tree can cause biliary colic, acalculous cholecystitis, ascending cholangitis, or obstructive jaundice. The pancreatic duct may become obstructed, leading to pancreatitis. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of ascariasis is usually established via stool microscopy. Characteristic eggs may be seen on direct examination of stool or following concentration techniques (",
"      <a class=\"graphic graphic_picture graphicRef76433 \" href=\"UTD.htm?38/30/39392\">",
"       picture 2",
"      </a>",
"      ). However, eggs do not appear in the stool for at least 40 days after infection; thus stool microscopy cannot be used to establish an early diagnosis, including during the phase of respiratory symptoms. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Anthelminthic therapy is warranted for intestinal, biliary and pancreatic disease. In general, anthelminthic therapy should not be administered at the time of pulmonary symptoms because inflammation associated with dying organisms may cause more harm than symptoms associated with larval migration. Targeted treatment for individuals with symptomatic infection helps reduce the morbidity of infection but does not have a substantial effect on transmission. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/6/24678?source=see_link\">",
"       albendazole",
"      </a>",
"      (400 mg orally once) or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/42/12965?source=see_link\">",
"       mebendazole",
"      </a>",
"      (100 mg twice daily for three days or 500 mg as a single dose) for treatment of ascariasis (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). For treatment of pregnant women,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/62/4068?source=see_link\">",
"       pyrantel pamoate",
"      </a>",
"      (11",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      as a single dose up to a maximum of 1 g) should be used. In addition to anthelminthic therapy, in some cases surgical or endoscopic intervention is also warranted. In the setting of intestinal obstruction, surgical intervention may be required. Patients with hepatobiliary disease may require endoscopic or laparoscopic extraction of worms. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In regions where Ascaris worms are abundant in soil, prevention of reinfection is extremely difficult. Good sanitation measures, including washing hands before meals and drinking boiled water, are important. Mass treatment with single dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/42/12965?source=see_link\">",
"       mebendazole",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/6/24678?source=see_link\">",
"       albendazole",
"      </a>",
"      every three to four months for school-age children has been successful in some communities. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Prevention'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16520/abstract/1\">",
"      Khuroo MS. Ascariasis. Gastroenterol Clin North Am 1996; 25:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16520/abstract/2\">",
"      Tietze PE, Tietze PH. The roundworm, Ascaris lumbricoides. Prim Care 1991; 18:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16520/abstract/3\">",
"      Warren KS, Mahmoud AA. Algorithms in the diagnosis and management of exotic diseases. xxii. ascariasis and toxocariasis. J Infect Dis 1977; 135:868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16520/abstract/4\">",
"      Sarinas PS, Chitkara RK. Ascariasis and hookworm. Semin Respir Infect 1997; 12:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16520/abstract/5\">",
"      Reeder MM. The radiological and ultrasound evaluation of ascariasis of the gastrointestinal, biliary, and respiratory tracts. Semin Roentgenol 1998; 33:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16520/abstract/6\">",
"      Haswell-Elkins M, Elkins D, Anderson RM. The influence of individual, social group and household factors on the distribution of Ascaris lumbricoides within a community and implications for control strategies. Parasitology 1989; 98 ( Pt 1):125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16520/abstract/7\">",
"      Jones JE. Parasites in Kentucky: the past seven decades. J Ky Med Assoc 1983; 81:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16520/abstract/8\">",
"      Jones JE. The royal roundworm: Ascaris lumbricoides. J Fam Pract 1981; 13:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16520/abstract/9\">",
"      Anand L, Dhanachand C, Brajachand N. Prevalence and epidemiologic characteristics of opportunistic and non-opportunistic intestinal parasitic infections in HIV positive patients in Manipur. J Commun Dis 1998; 30:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16520/abstract/10\">",
"      Lindo JF, Dubon JM, Ager AL, et al. Intestinal parasitic infections in human immunodeficiency virus (HIV)-positive and HIV-negative individuals in San Pedro Sula, Honduras. Am J Trop Med Hyg 1998; 58:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16520/abstract/11\">",
"      Kakihara D, Yoshimitsu K, Ishigami K, et al. Liver lesions of visceral larva migrans due to Ascaris suum infection: CT findings. Abdom Imaging 2004; 29:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16520/abstract/12\">",
"      Chu WG, Chen PM, Huang CC, Hsu CT. Neonatal ascariasis. J Pediatr 1972; 81:783.",
"     </a>",
"    </li>",
"    <li>",
"     Diemert DJ. Ascariasis. In: Tropical Infectious Diseases: Principles, Pathogens and Practice, 3rd, Guerrant RL, Weller PF, Walker DH.  (Eds), Elsevier, 2011. p.794.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16520/abstract/14\">",
"      Bundy DA, Cooper ES, Thompson DE, et al. Epidemiology and population dynamics of Ascaris lumbricoides and Trichuris trichiura infection in the same community. Trans R Soc Trop Med Hyg 1987; 81:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16520/abstract/15\">",
"      Hadidjaja P, Bonang E, Suyardi MA, et al. The effect of intervention methods on nutritional status and cognitive function of primary school children infected with Ascaris lumbricoides. Am J Trop Med Hyg 1998; 59:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16520/abstract/16\">",
"      Oberhelman RA, Guerrero ES, Fernandez ML, et al. Correlations between intestinal parasitosis, physical growth, and psychomotor development among infants and children from rural Nicaragua. Am J Trop Med Hyg 1998; 58:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16520/abstract/17\">",
"      Hlaing T. Ascariasis and childhood malnutrition. Parasitology 1993; 107 Suppl:S125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16520/abstract/18\">",
"      Rousham EK, Mascie-Taylor CG. An 18-month study of the effect of periodic anthelminthic treatment on the growth and nutritional status of pre-school children in Bangladesh. Ann Hum Biol 1994; 21:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16520/abstract/19\">",
"      Watkins WE, Cruz JR, Pollitt E. The effects of deworming on indicators of school performance in Guatemala. Trans R Soc Trop Med Hyg 1996; 90:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16520/abstract/20\">",
"      Raj SM, Naing NN. Ascariasis, trichuriasis, and growth of schoolchildren in Northeastern Peninsular Malaysia. Southeast Asian J Trop Med Public Health 1998; 29:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16520/abstract/21\">",
"      Greenberg BL, Gilman RH, Shapiro H, et al. Single dose piperazine therapy for Ascaris lumbricoides: an unsuccessful method of promoting growth. Am J Clin Nutr 1981; 34:2508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16520/abstract/22\">",
"      Tshikuka JG, Gray-Donald K, Scott M, Olela KN. Relationship of childhood protein-energy malnutrition and parasite infections in an urban African setting. Trop Med Int Health 1997; 2:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16520/abstract/23\">",
"      Blumenthal DS, Schultz MG. Effects of Ascaris infection of nutritional status in children. Am J Trop Med Hyg 1976; 25:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16520/abstract/24\">",
"      Gupta MC. Effect of ascariasis upon nutritional status of children. J Trop Pediatr 1990; 36:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16520/abstract/25\">",
"      Crompton DW. Ascariasis and childhood malnutrition. Trans R Soc Trop Med Hyg 1992; 86:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16520/abstract/26\">",
"      Teneza-Mora NC, Lavery EA, Chun HM. Partial small bowel obstruction in a traveler. Clin Infect Dis 2006; 43:214, 256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16520/abstract/27\">",
"      de Silva NR, Guyatt HL, Bundy DA. Worm burden in intestinal obstruction caused by Ascaris lumbricoides. Trop Med Int Health 1997; 2:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16520/abstract/28\">",
"      de Silva NR, Guyatt HL, Bundy DA. Morbidity and mortality due to Ascaris-induced intestinal obstruction. Trans R Soc Trop Med Hyg 1997; 91:31.",
"     </a>",
"    </li>",
"    <li>",
"     Pawlowski ZS. Morbidity and mortality in Ascariasis. In: Ascariasis and Its Prevention and Control, Crompton DWT, Pawlowski ZS (Eds), Taylor and Francis, London 1989. p.45.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16520/abstract/30\">",
"      al-Karawi M, Sanai FM, Yasawy MI, Mohammed AE. Biliary strictures and cholangitis secondary to ascariasis: endoscopic management. Gastrointest Endosc 1999; 50:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16520/abstract/31\">",
"      Javid G, Wani NA, Gulzar GM, et al. Ascaris-induced liver abscess. World J Surg 1999; 23:1191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16520/abstract/32\">",
"      Khuroo MS. Hepatobiliary and pancreatic ascariasis. Indian J Gastroenterol 2001; 20 Suppl 1:C28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16520/abstract/33\">",
"      Khuroo MS, Mahajan R, Zargar SA, et al. Prevalence of biliary tract disease in India: a sonographic study in adult population in Kashmir. Gut 1989; 30:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16520/abstract/34\">",
"      Khuroo MS, Zargar SA. Biliary ascariasis. A common cause of biliary and pancreatic disease in an endemic area. Gastroenterology 1985; 88:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16520/abstract/35\">",
"      Sandouk F, Haffar S, Zada MM, et al. Pancreatic-biliary ascariasis: experience of 300 cases. Am J Gastroenterol 1997; 92:2264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16520/abstract/36\">",
"      Weller PF. Eosinophilia in travelers. Med Clin North Am 1992; 76:1413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16520/abstract/37\">",
"      Schulman A. Ultrasound appearances of intra- and extrahepatic biliary ascariasis. Abdom Imaging 1998; 23:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16520/abstract/38\">",
"      Wu S. Sonographic findings of ascaris lumbricoides in the gastrointestinal and biliary tracts. Ultrasound Q 2009; 25:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16520/abstract/39\">",
"      Malde HM, Chadha D. Roundworm obstruction: sonographic diagnosis. Abdom Imaging 1993; 18:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16520/abstract/40\">",
"      Misra SP, Dwivedi M. Clinical features and management of biliary ascariasis in a non-endemic area. Postgrad Med J 2000; 76:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16520/abstract/41\">",
"      McSharry C, Xia Y, Holland CV, Kennedy MW. Natural immunity to Ascaris lumbricoides associated with immunoglobulin E antibody to ABA-1 allergen and inflammation indicators in children. Infect Immun 1999; 67:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16520/abstract/42\">",
"      Taniuchi M, Verweij JJ, Noor Z, et al. High throughput multiplex PCR and probe-based detection with Luminex beads for seven intestinal parasites. Am J Trop Med Hyg 2011; 84:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16520/abstract/43\">",
"      Hall A, Anwar KS, Tomkins AM. Intensity of reinfection with Ascaris lumbricoides and its implications for parasite control. Lancet 1992; 339:1253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16520/abstract/44\">",
"      Anderson RM, Medley GF. Community control of helminth infections of man by mass and selective chemotherapy. Parasitology 1985; 90 ( Pt 4):629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16520/abstract/45\">",
"      Holland CV, Asaolu SO, Crompton DW, et al. Targeted anthelminthic treatment of school children: effect of frequency of application on the intensity of Ascaris lumbricoides infection in children from rural Nigerian villages. Parasitology 1996; 113 ( Pt 1):87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16520/abstract/46\">",
"      Bethony J, Brooker S, Albonico M, et al. Soil-transmitted helminth infections: ascariasis, trichuriasis, and hookworm. Lancet 2006; 367:1521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16520/abstract/47\">",
"      Norhayati M, Oothuman P, Azizi O, Fatmah MS. Efficacy of single dose albendazole on the prevalence and intensity of infection of soil-transmitted helminths in Orang Asli children in Malaysia. Southeast Asian J Trop Med Public Health 1997; 28:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16520/abstract/48\">",
"      Vercruysse J, Behnke JM, Albonico M, et al. Assessment of the anthelmintic efficacy of albendazole in school children in seven countries where soil-transmitted helminths are endemic. PLoS Negl Trop Dis 2011; 5:e948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16520/abstract/49\">",
"      Bartoloni A, Guglielmetti P, Cancrini G, et al. Comparative efficacy of a single 400 mg dose of albendazole or mebendazole in the treatment of nematode infections in children. Trop Geogr Med 1993; 45:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16520/abstract/50\">",
"      Legesse M, Erko B, Medhin G. Comparative efficacy of albendazole and three brands of mebendazole in the treatment of ascariasis and trichuriasis. East Afr Med J 2004; 81:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16520/abstract/51\">",
"      Keiser J, Utzinger J. Efficacy of current drugs against soil-transmitted helminth infections: systematic review and meta-analysis. JAMA 2008; 299:1937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16520/abstract/52\">",
"      Albonico M, Smith PG, Hall A, et al. A randomized controlled trial comparing mebendazole and albendazole against Ascaris, Trichuris and hookworm infections. Trans R Soc Trop Med Hyg 1994; 88:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16520/abstract/53\">",
"      Jongsuksuntigul P, Jeradit C, Pornpattanakul S, Charanasri U. A comparative study on the efficacy of albendazole and mebendazole in the treatment of ascariasis, hookworm infection and trichuriasis. Southeast Asian J Trop Med Public Health 1993; 24:724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16520/abstract/54\">",
"      Maipanich W, Pubampen S, Sa-nguankiat S, et al. Effect of albendazole and mebendazole on soil-transmitted helminth eggs. Southeast Asian J Trop Med Public Health 1997; 28:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16520/abstract/55\">",
"      Belizario VY, Amarillo ME, de Leon WU, et al. A comparison of the efficacy of single doses of albendazole, ivermectin, and diethylcarbamazine alone or in combinations against Ascaris and Trichuris spp. Bull World Health Organ 2003; 81:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16520/abstract/56\">",
"      Fox LM, Saravolatz LD. Nitazoxanide: a new thiazolide antiparasitic agent. Clin Infect Dis 2005; 40:1173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16520/abstract/57\">",
"      Diaz E, Mondragon J, Ramirez E, Bernal R. Epidemiology and control of intestinal parasites with nitazoxanide in children in Mexico. Am J Trop Med Hyg 2003; 68:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16520/abstract/58\">",
"      Romero Cabello R, Guerrero LR, Mu&ntilde;&oacute;z Garc&iacute;a MR, Geyne Cruz A. Nitazoxanide for the treatment of intestinal protozoan and helminthic infections in Mexico. Trans R Soc Trop Med Hyg 1997; 91:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16520/abstract/59\">",
"      Juan JO, Lopez Chegne N, Gargala G, Favennec L. Comparative clinical studies of nitazoxanide, albendazole and praziquantel in the treatment of ascariasis, trichuriasis and hymenolepiasis in children from Peru. Trans R Soc Trop Med Hyg 2002; 96:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16520/abstract/60\">",
"      Astudillo JA, Sporn E, Serrano B, Astudillo R. Ascariasis in the hepatobiliary system: laparoscopic management. J Am Coll Surg 2008; 207:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16520/abstract/61\">",
"      Crompton DW. Ascaris and ascariasis. Adv Parasitol 2001; 48:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16520/abstract/62\">",
"      Massara CL, Enk MJ. Treatment options in the management of Ascaris lumbricoides. Expert Opin Pharmacother 2004; 5:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16520/abstract/63\">",
"      Gunawardena GS, Karunaweera ND, Ismail MM. Socio-economic and behavioural factors affecting the prevalence of Ascaris infection in a low-country tea plantation in Sri Lanka. Ann Trop Med Parasitol 2004; 98:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16520/abstract/64\">",
"      Holland CV, O'Shea E, Asaolu SO, et al. A cost-effectiveness analysis of anthelminthic intervention for community control of soil-transmitted helminth infection: levamisole and Ascaris lumbricoides. J Parasitol 1996; 82:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16520/abstract/65\">",
"      Taylor-Robinson DC, Maayan N, Soares-Weiser K, et al. Deworming drugs for soil-transmitted intestinal worms in children: effects on nutritional indicators, haemoglobin and school performance. Cochrane Database Syst Rev 2012; 7:CD000371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16520/abstract/66\">",
"      Asaolu SO, Holland CV, Crompton DW. Community control of Ascaris lumbricoides in rural Oyo State, Nigeria: mass, targeted and selective treatment with levamisole. Parasitology 1991; 103 Pt 2:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16520/abstract/67\">",
"      . The impact of three-monthly age-targetted chemotherapy on Ascaris lumbricoides infection. Trans R Soc Trop Med Hyg 1991; 85:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16520/abstract/68\">",
"      . Control of ascariasis through age-targeted chemotherapy: impact of 6-monthly chemotherapeutic regimens. Bull World Health Organ 1990; 68:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16520/abstract/69\">",
"      Albonico M, Stoltzfus RJ, Savioli L, et al. A controlled evaluation of two school-based anthelminthic chemotherapy regimens on intensity of intestinal helminth infections. Int J Epidemiol 1999; 28:591.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5673 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-61.234.146.186-D201336892-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_8_16520=[""].join("\n");
var outline_f16_8_16520=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H3293273\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8718740\">",
"      Life cycle",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Transmission",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Pulmonary and hypersensitivity manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Intestinal symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Intestinal obstruction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Hepatobiliary and pancreatic symptoms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Microscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Eosinophilia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Serology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H881290663\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Selecting therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17356140\">",
"      - First line agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17356148\">",
"      - Alternative agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Follow-up",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Endoscopy and surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3293273\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/5673\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/5673|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?17/51/18224\" title=\"diagnostic image 1\">",
"      Ascariasis - abdominal film 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?13/47/14065\" title=\"diagnostic image 2\">",
"      Ascariasis - abdominal film 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?17/62/18403\" title=\"diagnostic image 3\">",
"      Ascariasis - computed tomography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?21/8/21647\" title=\"diagnostic image 4\">",
"      Biliary ascariasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/5673|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/45/15064\" title=\"figure 1\">",
"      Ascaris lumbricoides life cycle",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/5673|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/43/42673\" title=\"picture 1\">",
"      A lumbricoides adult worm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?38/30/39392\" title=\"picture 2\">",
"      Ascaris ovum in stool",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/43/23221?source=related_link\">",
"      Anthelminthic therapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/6/42087?source=related_link\">",
"      Endoscopic diagnosis and management of biliary parasitosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/25/11668?source=related_link\">",
"      Pulmonary manifestations of ascariasis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_8_16521="Levofloxacin (systemic): Drug information";
var content_f16_8_16521=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Levofloxacin (systemic): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?13/32/13830?source=see_link\">",
"    see \"Levofloxacin (systemic): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?23/13/23768?source=see_link\">",
"    see \"Levofloxacin (systemic): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F8398365\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8398376\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Levaquin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F8398377\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      APO-Levofloxacin;",
"     </li>",
"     <li>",
"      AVA-Levofloxacin;",
"     </li>",
"     <li>",
"      CO Levofloxacin;",
"     </li>",
"     <li>",
"      Levaquin&reg;;",
"     </li>",
"     <li>",
"      Mylan-Levofloxacin;",
"     </li>",
"     <li>",
"      Novo-Levofloxacin;",
"     </li>",
"     <li>",
"      PMS-Levofloxacin;",
"     </li>",
"     <li>",
"      Sandoz-Levofloxacin",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F8398383\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antibiotic, Quinolone;",
"     </li>",
"     <li>",
"      Respiratory Fluoroquinolone",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F8406522\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Sequential therapy (intravenous to oral) may be instituted based on prescriber's discretion.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Acute bacterial rhinosinusitis:",
"     </b>",
"     Oral, I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Manufacturer&rsquo;s recommendations: 750 mg every 24 hours for 5 days or 500 mg every 24 hours for 10-14 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Alternate recommendations: 500 mg every 24 hours for 5-7 days (Chow, 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Anthrax (inhalational):",
"     </b>",
"     Oral, I.V.: 500 mg every 24 hours for 60 days, beginning as soon as possible after exposure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Chlamydia trachomatis",
"      </i>",
"      sexually-transmitted infections (unlabeled use) (CDC, 2010):",
"     </b>",
"     Oral: 500 mg every 24 hours for 7 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Chronic bronchitis (acute bacterial exacerbation):",
"     </b>",
"     Oral: 500 mg every 24 hours for 7 days; Canadian labeling (not in U.S. labeling) also includes a dosage regimen of 750 mg every 24 hours for 5 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Diverticulitis, peritonitis (unlabeled use) (Solomkin, [IDSA] 2010):",
"     </b>",
"     Oral, I.V.: 750 mg every 24 hours for 7-10 days; use adjunctive metronidazole therapy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Epididymitis, nongonococcal (unlabeled use) (CDC, 2010):",
"     </b>",
"     Oral: 500 mg once daily for 10 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Gonococcal infection (unlabeled use) (CDC, 2010):",
"     </b>",
"     As of April 2007, the CDC no longer recommends the use of fluoroquinolones for the treatment of uncomplicated or more serious gonococcal disease, unless no other options exist and susceptibility can be confirmed via culture.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Intra-abdominal infection, complicated, community-acquired (in combination with metronidazole) (unlabeled use) (Solomkin, [IDSA] 2010):",
"     </b>",
"     I.V.: 750 mg once daily for 4-7 days (provided source controlled).",
"     <b>",
"      Note:",
"     </b>",
"     Avoid using in settings where",
"     <i>",
"      E. coli",
"     </i>",
"     susceptibility to fluoroquinolones is &lt;90%.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Pelvic inflammatory disease (unlabeled use) (CDC, 2010):",
"     </b>",
"     Oral: 500 mg once daily for 14 days with or without concomitant metronidazole;",
"     <b>",
"      Note:",
"     </b>",
"     The CDC recommends use as an alternative therapy only if standard parenteral cephalosporin therapy is not feasible and community prevalence of quinolone-resistant gonococcal organisms is low. Culture sensitivity must be confirmed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Plague (prophylaxis and treatment):",
"     </b>",
"     Oral, I.V.: 500 mg every 24 hours for 10-14 days, beginning as soon as possible after exposure.",
"     <b>",
"      Note:",
"     </b>",
"     Dose of 750 mg once daily may be considered if clinically warranted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Pneumonia:",
"     </b>",
"     Oral, I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Community-acquired (CAP):",
"     </i>",
"     500 mg every 24 hours for 7-14 days or 750 mg every 24 hours for 5 days (efficacy of 5-day regimen for MDRSP not established)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Healthcare-associated (HAP):",
"     </i>",
"     750 mg every 24 hours for 7-14 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Prostatitis (chronic bacterial):",
"     </b>",
"     Oral, I.V.: 500 mg every 24 hours for 28 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Skin and skin structure infections:",
"     </b>",
"     Oral, I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Uncomplicated:",
"     </i>",
"     500 mg every 24 hours for 7-10 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Complicated:",
"     </i>",
"     750 mg every 24 hours for 7-14 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Traveler's diarrhea (unlabeled use):",
"     </b>",
"     Oral: 500 mg for one dose (Sanders, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Tuberculosis, drug-resistant tuberculosis, or intolerance to first-line agents (unlabeled use):",
"     </b>",
"     Oral: 500-1000 mg every 24 hours (CDC, 2003)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Urethritis, nongonococcal (unlabeled use) (CDC, 2010):",
"     </b>",
"     Oral: 500 mg every 24 hours for 7 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Urinary tract infections:",
"     </b>",
"     Oral, I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Uncomplicated:",
"     </i>",
"     250 mg once daily for 3 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Complicated, including pyelonephritis:",
"     </i>",
"     250 mg once daily for 10 days",
"     <b>",
"      or",
"     </b>",
"     750 mg once daily for 5 days",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F8406521\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?23/13/23768?source=see_link\">",
"      see \"Levofloxacin (systemic): Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Acute bacterial rhinosinusitis (unlabeled use):",
"     </b>",
"     Oral, I.V.: 10-20 mg/kg/day divided every 12-24 hours for 10-14 days (maximum: 500 mg daily).",
"     <b>",
"      Note:",
"     </b>",
"     Recommended in patients with a type I penicillin allergy, after failure of initial therapy or in patients at risk for antibiotic resistance (eg, daycare attendance, age &lt;2 years, recent hospitalization, antibiotic use within the past month) (Chow, 2012).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Anthrax (inhalational, postexposure):",
"     </b>",
"     Oral, I.V.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Infants &ge;6 months and Children &le;50 kg: 8 mg/kg every 12 hours for 60 days (do not exceed 250 mg/dose), beginning as soon as possible after exposure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children &gt;50 kg: 500 mg every 24 hours for 60 days, beginning as soon as possible after exposure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Community-acquired pneumonia (CAP) (IDSA/PIDS, 2011):",
"     </b>",
"     <b>",
"      Note:",
"     </b>",
"     May consider addition of vancomycin or clindamycin to empiric therapy if community-acquired MRSA suspected; alternative to ceftriaxone or cefotaxime in patients not fully immunized for",
"     <i>",
"      H. influenzae",
"     </i>",
"     type b and",
"     <i>",
"      S. pneumoniae",
"     </i>",
"     , or significant local resistance to penicillin in invasive pneumococcal strains.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Infants &ge;6 months and Children &le;4 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <i>",
"      S. pneumoniae",
"     </i>",
"     (MICs to penicillin &le;2.0 mcg/mL), mild infection or step-down therapy (alternative to amoxicillin): Oral: 8-10 mg/kg/dose every 12 hours (maximum: 750 mg daily)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <i>",
"      S. pneumoniae",
"     </i>",
"     (MICs to penicillin &ge;4.0 mcg/mL):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Moderate-to-severe infection (alternative to ceftriaxone): I.V.: 8-10 mg/kg/dose every 12 hours (maximum: 750 mg daily)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Mild infection, step-down therapy (preferred): Oral: 8-10 mg/kg/dose every 12 hours (maximum: 750 mg daily)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <i>",
"      H. influenzae",
"     </i>",
"     , moderate-to-severe infection (alternative to ampicillin, ceftriaxone, or cefotaxime): I.V.: 8-10 mg/kg/dose every 12 hours (maximum: 750 mg daily)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Atypical pathogens, moderate-to-severe infection (alternative to azithromycin) or empiric treatment (alternative to azithromycin +/- beta-lactam; should be limited to macrolide allergic/intolerant patients): Oral, I.V.: 8-10 mg/kg/dose every 12 hours (maximum: 750 mg daily)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children 5-16 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <i>",
"      S. pneumoniae",
"     </i>",
"     (MICs to penicillin &le;2.0 mcg/mL), mild infection or step-down therapy (alternative to amoxicillin): Oral: 8-10 mg/kg/dose once daily (maximum: 750 mg daily)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <i>",
"      S. pneumoniae",
"     </i>",
"     (MICs to penicillin &ge;4.0 mcg/mL):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Moderate-to-severe infection (alternative to ceftriaxone): I.V.: 8-10 mg/kg/dose once daily (maximum: 750 mg daily)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Mild infection, step-down therapy (preferred): Oral: 8-10 mg/kg/dose once daily (maximum: 750 mg daily)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <i>",
"      H. influenzae",
"     </i>",
"     , moderate-to-severe infection (alternative to ampicillin, ceftriaxone, or cefotaxime): I.V.: 8-10 mg/kg/dose once daily (maximum: 750 mg daily)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Atypical pathogens:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Moderate-to-severe infection (alternative to azithromycin): Oral, I.V.: 8-10 mg/kg/dose once daily (maximum: 750 mg daily)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Mild infection, step-down therapy (alternative to azithromycin in adolescents with skeletal maturity): Oral: 500 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Plague (prophylaxis and treatment):",
"     </b>",
"     Oral, I.V.: Infants &ge;6 months and Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &le;50 kg: 8 mg/kg every 12 hours for 10-14 days (do not exceed 250 mg/dose), beginning as soon as possible after exposure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &gt;50 kg: 500 mg every 24 hours for 10-14 days, beginning as soon as possible after exposure.",
"     <b>",
"      Note:",
"     </b>",
"     Dose of 750 mg once daily may be considered if clinically warranted.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F8406523\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F8407064\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;display:inline\">",
"     I.V., Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Normal renal function dosing of 750 mg daily:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     20-49 mL/minute: Administer 750 mg every 48 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-19 mL/minute: Administer 750 mg initial dose, followed by 500 mg every 48 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hemodialysis/chronic ambulatory peritoneal dialysis (CAPD): Administer 750 mg initial dose, followed by 500 mg every 48 hours; supplemental doses are not required following either hemodialysis or CAPD.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Normal renal function dosing of 500 mg daily:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     20-49 mL/minute: Administer 500 mg initial dose, followed by 250 mg every 24 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-19 mL/minute: Administer 500 mg initial dose, followed by 250 mg every 48 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hemodialysis/chronic ambulatory peritoneal dialysis (CAPD): Administer 500 mg initial dose, followed by 250 mg every 48 hours; supplemental doses are not required following either hemodialysis or CAPD",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Normal renal function dosing of 250 mg daily:",
"    </p>",
"    <p style=\"text-indent:-4em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     20-49 mL/minute: No dosage adjustment required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-19 mL/minute: Administer 250 mg every 48 hours (except in uncomplicated UTI, where no dosage adjustment is required).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hemodialysis/chronic ambulatory peritoneal dialysis (CAPD): No information available.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Continuous renal replacement therapy (CRRT) (Heintz, 2009; Trotman, 2005): Drug clearance is highly dependent on the method of renal replacement, filter type, and flow rate. Appropriate dosing requires close monitoring of pharmacologic response, signs of adverse reactions due to drug accumulation, as well as drug concentrations in relation to target trough (if appropriate). The following are general recommendations only (based on dialysate flow/ultrafiltration rates of 1-2 L/hour and minimal residual renal function) and should not supersede clinical judgment:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     CVVH: Loading dose of 500-750 mg followed by 250 mg every 24 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     CVVHD: Loading dose of 500-750 mg followed by 250-500 mg every 24 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     CVVHDF: Loading dose of 500-750 mg followed by 250-750 mg every 24 hours.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15030188\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.V., Oral: No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied). However, dosage adjustment unlikely due to limited hepatic metabolism.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F8408135\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infusion, premixed in D",
"     <sub>",
"      5",
"     </sub>",
"     W [preservative free]: 250 mg (50 mL); 500 mg (100 mL); 750 mg (150 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Levaquin&reg;: 250 mg (50 mL); 500 mg (100 mL); 750 mg (150 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [preservative free]: 25 mg/mL (20 mL, 30 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral: 25 mg/mL (100 mL, 200 mL, 480 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Levaquin&reg;: 25 mg/mL (480 mL) [contains benzyl alcohol, propylene glycol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 250 mg, 500 mg, 750 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Levaquin&reg;: 250 mg, 500 mg, 750 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F8398378\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F8398367\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088619.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088619.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F8407067\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: Tablets may be administered without regard to meals. Oral solution should be administered 1 hour before or 2 hours after meals. Maintain adequate hydration of patient to prevent crystalluria.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.V.: Infuse 250-500 mg I.V. solution over 60 minutes; infuse 750 mg I.V. solution over 90 minutes. Too rapid of infusion can lead to hypotension. Avoid administration through an intravenous line with a solution containing multivalent cations (eg, magnesium, calcium). Maintain adequate hydration of patient to prevent crystalluria or cylindruria.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F8404709\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     LR, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS with 20 mEq/L KCl, D",
"     <sub>",
"      5",
"     </sub>",
"     W, NS, Plasma-Lyte&reg; 56 in 5% dextrose, sodium lactate (M/6);",
"     <b>",
"      incompatible",
"     </b>",
"     with mannitol 20%, sodium bicarbonate 5%.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Amikacin, aminophylline, ampicillin, anidulafungin, bivalirudin, caffeine citrate, cefotaxime, cimetidine, clindamycin, daptomycin, dexamethasone sodium phosphate, dexmedetomidine, dobutamine, dopamine, doripenem, epinephrine, fenoldopam, fentanyl, gentamicin, hetastarch in lactated electrolyte injection (Hextend&reg;), hydromorphone, isoproterenol, lidocaine, linezolid, lorazepam, magnesium sulfate, metoclopramide, metronidazole, morphine, octreotide, oxacillin, pancuronium, penicillin G sodium, phenobarbital, phenylephrine, potassium chloride, sodium bicarbonate, vancomycin.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Acyclovir, alprostadil, azithromycin, furosemide, heparin, indomethacin, nitroglycerin, nitroprusside, pantoprazole, propofol, telavancin.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Caspofungin, insulin (regular).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Incompatible:",
"     </b>",
"     Heparin.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F8400749\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     Treatment of community-acquired pneumonia, including multidrug resistant strains of",
"     <i>",
"      S. pneumoniae",
"     </i>",
"     (MDRSP); nosocomial pneumonia; chronic bronchitis (acute bacterial exacerbation); acute bacterial rhinosinusitis (ABRS); prostatitis (chronic bacterial), urinary tract infection (uncomplicated or complicated); acute pyelonephritis; skin or skin structure infections (uncomplicated or complicated); reduce incidence or disease progression of inhalational anthrax (postexposure); prophylaxis and treatment of plague (pneumonic and septicemic) due to",
"     <i>",
"      Y. pestis",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F8400750\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Diverticulitis, enterocolitis (",
"     <i>",
"      Shigella",
"     </i>",
"     spp), epididymitis (nongonococcal), urethritis (nongonococcal), complicated intra-abdominal infections (in combination with metronidazole), Legionnaires' disease, peritonitis, PID (alternative therapy); traveler&rsquo;s diarrhea; oral phase treatment of prosthetic joint infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     As of April 2007, the CDC no longer recommends the use of fluoroquinolones for the treatment of gonococcal disease due to increased prevalence of fluoroquinolone-resistant",
"     <i>",
"      Neisseria gonorrhoeae",
"     </i>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F8398366\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Levaquin&reg; may be confused with Levoxyl&reg;, Levsin/SL&reg;, Lovenox&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Levofloxacin may be confused with levETIRAcetam, levodopa, Levophed&reg;, levothyroxine",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F8401455\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Chest pain (1%), edema (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (6%), insomnia (4%), dizziness (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash (2%), pruritus (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (7%), diarrhea (5%), constipation (3%), abdominal pain (2%), dyspepsia (2%), vomiting (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Vaginitis (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Injection site reaction (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Dyspnea (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Moniliasis (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Abnormal taste, acute renal failure, agitation, agranulocytosis, alkaline phosphatase increased, altered sense of smell, allergic reaction (including anaphylaxis, angioedema,  rash, pneumonitis, and serum sickness); anaphylactoid reaction, anemia (including aplastic and hemolytic) anorexia, anxiety, arrhythmia (including ventricular tachycardia/fibrillation and torsade de pointes), arthralgia, bronchospasm, cardiac arrest,",
"     <i>",
"      C. difficile",
"     </i>",
"     -associated diarrhea (CDAD), confusion, depression, dysphonia, EEG abnormalities, encephalopathy (rare), eosinophilia, epistaxis, erythema multiforme, esophagitis, fever, gait abnormal, gastritis (including gastroenteritis), glossitis, granulocytopenia, hallucination, hepatic failure (some fatal), hepatic function abnormal, hepatitis, hyper-/hypoglycemia, hyperkalemia, hyperkinesias, hyper-/hypotension, hypertonia, hypoacusis, INR increased, intestinal obstruction, intracranial pressure increased, involuntary muscle contractions, jaundice, leukocytosis, leukopenia, leukorrhea, loss of taste perception, lymphadenopathy, multiple organ failure, muscle injury, myalgia, myasthenia gravis exacerbation, nephritis (interstitial), palpitation, pancreatitis, pancytopenia, paralysis, paranoia, paresthesia, peripheral neuropathy, phlebitis,photosensitivity/phototoxicity, pneumonitis, prothrombin time increased, pseudotumor cerebri, psychosis, QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation, renal function abnormal, rhabdomyolysis, seizure, skeletal pain, skin disorder, sleep disorders (including abnormal dreams and nightmares) somnolence, Stevens-Johnson syndrome, stomatitis, suicide attempt/ideation, syncope, tachycardia, tendonitis, tendon rupture, tinnitus, toxic epidermal necrolysis, transaminases increased, thrombocytopenia, tremor, urticaria, vasculitis (leukocytoclastic), vasodilatation, vertigo, visual disturbances",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F8401447\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to levofloxacin, any component of the formulation, or other quinolones",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Canadian labeling: Additional contraindications (not in U.S. labeling): History of tendonitis or tendon rupture associated with use of any quinolone antimicrobial agent",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F8401448\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Altered cardiac conduction: Fluoroquinolones may prolong QT",
"     <sub>",
"      c",
"     </sub>",
"     interval; avoid use in patients with a history of QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation, uncorrected hypokalemia, hypomagnesemia, or concurrent administration of other medications known to prolong the QT interval (including Class Ia and Class III antiarrhythmics, cisapride, erythromycin, antipsychotics, and tricyclic antidepressants).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS effects:Toxic psychosis, increased intracranial pressure (including pseudotumor cerebri), tremor, restlessness, confusion, and very rarely hallucinations or seizures may occur; use with caution in patients with known or suspected CNS disorder. Discontinue in patients who experience significant CNS adverse effects (eg, dizziness, hallucinations, suicidal ideations or actions).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Glucose regulation: Fluoroquinolones have been associated with the development of serious, and sometimes fatal, hypoglycemia. These events have occurred most often in elderly patients with diabetes, but have also been reported in patients without a prior history of diabetes. Prompt identification and treatment of hypoglycemia is essential. Individual quinolones may differ in their potential to cause this effect. It was most evident with gatifloxacin (no longer marketed as systemic formulation). Hyperglycemia has also been associated with the use of fluoroquinolones. Patients should be monitored closely for signs/symptoms of disordered glucose regulation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatotoxicity: Unrelated to hypersensitivity, severe hepatotoxicity (including acute hepatitis and fatalities) has been reported. Elderly patients may be at greater risk. Discontinue therapy immediately if signs and symptoms of hepatitis occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reactions: Severe hypersensitivity reactions, including anaphylaxis, have occurred with quinolone therapy. The spectrum of these reactions can vary widely; reactions may present as typical allergic symptoms (eg, itching, urticaria, rash, edema) after a single dose, or may manifest as severe idiosyncratic dermatologic (eg, Stevens-Johnson, toxic epidermal necrolysis), vascular (eg, vasculitis), pulmonary (eg, pneumonitis), renal (eg, nephritis), hepatic (eg, hepatic failure or necrosis), and/or hematologic (eg, anemia, cytopenias) events, usually after multiple doses. Prompt discontinuation of drug should occur if skin rash or other symptoms arise.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Peripheral neuropathy: The use of quinolones has been linked to peripheral neuropathy (rare); discontinue if symptoms of sensory or sensorimotor neuropathy occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Phototoxicity: Avoid excessive sunlight and take precautions to limit exposure (eg, loose fitting clothing, sunscreen); may cause moderate-to-severe phototoxicity reactions. Discontinue use if photosensitivity occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including",
"     <i>",
"      C. difficile",
"     </i>",
"     -associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Tendon inflammation/rupture:",
"     <b>",
"      [U.S. Boxed Warning]: There have been reports of tendon inflammation and/or rupture with quinolone antibiotics; risk may be increased with concurrent corticosteroids, organ transplant recipients, and in patients &gt;60 years of age.",
"     </b>",
"     Rupture of the Achilles tendon sometimes requiring surgical repair has been reported most frequently; but other tendon sites (eg, rotator cuff, biceps) have also been reported. Strenuous physical activity may be an independent risk factor for tendonitis. Discontinue at first sign of tendon inflammation or pain. May occur even after discontinuation of therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myasthenia gravis:",
"     <b>",
"      [U.S. Boxed Warning]: May exacerbate muscle weakness related to myasthenia gravis.",
"     </b>",
"     Cases of severe exacerbations, including the need for ventilatory support and deaths have been reported; avoid use in patients with myasthenia gravis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; dosage adjustment required. May increase risk of tendon rupture.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Rheumatoid arthritis: Use with caution in patients with rheumatoid arthritis; may increase risk of tendon rupture.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizures: Use with caution in individuals at risk of seizures (CNS disorders or concurrent therapy with medications which may lower seizure threshold). Potential for seizures, although very rare, may be increased with concomitant NSAID therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Adverse effects (eg, hepatotoxicity, tendon rupture, QT changes) may be increased in the elderly.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; G6PD deficiency: Hemolytic reactions may (rarely) occur with quinolone use in patients with latent or actual G6PD deficiency.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Safety of use in pediatric patients for &gt;14 days of therapy has not been studied; increased incidence of musculoskeletal disorders (eg, arthralgia, tendon rupture) has been observed in children.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299595\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F8401459\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the absorption of Quinolone Antibiotics. Of concern only with oral administration of quinolones.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Sodium Bicarbonate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Salts: May decrease the absorption of Quinolone Antibiotics. Of concern only with oral administration of both agents.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Calcium Chloride.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): Quinolone Antibiotics may enhance the adverse/toxic effect of Corticosteroids (Systemic). Risk of tendon-related side effects, including tendonitis and rupture, may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Didanosine: May decrease the serum concentration of Quinolone Antibiotics. Quinolone Antibiotics may decrease the serum concentration of Didanosine. Management: Administer oral quinolones at least 2 hours before or 6 hours after didanosine. Monitor for decreased therapeutic effects of quinolones, particularly if doses cannot be separated as recommended. This does not apply to unbuffered enteric coated didanosine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: Moderate Risk QTc-Prolonging Agents may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Insulin: May enhance the hyperglycemic effect of Quinolone Antibiotics. Insulin may enhance the hypoglycemic effect of Quinolone Antibiotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iron Salts: May decrease the absorption of Quinolone Antibiotics. Of concern only with oral administration of both agents.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ferric Gluconate; Ferumoxytol; Iron Dextran Complex; Iron Sucrose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lanthanum: May decrease the serum concentration of Quinolone Antibiotics. Management: Administer oral quinolone antibiotics at least two hours before or after lanthanum.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Salts: May decrease the absorption of Quinolone Antibiotics. Of concern only with oral administration of both agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: May enhance the QTc-prolonging effect of other Moderate Risk QTc-Prolonging Agents. Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May decrease the serum concentration of Quinolone Antibiotics. Specifically, polyvalent cations in multivitamin products may decrease the absorption of orally administered quinolone antibiotics. Management: Interactions can be minimized by administering the oral quinolone at least 2 hours before, or 6 hours after, the dose of a multivitamin that contains polyvalent cations (i.e., calcium, iron, magnesium, selenium, zinc).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mycophenolate: Quinolone Antibiotics may decrease the serum concentration of Mycophenolate. Specifically, quinolones may decrease concentrations of the active metabolite of mycophenolate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May enhance the neuroexcitatory and/or seizure-potentiating effect of Quinolone Antibiotics. Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Quinolone Antibiotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase the serum concentration of Quinolone Antibiotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinapril: May decrease the serum concentration of Quinolone Antibiotics. Management: Separate doses of quinapril and oral quinolones by at least 2 hours in order to reduce the risk of interaction. Monitor for reduced efficacy of the quinolone if these products are used concomitantly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sevelamer: May decrease the absorption of Quinolone Antibiotics.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Strontium Ranelate: May decrease the serum concentration of Quinolone Antibiotics. Management: In order to minimize any potential impact of strontium ranelate on quinolone antibiotic concentrations, it is recommended that strontium ranelate treatment be interrupted during quinolone therapy.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sucralfate: May decrease the serum concentration of Quinolone Antibiotics. Management: Administer oral quinolones at least 2 hours before or 6 hours after the sucralfate dose.  Greater separation of doses may further lessen the risk for a significant interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sulfonylureas: Quinolone Antibiotics may enhance the hypoglycemic effect of Sulfonylureas. This appears to be particularly concerning early in the course of combination therapy. Quinolone Antibiotics may diminish the hypoglycemic effect of Sulfonylureas. With longer-term combination, there is a greater risk of hyperglycemia.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 24 hours after cessation of antibacterial agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Varenicline: Quinolone Antibiotics may increase the serum concentration of Varenicline.  Management: Monitor for increased varenicline adverse effects with concurrent use of levofloxacin or other quinolone antibiotics, particularly in patients with severe renal impairment. International product labeling recommendations vary. Consult appropriate labeling.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Quinolone Antibiotics may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zinc Salts: May decrease the absorption of Quinolone Antibiotics. Of concern only with oral administration of both agents.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Zinc Chloride.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F8400751\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F8400752\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed in some animal studies; therefore, the manufacturer classifies levofloxacin as pregnancy category C. Levofloxacin crosses the placenta. Quinolone exposure during human pregnancy has been reported with other agents (see  Ciprofloxacin [Systemic], Ofloxacin [Systemic], and Norfloxacin [Systemic] monographs). To date, no specific teratogenic effect or increased pregnancy risk has been identified; however, because of concerns of cartilage damage in immature animals exposed to quinolones and the limited levofloxacin specific data, levofloxacin should only be used during pregnancy if a safer option is not available.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F8400755\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F8401446\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Based on data from a case report, small amounts of levofloxacin are excreted in breast milk. Breast-feeding is not recommended by the manufacturer. Levofloxacin is the L-isomer of ofloxacin. Ofloxacin has also been shown to have minimal concentrations in human milk. Nondose-related effects could include modification of bowel flora.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F8407066\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Tablets may be taken without regard to meals. Oral solution should be administered on an empty stomach (1 hour before or 2 hours after a meal). Take 2 hours before or 2 hours after multiple vitamins, antacids, or other products containing magnesium, aluminum, iron, or zinc.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F8408137\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Levaquin Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250 mg/50 mL (50 mL): $11.10",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg/100 mL (100 mL): $21.90",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     750 mg/150 mL (150 mL): $29.10",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Levaquin Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg/mL (480 mL): $775.38",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Levofloxacin in D5W Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250 mg/50 mL (50 mL): $8.40",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg/100 mL (100 mL): $13.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     750 mg/150 mL (150 mL): $13.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Levofloxacin Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg/mL (20 mL): $19.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Levofloxacin Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg/mL (200 mL): $254.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Levaquin Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250 mg (50): $1129.27",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (50): $1294.24",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     750 mg (20): $969.41",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Levofloxacin Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250 mg (50): $841.48",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (50): $964.40",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     750 mg (100): $2921.60",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F8407071\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Evaluation of organ system functions (renal, hepatic, and hematopoietic) is recommended periodically during therapy; the possibility of crystalluria should be assessed; WBC and signs of infection",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F10961985\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Adlox (IN);",
"     </li>",
"     <li>",
"      Auxxil (CN);",
"     </li>",
"     <li>",
"      Axoflon (PH);",
"     </li>",
"     <li>",
"      Bacflocin (TW);",
"     </li>",
"     <li>",
"      Corvox (ID);",
"     </li>",
"     <li>",
"      Cravit (CL, HK, ID, JP, MY, PK, SG, TH, TW);",
"     </li>",
"     <li>",
"      Cravox (ID);",
"     </li>",
"     <li>",
"      Elequine (BB, BM, BS, EC, JM, NL, PR, SR, TT);",
"     </li>",
"     <li>",
"      Floxacap (ID);",
"     </li>",
"     <li>",
"      Floxel (PH);",
"     </li>",
"     <li>",
"      Glevo IV (PH);",
"     </li>",
"     <li>",
"      Hailun (CL);",
"     </li>",
"     <li>",
"      Lecrav (ID);",
"     </li>",
"     <li>",
"      Leflodal (TW);",
"     </li>",
"     <li>",
"      Lefloxin (TH);",
"     </li>",
"     <li>",
"      Lefocin (KP);",
"     </li>",
"     <li>",
"      Leroxacin (KP);",
"     </li>",
"     <li>",
"      Lesacin (KP);",
"     </li>",
"     <li>",
"      Levaquin (AR, BR, CO, PE);",
"     </li>",
"     <li>",
"      Levo (IL);",
"     </li>",
"     <li>",
"      Levobact (PH);",
"     </li>",
"     <li>",
"      Levocin (ID, PH, TH);",
"     </li>",
"     <li>",
"      Levokacin (KP);",
"     </li>",
"     <li>",
"      Levomicin (KP);",
"     </li>",
"     <li>",
"      Levoquin (PH);",
"     </li>",
"     <li>",
"      Levores (ID);",
"     </li>",
"     <li>",
"      Levox (PH);",
"     </li>",
"     <li>",
"      Levoxacin (IT);",
"     </li>",
"     <li>",
"      Levoxin (HK);",
"     </li>",
"     <li>",
"      Levunid (PE);",
"     </li>",
"     <li>",
"      Lovequin (ID);",
"     </li>",
"     <li>",
"      Mosardal (ID);",
"     </li>",
"     <li>",
"      Nislev (ID);",
"     </li>",
"     <li>",
"      Nofaxin (KP);",
"     </li>",
"     <li>",
"      Olfovel (TH);",
"     </li>",
"     <li>",
"      Omnivox (PH);",
"     </li>",
"     <li>",
"      Pneumocal (PH);",
"     </li>",
"     <li>",
"      Ponaris (PE);",
"     </li>",
"     <li>",
"      Quinomed L (AR);",
"     </li>",
"     <li>",
"      Reskuin (ID);",
"     </li>",
"     <li>",
"      Rinvox (ID);",
"     </li>",
"     <li>",
"      Rozoxin (TW);",
"     </li>",
"     <li>",
"      Tavanic (AR, AT, BE, BG, BM, BS, CH, CN, CR, CZ, DE, DO, EE, FI, FR, GB, GT, HN, IE, IL, JM, NI, NL, PA, PE, PT, PY, SE, SV, VE);",
"     </li>",
"     <li>",
"      Truxa (EC, UY);",
"     </li>",
"     <li>",
"      Volequin (ID);",
"     </li>",
"     <li>",
"      VoLox (ID);",
"     </li>",
"     <li>",
"      Vorotal (TW);",
"     </li>",
"     <li>",
"      Wilovex (PH);",
"     </li>",
"     <li>",
"      Zidalex (ID)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F8404710\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     As the S(-) enantiomer of the fluoroquinolone, ofloxacin, levofloxacin, inhibits DNA-gyrase in susceptible organisms thereby inhibits relaxation of supercoiled DNA and promotes breakage of DNA strands. DNA gyrase (topoisomerase II), is an essential bacterial enzyme that maintains the superhelical structure of DNA and is required for DNA replication and transcription, DNA repair, recombination, and transposition.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F8404755\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Rapid and complete",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 74-112 L; CSF concentrations ~15% of serum levels; high concentrations are achieved in prostate, lung, and gynecological tissues, sinus, saliva",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: ~24% to 38%; primarily to albumin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Minimally hepatic",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: ~99%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: ~6-8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: Oral: 1-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (~87% as unchanged drug, &lt;5% as metabolites); feces (&lt;4%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Transfer of Drugs and Other Chemicals Into Human Milk,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/8/16521/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Thoracic Society and Infectious Diseases Society of America, &ldquo;Guidelines for the Management of Adults With Hospital-Acquired, Ventilator-Associated, and Healthcare-Associated Pneumonia,&rdquo;",
"      <i>",
"       Am J Respir Crit Care Med",
"      </i>",
"      , 2005, 171(4):388-416.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/8/16521/abstract-text/15699079/pubmed\" id=\"15699079\" target=\"_blank\">",
"        15699079",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bradley JS, Byington CL, Shah SS, et al.  &ldquo;The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America&rdquo;,",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2011, 53(7):e25-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/8/16521/abstract-text/21880587/pubmed\" id=\"21880587\" target=\"_blank\">",
"        21880587",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bratzler DW, Dellinger EP, Olsen KM, et al, &ldquo;Clinical Practice Guidelines for Antimicrobial Prophylaxis in Surgery,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 2013, 70(3):195-283.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/8/16521/abstract-text/23327981/pubmed\" id=\"23327981\" target=\"_blank\">",
"        23327981",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Sexually Transmitted Diseases Treatment Guidelines, 2010,\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2010, 59(RR-12):1-110.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/8/16521/abstract-text/21160459/pubmed\" id=\"21160459\" target=\"_blank\">",
"        21160459",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention, \"Sexually Transmitted Diseases Treatment Guidelines, 2006,\"",
"      <i>",
"       MMWR",
"      </i>",
"      , 2006, 55(RR-11): 1-94.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/8/16521/abstract-text/16760892/pubmed\" id=\"16760892\" target=\"_blank\">",
"        16760892",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention, &ldquo;Treatment of Tuberculosis. American Thoracic Society, CDC, and Infectious Diseases Society of America,&rdquo; 2003,",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 52(RR-11):3-5. Available at",
"      <a href=\"file://www.cdc.gov/mmwr/preview/mmwrhtml/rr5211a1.htm\" target=\"_blank\">",
"       file://www.cdc.gov/mmwr/preview/mmwrhtml/rr5211a1.htm",
"      </a>",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/8/16521/abstract-text/12836625/pubmed\" id=\"12836625\" target=\"_blank\">",
"        12836625",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease  Control and Prevention, &ldquo;Update to CDC's Sexually Transmitted Diseases Treatment Guidelines, 2006: Fluoroquinolones No Longer Recommended for Treatment of Gonococcal Infections,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2007, 56(14):332-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/8/16521/abstract-text/17431378/pubmed\" id=\"17431378\" target=\"_blank\">",
"        17431378",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chey WD and Wong B, &ldquo;American College of Gastroenterology Guideline on the Management of",
"      <i>",
"       Helicobacter pylori",
"      </i>",
"      Infection,&rdquo;",
"      <i>",
"       Am J Gastroenterol",
"      </i>",
"      , 2007 102(8):1808-25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/8/16521/abstract-text/17608775/pubmed\" id=\"17608775\" target=\"_blank\">",
"        17608775",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chow AW, Benninger MS, Brook I, et al, &ldquo;IDSA Clinical Practice Guideline for Acute Bacterial Rhinosinusitis in Children and Adults,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2012, 54(8):e72-112.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/8/16521/abstract-text/22438350/pubmed\" id=\"22438350\" target=\"_blank\">",
"        22438350",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Friedrich LV and Dougherty R, &ldquo;Fatal Hypoglycemia Associated With Levofloxacin,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2004, 24(12):1807-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/8/16521/abstract-text/15585448/pubmed\" id=\"15585448\" target=\"_blank\">",
"        15585448",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Frothingham R, &ldquo;Glucose Homeostasis Abnormalities Associated With Use of Gatifloxacin,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2005, 41(9):1269-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/8/16521/abstract-text/16206101/pubmed\" id=\"16206101\" target=\"_blank\">",
"        16206101",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gavin JR 3rd, Kubin R, Choudhri S, et al, &ldquo;Moxifloxacin and Glucose Homeostasis: A Pooled-Analysis of the Evidence From Clinical and Postmarketing Studies,&rdquo;",
"      <i>",
"       Drug Saf",
"      </i>",
"      , 2004, 27(9):671-86.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/8/16521/abstract-text/15230648/pubmed\" id=\"15230648\" target=\"_blank\">",
"        15230648",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Graumlich JF, Habis S, Avelino RR, et al, &ldquo;Hypoglycemia in Inpatients After Gatifloxacin or Levofloxacin Therapy: Nested Case-Control Study,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2005, 25(10):1296-302.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/8/16521/abstract-text/16185172/pubmed\" id=\"16185172\" target=\"_blank\">",
"        16185172",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Heintz BH, Matzke GR, Dager WE, &ldquo;Antimicrobial Dosing Concepts and Recommendations for Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy or Intermittent Hemodialysis,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2009, 29(5):562-77.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/8/16521/abstract-text/19397464/pubmed\" id=\"19397464\" target=\"_blank\">",
"        19397464",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Khaliq Y and Zhanel GG, &ldquo;Fluoroquinolone-Associated Tendinopathy: A Critical Review of the Literature,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2003, 36(11):1404-10.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/8/16521/abstract-text/12766835/pubmed\" id=\"12766835\" target=\"_blank\">",
"        12766835",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lawrence KR, Adra M, and Keir C, &ldquo;Hypoglycemia-Induced Anoxic Brain Injury Possibly Associated With Levofloxacin,&rdquo;",
"      <i>",
"       J Infect",
"      </i>",
"      , 2006, 52(6):e177-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/8/16521/abstract-text/16269178/pubmed\" id=\"16269178\" target=\"_blank\">",
"        16269178",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lipsky BA, Berendt AR, Cornia PB, et al, \"2012 Infectious Diseases Society of America Clinical Practice Guideline for the Diagnosis and Treatment of Diabetic Foot Infections,\"",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2012, 54(12):e132-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/8/16521/abstract-text/22619242/pubmed\" id=\"22619242\" target=\"_blank\">",
"        22619242",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Malone RS, Fish DN, Abraham E, et al, &ldquo;Pharmacokinetics of Levofloxacin and Ciprofloxacin During Continuous Renal Replacement Therapy in Critically Ill Patients,&rdquo;",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 2001, 45(10):2949-54.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/8/16521/abstract-text/11557500/pubmed\" id=\"11557500\" target=\"_blank\">",
"        11557500",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mohr JF, McKinnon PS, Peymann PJ, et al, &ldquo;A Retrospective, Comparative Evaluation of Dysglycemias in Hospitalized Patients Receiving Gatifloxacin, Levofloxacin, Ciprofloxacin, or Ceftriaxone,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2005, 25(10):1303-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/8/16521/abstract-text/16185173/pubmed\" id=\"16185173\" target=\"_blank\">",
"        16185173",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nicolle LN, Bradley S, Colgan R et al, &ldquo;Infectious Disease Society of America Guidelines for the Diagnosis and Treatment of Asymptomatic Bacteriuria in Adults,&rdquo;",
"      <i>",
"       Clinical Infectious Diseases",
"      </i>",
"      , 2005, 40:643-54.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/8/16521/abstract-text/15714408/pubmed\" id=\"15714408\" target=\"_blank\">",
"        15714408",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Osmon DR, Berbari EF, Berendt AR, et al, &ldquo;Diagnosis and Management of Prosthetic Joint Infection: Clinical Practice Guideline by the Infectious Diseases Society of America,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2013, 56(1):e1-25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/8/16521/abstract-text/23223583/pubmed\" id=\"23223583\" target=\"_blank\">",
"        23223583",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Park-Wyllie LY, Juurlink DN, Kopp A, et al, &ldquo;Outpatient Gatifloxacin Therapy and Dysglycemia in Older Adults,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2006, 354(13):1352-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/8/16521/abstract-text/16510739/pubmed\" id=\"16510739\" target=\"_blank\">",
"        16510739",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sanders JW, Frenck RW, Putnam SD, et al, &ldquo;Azithromycin and Loperamide are Comparable to Levofloxacin and Loperamide for the Treatment of Traveler&rsquo;s Diarrhea in United States Military Personnel in Turkey,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2007, 45(3):294-301.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/8/16521/abstract-text/18688944/pubmed\" id=\"18688944\" target=\"_blank\">",
"        18688944",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Solomkin JS, Mazuski JE, Bradley JS, et al, &ldquo;Diagnosis and Management of Complicated Intra-Abdominal Infections in Adults and Children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      ,  2010, 50(2):133-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/8/16521/abstract-text/20034345/pubmed\" id=\"20034345\" target=\"_blank\">",
"        20034345",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Szarfman A, Chen M, and Blum MD, &ldquo;More on Fluoroquinolone Antibiotics and Tendon Rupture,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1995, 332(3):193.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Trotman RL, Williamson JC, Shoemaker DM, et al, &ldquo;Antibiotic Dosing in Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2005, 41(8):1159-66.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/8/16521/abstract-text/16163635/pubmed\" id=\"16163635\" target=\"_blank\">",
"        16163635",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wang S and Rizvi AA, &ldquo;Levofloxacin-Induced Hypoglycemia in a Nondiabetic Patient,&rdquo;",
"      <i>",
"       Am J Med Sci",
"      </i>",
"      , 2006, 331(6):334-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/8/16521/abstract-text/16775443/pubmed\" id=\"16775443\" target=\"_blank\">",
"        16775443",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Zacher JL and Givone DM, &ldquo;False-Positive Urine Opiate Screening Associated With Fluoroquinolone Use,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2004, 38:1525-28.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/8/16521/abstract-text/15252190/pubmed\" id=\"15252190\" target=\"_blank\">",
"        15252190",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10214 Version 51.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-222.190.118.195-812927D4EA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_8_16521=[""].join("\n");
var outline_f16_8_16521=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8398365\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8398376\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8398377\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8398383\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8406522\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8406521\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8406523\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8407064\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15030188\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8408135\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8398378\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8398367\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8407067\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8404709\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8400749\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8400750\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8398366\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8401455\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8401447\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8401448\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299595\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8401459\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8400751\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8400752\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8400755\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8401446\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8407066\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8408137\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8407071\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10961985\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8404710\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8404755\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10214\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10214|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?36/11/37043?source=related_link\">",
"      Levofloxacin (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?23/63/24564?source=related_link\">",
"      Levofloxacin (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/11/5299?source=related_link\">",
"      Levofloxacin (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?13/32/13830?source=related_link\">",
"      Levofloxacin (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?23/13/23768?source=related_link\">",
"      Levofloxacin (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_8_16522="Management of cutaneous sarcoidosis";
var content_f16_8_16522=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of cutaneous sarcoidosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/8/16522/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/8/16522/contributors\">",
"     Steven Prystowsky, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/8/16522/contributors\">",
"     Miguel Sanchez, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/8/16522/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/8/16522/contributors\">",
"     Jeffrey Callen, MD, FACP, FAAD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/8/16522/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/8/16522/contributors\">",
"     Abena O Ofori, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?16/8/16522/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 3, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H323808\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sarcoidosis is a multisystem granulomatous disorder characterized by the presence of noncaseating granulomas in tissue. Skin involvement is common, and a variety of therapeutic interventions have been utilized for the treatment of cutaneous disease. When managing patients with cutaneous sarcoidosis, clinicians must first consider whether treatment is indicated. The options available for the treatment of skin lesions include both local and systemic therapies.",
"   </p>",
"   <p>",
"    The treatment of the cutaneous manifestations of sarcoidosis will be reviewed here. The clinical manifestations of cutaneous sarcoidosis and the management of other forms of sarcoidosis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/20/19786?source=see_link\">",
"     \"Cutaneous manifestations of sarcoidosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/43/11961?source=see_link\">",
"     \"Treatment of pulmonary sarcoidosis with glucocorticoids\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/11/38074?source=see_link\">",
"     \"Treatment of pulmonary sarcoidosis with alternatives to glucocorticoids\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/19/17722?source=see_link\">",
"     \"Cardiac sarcoidosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/8/20616?source=see_link\">",
"     \"Neurologic sarcoidosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/31/40438?source=see_link\">",
"     \"Renal disease in sarcoidosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/14/17638?source=see_link\">",
"     \"Gastrointestinal sarcoidosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/12/11463?source=see_link\">",
"     \"Sarcoid arthropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16711891\">",
"    <span class=\"h1\">",
"     APPROACH TO THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although cutaneous sarcoidosis is not life-threatening and leads to physical impairment in only a minority of patients, the psychological and social impact of disease can be devastating, supporting the need for treatment. In general, treatment is indicated in patients with cosmetically disfiguring, symptomatic, ulcerating, or progressively worsening skin disease.",
"   </p>",
"   <p>",
"    However, the decision to treat is complicated by the unpredictable course of the disease (which includes the possibility for spontaneous remission in up to two-thirds of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16522/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]), variability in the response to treatment, and the severe adverse effects associated with some therapies. In patients with stable, asymptomatic disease that is not associated with cosmetic disfigurement, forgoing treatment is reasonable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3545700\">",
"    <span class=\"h2\">",
"     Choice of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;When cutaneous lesions are the only indication for treatment of sarcoidosis, the risks and benefits of treatment must be considered carefully. Few randomized trials have evaluated the efficacy of therapies for cutaneous sarcoidosis, and data on the various treatment options are primarily limited to the results of small uncontrolled prospective studies, retrospective analyses, and case reports [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16522/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite the lack of high quality evidence to support their efficacy, the relative safety of topical and intralesional corticosteroids has led to the frequent use of these agents as first-line therapy for cutaneous lesions. However, local therapy can be impractical to administer in patients with extensive lesions, and intralesional injection of sensitive areas such as the nose can be difficult for some patients to tolerate. In addition, our clinical experience indicates that many patients fail to achieve complete responses with local therapy alone. We consider treatment with systemic agents in patients who cannot be managed solely with local therapy. (See",
"    <a class=\"local\" href=\"#H16711898\">",
"     'First line agents'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Common systemic agents utilized for the treatment of cutaneous sarcoidosis include systemic glucocorticoids, antimalarial agents (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25447?source=see_link\">",
"     chloroquine",
"    </a>",
"    ), and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    . Although all of these agents appear to be useful for cutaneous sarcoidosis, the efficacies of these drugs have not been directly compared. Thus, the selection of the most appropriate systemic agent primarily is made based upon consideration of factors such as patient acceptance of the treatment regimen, drug monitoring requirements, and drug adverse effects. Due to the multiple side effects associated with long-term systemic glucocorticoids, antimalarial agents and methotrexate are often used in conjunction or in place of systemic glucocorticoids as glucocorticoid-sparing agents. (See",
"    <a class=\"local\" href=\"#H8964990\">",
"     'Second line agents'",
"    </a>",
"    below.)",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/10/3240?source=see_link\">",
"     Minocycline",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    have also been utilized for the treatment of cutaneous sarcoidosis, although there are few data to support their efficacy. The relatively favorable side effect profiles of these agents have contributed to their status as alternative systemic medications for cutaneous sarcoidosis. (See",
"    <a class=\"local\" href=\"#H8966978\">",
"     'Tetracycline derivatives'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    For patients who fail to improve adequately with local therapy, systemic glucocorticoids, antimalarials, or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    is a therapeutic option.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     Infliximab",
"    </a>",
"    also has been utilized for patients with refractory cutaneous sarcoidosis; however, there are conflicting data on its efficacy. A variety of other interventions, including alternative systemic agents, phototherapy, and laser therapy have been reported to be effective in small numbers of patients. Additional studies are necessary to explore the efficacy and safety of treatments for cutaneous sarcoidosis. (See",
"    <a class=\"local\" href=\"#H8965978\">",
"     'Refractory disease'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3545693\">",
"    <span class=\"h2\">",
"     Specific variants",
"    </span>",
"    &nbsp;&mdash;&nbsp;The best approach to management for specific variants of cutaneous sarcoidosis remains unclear. Treatment of lupus pernio almost always is required due to its disfiguring nature, and the efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    in lupus pernio has been evaluated in a randomized trial [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16522/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Treatment data for other variants of cutaneous sarcoidosis are more limited [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16522/abstract/7-11\">",
"     7-11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/20/19786?source=see_link&amp;anchor=H18191778#H18191778\">",
"     \"Cutaneous manifestations of sarcoidosis\", section on 'Clinical manifestations'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H16711999\">",
"     'Infliximab'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16711898\">",
"    <span class=\"h1\">",
"     FIRST LINE AGENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Formal studies of local therapies for cutaneous sarcoidosis are limited, and the widespread use of topical and intralesional corticosteroids for this disease primarily is based upon clinical experience. The relative safety of topical corticosteroids and intralesional corticosteroids is a characteristic that favors their use as first-line agents. Local corticosteroid therapy also may be used as an adjunctive intervention in patients who achieve only partial responses to systemic medications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16714853\">",
"    <span class=\"h2\">",
"     Topical corticosteroids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Superpotent topical corticosteroids are widely used for the treatment of cutaneous sarcoidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16522/abstract/12-15\">",
"     12-15",
"    </a>",
"    ]. In an uncontrolled study that included patients with a variety of chronic skin diseases, once-weekly application of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/16/10502?source=see_link\">",
"     clobetasol",
"    </a>",
"    propionate lotion under a hydrocolloid dressing led to improvement in sarcoidal papules in all three patients with cutaneous sarcoidosis within three to five weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16522/abstract/16\">",
"     16",
"    </a>",
"    ]. In a separate case report, application of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/44/9925?source=see_link\">",
"     halobetasol",
"    </a>",
"    propionate 0.05% ointment twice daily for 10 weeks led to considerable flattening of lesions of lupus pernio [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16522/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We typically instruct patients to apply",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/16/10502?source=see_link\">",
"     clobetasol",
"    </a>",
"    propionate or another superpotent topical corticosteroid (",
"    <a class=\"graphic graphic_table graphicRef62402 \" href=\"UTD.htm?38/56/39809\">",
"     table 1",
"    </a>",
"    ) to skin lesions twice daily or once daily with occlusion. Because the risk for corticosteroid-induced cutaneous atrophy rises with drug potency, and atrophy is more likely to occur on the face than on the trunk or extremities, we frequently utilize medium potency agents (group IV) when treating facial lesions. An exception to this practice is lupus pernio, which we have found usually requires the application of high potency agents.",
"   </p>",
"   <p>",
"    We follow patients every two weeks to assess response and to evaluate for signs of atrophy. If there is no improvement after four weeks, we discontinue topical corticosteroids and initiate treatment with intralesional corticosteroids or systemic therapy.",
"   </p>",
"   <p>",
"    Advantages of topical corticosteroids include their relative safety, ease of use, and lack of pain associated with administration. However, in our experience, topical corticosteroid monotherapy often fails to achieve complete lesion resolution without simultaneously inducing cutaneous atrophy. In addition, we have noted that intralesional therapy appears to be more effective than topical therapy for lupus pernio and other thick or nodular lesions, a finding that is likely related to insufficient drug penetration.",
"   </p>",
"   <p>",
"    Topical corticosteroid use can result in suppression of the hypothalamic-pituitary-adrenal axis, particularly when high potency agents are utilized and large areas of skin are treated. The local and systemic adverse effects of topical corticosteroids are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/6/27752?source=see_link&amp;anchor=H16#H16\">",
"     \"General principles of dermatologic therapy and topical corticosteroid use\", section on 'Side effects'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16711906\">",
"    <span class=\"h2\">",
"     Intralesional corticosteroids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although data on the use of intralesional corticosteroids for cutaneous sarcoidosis are limited to case series and case reports [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16522/abstract/18-20\">",
"     18-20",
"    </a>",
"    ], it is generally accepted that intralesional injection of corticosteroids can lead to flattening or resolution of cutaneous lesions. As with topical corticosteroids, intralesional corticosteroids are often used in combination with systemic agents [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16522/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/38/39520?source=see_link\">",
"     Triamcinolone",
"    </a>",
"    acetonide, an intermediate-acting corticosteroid, is preferred for intralesional injection due to its availability as a suspension, drug potency, low induction of pain with injection, and fairly long duration of action [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16522/abstract/22\">",
"     22",
"    </a>",
"    ]. Concentrations of triamcinolone acetonide between 3 and 10",
"    <span class=\"nowrap\">",
"     mg/mL",
"    </span>",
"    are usually injected every three to four weeks until lesion resolution [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16522/abstract/18,20\">",
"     18,20",
"    </a>",
"    ]. Higher concentrations (up to 20",
"    <span class=\"nowrap\">",
"     mg/mL)",
"    </span>",
"    are sometimes utilized, but may increase the risk for adverse effects.",
"   </p>",
"   <p>",
"    We inject approximately 0.1 mL into each injection site. Injections into lesions greater than 1 cm in size should be placed about 1 cm apart. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/45/40660?source=see_link\">",
"     \"Intralesional injection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The pain associated with intralesional injection may be difficult for some patients to tolerate, particularly if lesions are located in sensitive areas or multiple lesions are present. Potential adverse effects of intralesional corticosteroid therapy include cutaneous atrophy, hypopigmentation, and suppression of the hypothalamic-pituitary-adrenal axis. In order to reduce the risk of the latter, we limit the total dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/38/39520?source=see_link\">",
"     triamcinolone",
"    </a>",
"    acetonide administered during a single treatment session to &le;20 mg [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16522/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/45/40660?source=see_link&amp;anchor=H7#H7\">",
"     \"Intralesional injection\", section on 'Side effects, complications, and pitfalls'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8964990\">",
"    <span class=\"h1\">",
"     SECOND LINE AGENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;When local therapy is ineffective or impractical (eg, patients with extensive skin involvement), systemic agents such as systemic glucocorticoids, antimalarial agents,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    derivatives can be used for treatment. Data on the efficacy of all of these agents are limited. The time of therapeutic onset for these agents ranges from a few weeks to several months.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8965336\">",
"    <span class=\"h2\">",
"     Systemic glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although systemic glucocorticoids are considered the standard of care for sarcoidosis, data on the efficacy of these agents for cutaneous sarcoidosis are limited [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16522/abstract/7,8,24-27\">",
"     7,8,24-27",
"    </a>",
"    ]. In a retrospective study of 116 treatment courses in 54 patients with lupus pernio, monotherapy with systemic glucocorticoids was associated with complete or near resolution of skin lesions in 20 percent of treatment courses and at least some improvement in 72 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16522/abstract/24\">",
"     24",
"    </a>",
"    ]. In addition, a 1997 systematic review of published reports found that skin lesions resolved in 12 out of 16 patients with ulcerative sarcoidosis who were treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    as monotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16522/abstract/7\">",
"     7",
"    </a>",
"    ], and a small retrospective study and case series have documented improvement in subcutaneous sarcoidosis during treatment with systemic glucocorticoids [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16522/abstract/8,25\">",
"     8,25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/43/11961?source=see_link&amp;anchor=H3#H3\">",
"     \"Treatment of pulmonary sarcoidosis with glucocorticoids\", section on 'Mechanism of action of glucocorticoids'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The optimal regimen for systemic glucocorticoids therapy is unknown. Although long-term glucocorticoid therapy is unfavorable due to the multiple adverse effects associated with extended therapy, some patients relapse during glucocorticoid tapering [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16522/abstract/7\">",
"     7",
"    </a>",
"    ]. Combination therapy with other systemic agents, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    , may facilitate reductions in the dose of systemic glucocorticoids [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16522/abstract/4,14\">",
"     4,14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=see_link\">",
"     \"Major side effects of systemic glucocorticoids\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatment with 20 to 40",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    followed by a taper to the lowest dose feasible has been described [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16522/abstract/28\">",
"     28",
"    </a>",
"    ]. Other authors have suggested treatment with 30 mg prednisone every other day followed by a taper to 15 mg every other day [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16522/abstract/14\">",
"     14",
"    </a>",
"    ]. In our practice, we begin treatment with 0.5",
"    <span class=\"nowrap\">",
"     mg/kg/day",
"    </span>",
"    of prednisone, and if significant improvement is not evident after two weeks, we increase the dose to 1.0",
"    <span class=\"nowrap\">",
"     mg/kg/day",
"    </span>",
"    and initiate simultaneous treatment with a glucocorticoid-sparing agent (usually",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    ). Once satisfactory improvement is attained, we taper the dose of prednisone by 10",
"    <span class=\"nowrap\">",
"     mg/week.",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/37/22103?source=see_link&amp;anchor=H16#H16\">",
"     \"Glucocorticoid withdrawal\", section on 'Recommended tapering regimen'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Tapering of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    by 5",
"    <span class=\"nowrap\">",
"     mg/week",
"    </span>",
"    can be attempted in patients who respond well to the initial 0.5",
"    <span class=\"nowrap\">",
"     mg/kg/day",
"    </span>",
"    dose. If disease activity recurs, we return to the lowest effective dose of prednisone and add a glucocorticoid-sparing agent prior to additional attempts at tapering.",
"   </p>",
"   <p>",
"    Calcium and vitamin D supplementation for prevention of osteoporosis are generally recommended for patients who receive long-term glucocorticoids and should be considered in all patients who do not have sarcoidosis-induced hypercalcemia [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16522/abstract/29\">",
"     29",
"    </a>",
"    ]. Periodic monitoring of serum calcium levels is appropriate in patients receiving calcium and vitamin D supplementation [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16522/abstract/1,30\">",
"     1,30",
"    </a>",
"    ]. The adverse effects of systemic glucocorticoid therapy are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=see_link\">",
"     \"Major side effects of systemic glucocorticoids\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8965351\">",
"    <span class=\"h2\">",
"     Antimalarials",
"    </span>",
"    &nbsp;&mdash;&nbsp;The utility of 4-aminoquinolines (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25447?source=see_link\">",
"     chloroquine",
"    </a>",
"    ) in cutaneous sarcoidosis may be related to the immunomodulatory effects of these drugs. These medications can impede the presentation of antigenic peptides to CD4-positive helper T cells and interfere with the release of cytokines and other mediators associated with granuloma formation [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16522/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Data on the efficacy of antimalarial drugs for cutaneous sarcoidosis are limited to a few small uncontrolled studies, most of which indicate a favorable effect of antimalarials in the majority of treated patients [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16522/abstract/4,32\">",
"     4,32",
"    </a>",
"    ]. A systematic review of the available study data prior to 2004 found that 84 out of 103 patients (82 percent) treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25447?source=see_link\">",
"     chloroquine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    for cutaneous sarcoidosis had a positive response to therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16522/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The response to treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25447?source=see_link\">",
"     chloroquine",
"    </a>",
"    often is delayed. In one uncontrolled study in which 12 out of 17 patients improved during hydroxychloroquine therapy, treatment responses were first observed after four weeks; most patients had maximum treatment responses at 12 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16522/abstract/33\">",
"     33",
"    </a>",
"    ]. Discontinuation of treatment may result in disease relapse. In an uncontrolled study in which all 14 patients treated with chloroquine responded to treatment, relapse occurred in 9 out of 13 patients after the discontinuation of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16522/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Antimalarial therapy generally is well-tolerated. Adverse effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25447?source=see_link\">",
"     chloroquine",
"    </a>",
"    include gastrointestinal distress, ocular toxicity, and neurologic or hematologic abnormalities. Patients treated with these agents should receive a baseline ophthalmologic exam and periodic ophthalmologic exams thereafter. In order to reduce the risk for ocular disorders, daily doses of hydroxychloroquine and chloroquine should not exceed 6.5",
"    <span class=\"nowrap\">",
"     mg/kg/day",
"    </span>",
"    and 3",
"    <span class=\"nowrap\">",
"     mg/kg/day,",
"    </span>",
"    respectively. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/9/43161?source=see_link&amp;anchor=H7#H7\">",
"     \"Antimalarial drugs in the treatment of rheumatic disease\", section on 'Adverse effects'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The risk of ocular toxicity is lower with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25447?source=see_link\">",
"     chloroquine",
"    </a>",
"    , and the former is often preferred for this reason. However, the response to hydroxychloroquine appears to be less consistent [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16522/abstract/4\">",
"     4",
"    </a>",
"    ]. Typical dosing for hydroxychloroquine in cutaneous sarcoidosis is 200 to 400",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16522/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8965358\">",
"    <span class=\"h2\">",
"     Methotrexate",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    for cutaneous sarcoidosis has been documented in small uncontrolled studies and case reports [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16522/abstract/35-39\">",
"     35-39",
"    </a>",
"    ]. The drug may be efficacious in as many as 80 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16522/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In an uncontrolled study of 16 patients with cutaneous sarcoidosis who were treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    (25",
"    <span class=\"nowrap\">",
"     mg/",
"     <strong>",
"      week",
"     </strong>",
"     )",
"    </span>",
"    followed by a taper to 5 to 15",
"    <span class=\"nowrap\">",
"     mg/week",
"    </span>",
"    upon improvement, lesions completely resolved in 12 patients (75 percent), and the remaining 4 patients had partial improvement [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16522/abstract/40\">",
"     40",
"    </a>",
"    ]. In a case series that included 50 patients with sarcoidosis treated with methotrexate (10 to 15",
"    <span class=\"nowrap\">",
"     mg/",
"     <strong>",
"      week",
"     </strong>",
"     )",
"    </span>",
"    for at least two years, skin lesions improved in 16 out of 17 patients with cutaneous sarcoidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16522/abstract/35\">",
"     35",
"    </a>",
"    ]. Relapse of sarcoidosis was common after the discontinuation of therapy.",
"   </p>",
"   <p>",
"    Doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    typically range from 10 to 25 mg given on a",
"    <strong>",
"     weekly",
"    </strong>",
"    basis. Improvement may become evident within several weeks or may take up to six months to appear [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16522/abstract/36,41\">",
"     36,41",
"    </a>",
"    ]. The dose of methotrexate can be tapered once improvement is attained. In the uncontrolled study cited above, some patients maintained improvement with only 2.5",
"    <span class=\"nowrap\">",
"     mg/",
"     <strong>",
"      week",
"     </strong>",
"    </span>",
"    of methotrexate [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16522/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Adverse effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    include gastrointestinal upset, stomatitis, leukopenia, hepatotoxicity, and pulmonary fibrosis. Folic or folinic acid supplements can reduce the likelihood of some adverse effects. Due to the risk for hepatotoxicity, preexisting liver disease and alcohol abuse are contraindications to methotrexate. Dosing of methotrexate must be adjusted in patients with renal disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/61/11223?source=see_link\">",
"     \"Major side effects of low-dose methotrexate\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     Methotrexate",
"    </a>",
"    is teratogenic and should not be given to pregnant women. Methotrexate also should not be given to women within one to three menstrual cycles prior to pregnancy or to men within one month prior to an attempt to conceive.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8966978\">",
"    <span class=\"h2\">",
"     Tetracycline derivatives",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mechanism of action of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    derivatives in sarcoidosis is not fully understood, but is thought to involve immunomodulatory inhibition of granuloma formation rather than an antimicrobial effect [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16522/abstract/21,42,43\">",
"     21,42,43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/10/3240?source=see_link\">",
"     minocycline",
"    </a>",
"    is supported by an uncontrolled study in which 12 patients with cutaneous sarcoidosis (nine of whom had previously failed treatment with antimalarials) were treated with minocycline 100 mg twice daily for a median of 12 months [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16522/abstract/9\">",
"     9",
"    </a>",
"    ]. Skin lesions completely resolved in eight patients (67 percent) and partially improved in two patients (17 percent). Most of the responders (seven patients) showed initial signs of improvement within one month, and the time to achieve maximal improvement ranged from one to six months. Patients remained in remission for an average of 15.3 months (range 1 to 33 months) after the discontinuation of therapy. The three patients who relapsed after the cessation of minocycline subsequently responded to treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    100 mg twice daily. In addition, improvement in subcutaneous and tattoo sarcoidosis with doxycycline has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16522/abstract/44,45\">",
"     44,45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Potential adverse effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    antibiotics include photosensitivity, pigment changes in teeth and skin, and gastrointestinal distress.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/10/3240?source=see_link\">",
"     Minocycline",
"    </a>",
"    is less likely to cause photosensitivity, but has been associated with dizziness and a lupus-like syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/28/39370?source=see_link&amp;anchor=H27#H27\">",
"     \"Treatment of acne vulgaris\", section on 'Tetracyclines'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8965978\">",
"    <span class=\"h1\">",
"     REFRACTORY DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who fail to respond to conventional first- and second-line therapies may benefit from treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    . Tumor necrosis factor (TNF)-alpha plays an important role in the pathogenesis of sarcoidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16522/abstract/46\">",
"     46",
"    </a>",
"    ], and the anti-TNF properties of these agents are thought to contribute to the inhibition of granuloma formation in sarcoidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16522/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2163944\">",
"    <span class=\"h2\">",
"     Thalidomide",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     Thalidomide",
"    </a>",
"    may be effective in sarcoidosis due to its ability to inhibit TNF-alpha and interferon (IFN)-gamma, the major cytokines that drive granuloma formation in sarcoidosis, as well as other factors [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16522/abstract/47-49\">",
"     47-49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     Thalidomide",
"    </a>",
"    is efficacious for some patients who fail to improve adequately with first- and second-line agents [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16522/abstract/49-51\">",
"     49-51",
"    </a>",
"    ]. An open-label, dose escalation study evaluated the efficacy of thalidomide in patients with lupus pernio [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16522/abstract/52\">",
"     52",
"    </a>",
"    ]. All patients had previously been treated with systemic glucocorticoids, and most had also received other steroid-sparing agents. The patients were given 50 mg of thalidomide each night for one month, followed by 100 mg each night for one month, and 200 mg each night for two months. All 14 patients who completed the four-month study exhibited improvement and the median number of lesions decreased significantly (7.5 lesions to 3.5 lesions at the end of the study). One month after the completion of therapy, the median number of lesions was not significantly different from the count at study end; however, four patients were noted to have an increase in the number of lesions.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     Thalidomide",
"    </a>",
"    (100 to 200",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    also was effective in a retrospective study of 12 patients with various forms of sarcoidosis (lupus pernio, nodular, plaque, and angiolupoid) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16522/abstract/53\">",
"     53",
"    </a>",
"    ]. Lesions completely resolved in four patients and partially resolved in six patients. Improvement occurred after one to five months. The effect of thalidomide also was evident on histopathologic examination of specimens from eight patients with cutaneous sarcoidosis treated with the drug [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16522/abstract/48\">",
"     48",
"    </a>",
"    ]. Compared to pretreatment specimens, decreases in granuloma size and reductions in epidermal thickness were noted in all biopsies taken after 12 or 16 weeks of therapy.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     Thalidomide",
"    </a>",
"    is teratogenic. In the United States, patient and provider participation in the System for Thalidomide Education and Prescribing Safety (S.T.E.P.S.) program (",
"    <a class=\"external\" href=\"file://www.thalomid.com/steps_program.aspx\">",
"     file://www.thalomid.com/steps_program.aspx",
"    </a>",
"    ) is necessary for drug use. Other adverse effects associated with thalidomide include somnolence, peripheral neuropathy, thrombosis, constipation, endocrine dysfunction, and neutropenia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16711999\">",
"    <span class=\"h2\">",
"     Infliximab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     Infliximab",
"    </a>",
"    is an intravenously administered, chimeric, monoclonal antibody directed against TNF-alpha. Although infliximab has been associated with improvement of various forms of cutaneous sarcoidosis in small uncontrolled studies and case reports [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16522/abstract/54-61\">",
"     54-61",
"    </a>",
"    ], the results of larger studies conflict:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A randomized trial of 138 patients with pulmonary sarcoidosis compared the efficacy of 5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      , 3",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      of infliximab, or placebo given at 0, 2, 6, 12, 18, and 24 weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?16/8/16522/abstract/5\">",
"       5",
"      </a>",
"      ]. Analyses of the trial data revealed no significant differences in the response of lupus pernio (n = 19) or all forms of cutaneous sarcoidosis (n = 36) among the three groups [",
"      <a class=\"abstract\" href=\"UTD.htm?16/8/16522/abstract/5,6\">",
"       5,6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a retrospective study of 116 treatment courses in 54 patients,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      (as monotherapy or concomitant therapy) was superior to other medications for the treatment of lupus pernio [",
"      <a class=\"abstract\" href=\"UTD.htm?16/8/16522/abstract/24\">",
"       24",
"      </a>",
"      ]. The study found that resolution or near resolution of skin lesions occurred 77 percent of treatment courses with infliximab, 29 percent of courses containing a combination of systemic glucocorticoids and other agents, 20 percent of treatment courses with systemic glucocorticoids alone, and 11 percent of courses that did not include systemic glucocorticoids or infliximab.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Enthusiasm about the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    also is tempered by reports of the development of lesions consistent with cutaneous, pulmonary, and neural sarcoidosis in patients treated with infliximab for other disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16522/abstract/62-66\">",
"     62-66",
"    </a>",
"    ]. Additional studies are necessary to evaluate the efficacy and safety of infliximab for cutaneous sarcoidosis.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     Infliximab",
"    </a>",
"    is administered intravenously; 3 to 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    is usually given at weeks zero, two, and six, and then every six weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16522/abstract/5,24\">",
"     5,24",
"    </a>",
"    ]. Adverse effects of infliximab include infusion reactions and an increased risk for infections or malignancy. The side effects of biologic TNF inhibitors are discussed in greater detail separately (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/55/40825?source=see_link\">",
"     \"Tumor necrosis factor-alpha inhibitors: An overview of adverse effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/49/32538?source=see_link\">",
"     \"Tumor necrosis factor-alpha inhibitors: Risk of bacterial, viral, and fungal infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/53/33624?source=see_link\">",
"     \"Tumor necrosis factor-alpha inhibitors: Risk of malignancy\"",
"    </a>",
"    .).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8967268\">",
"    <span class=\"h1\">",
"     OTHER THERAPIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple other interventions have been used for patients with cutaneous sarcoidosis; however, the minimal amount of data in support of the efficacy of these agents precludes recommendations for their routine use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3545867\">",
"    <span class=\"h2\">",
"     Topical tacrolimus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    is a calcineurin inhibitor prescribed for the treatment of a variety of inflammatory disorders of the skin. Successful treatment of cutaneous sarcoidosis with tacrolimus 0.03% or 0.1% ointment has been documented in several case reports, including one patient who failed to respond to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    or fumaric acid esters, and a second who did not improve with topical or systemic glucocorticoids [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16522/abstract/67-71\">",
"     67-71",
"    </a>",
"    ]. Successful treatment also has been reported in a patient with sarcoidal involvement of eyebrow tattoos [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16522/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/41/29332?source=see_link\">",
"     pimecrolimus",
"    </a>",
"    , another topical calcineurin inhibitor, for cutaneous sarcoidosis has not been evaluated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H323844\">",
"    <span class=\"h2\">",
"     Mycophenolate mofetil",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     Mycophenolate",
"    </a>",
"    mofetil inhibits inosine monophosphate dehydrogenase, an enzyme critical for the production of guanosine nucleotides in lymphocytes. This impairs RNA, DNA, and protein synthesis in lymphocytes, leading to inhibition of lymphocyte proliferation and function. The favorable side effect profile of mycophenolate mofetil compared to other immunosuppressive agents has led to the use mycophenolate mofetil in multiple immune-mediated disorders. The drug has also been used in the treatment of extracutaneous sarcoidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16522/abstract/73\">",
"     73",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/11/38074?source=see_link&amp;anchor=H265670931#H265670931\">",
"     \"Treatment of pulmonary sarcoidosis with alternatives to glucocorticoids\", section on 'Mycophenolate mofetil'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil as monotherapy in cutaneous sarcoidosis is unknown. In a series of five patients with mucocutaneous manifestations of sarcoidosis that had failed to respond adequately to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    and other therapies, treatment with mycophenolate mofetil (30 to 45",
"    <span class=\"nowrap\">",
"     mg/kg/day)",
"    </span>",
"    led to clinical improvement and a reduction in systemic glucocorticoid dose [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16522/abstract/74\">",
"     74",
"    </a>",
"    ]. Four out of five patients were able to taper the dose of prednisone to 5 mg every other day. Improvement occurred six weeks to four months after the initiation of mycophenolate mofetil.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H323930\">",
"    <span class=\"h2\">",
"     Oral isotretinoin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Improvement in cutaneous sarcoidosis with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/62/1000?source=see_link\">",
"     isotretinoin",
"    </a>",
"    has been reported in patients who failed to respond to other systemic agents [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16522/abstract/75-77\">",
"     75-77",
"    </a>",
"    ]. Therapeutic doses reported in the literature have ranged from 0.4 to 1.3",
"    <span class=\"nowrap\">",
"     mg/kg/day.",
"    </span>",
"    Although early signs of improvement may be detected in some cases, treatment may need to be continued for six months or more to achieve adequate responses [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16522/abstract/75-77\">",
"     75-77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/62/1000?source=see_link\">",
"     Isotretinoin",
"    </a>",
"    is a potent teratogen. In the United States the drug can only be prescribed through the",
"    <a class=\"external\" href=\"https://www.ipledgeprogram.com/\">",
"     iPLEDGE program",
"    </a>",
"    , a computer-based risk management program intended to reduce the risk of pregnancy during treatment with isotretinoin. Additional side effects of isotretinoin include cheilitis, xerosis, hypertriglyceridemia, bone changes, and other findings. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/42/22184?source=see_link&amp;anchor=H7#H7\">",
"     \"Oral isotretinoin therapy for acne vulgaris\", section on 'Isotretinoin safety'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7842116\">",
"    <span class=\"h2\">",
"     Adalimumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"     Adalimumab",
"    </a>",
"    is an anti-TNF human monoclonal antibody that may be effective for cutaneous sarcoidosis. Favorable results have been observed in a randomized trial, case reports, and a case series [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16522/abstract/60,78-81\">",
"     60,78-81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the randomized trial, patients with cutaneous sarcoidosis were treated with either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    (40 mg once weekly) or placebo agent for 12 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16522/abstract/82\">",
"     82",
"    </a>",
"    ]. Continuation of other systemic medications was allowed provided the dose remained relatively stable. The trial found that 5 of 10 patients in the adalimumab group versus 1 of 5 patients in the placebo group achieved at least a two grade improvement in the physician global assessment score, a difference that was not statistically significant. However, a statistically significant difference in the amount of improvement observed in target lesions was detected between the two groups; the area of target lesions in the adalimumab group decreased by an average of 32 percent while the area of target lesions in the placebo group increased by an average of 54 percent. A non-statistically significant trend towards greater improvement in lesion volume was also detected in the adalimumab group (59 percent reduction in volume versus a 21 percent increase in volume in the placebo group). Larger randomized trials are necessary to confirm the efficacy of adalimumab for cutaneous sarcoidosis.",
"   </p>",
"   <p>",
"    Examples of case reports of that document improvement in cutaneous sarcoidosis refractory to other therapies during treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    include a patient with ulcerative cutaneous and systemic sarcoidosis who failed treatment with systemic glucocorticoids,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    , but responded to adalimumab (40 mg weekly) within nine weeks and then tolerated tapering of her systemic glucocorticoid dose [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16522/abstract/78\">",
"     78",
"    </a>",
"    ]. Another patient with cutaneous sarcoidosis unresponsive to systemic glucocorticoids improved significantly when adalimumab (40 mg once weekly for 10 weeks) was added to her treatment regimen (hydroxychloroquine and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/28/13765?source=see_link\">",
"     pentoxifylline",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16522/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"     Etanercept",
"    </a>",
"    , another biologic TNF inhibitor may not be as effective for cutaneous sarcoidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16522/abstract/83\">",
"     83",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16712048\">",
"    <span class=\"h2\">",
"     Allopurinol",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/40/25223?source=see_link\">",
"     Allopurinol",
"    </a>",
"    is thought to reduce granuloma formation through the inhibition of the formation of multinucleate giant cells [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16522/abstract/15\">",
"     15",
"    </a>",
"    ]. Beneficial effects of allopurinol in cutaneous sarcoidosis have been documented in multiple patients [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16522/abstract/84-91\">",
"     84-91",
"    </a>",
"    ]. In one series of six patients treated with allopurinol, four patients achieved improvement [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16522/abstract/91\">",
"     91",
"    </a>",
"    ]. The relapse of successfully treated skin disease in a patient after cessation of allopurinol, followed by remission after restarting the drug, supports the efficacy of this agent [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16522/abstract/84\">",
"     84",
"    </a>",
"    ]. Dosing of 100",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for the first week, followed by 200",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for the second week, and 300",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    thereafter has been suggested [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16522/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H323296\">",
"    <span class=\"h2\">",
"     Ultraviolet light",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultraviolet (UV) light is used in the treatment of multiple skin disorders, and is believed to exert immunomodulatory or immunosuppressive effects. Isolated cases in which treatment with UVA-1 (340 to 400 nm) light was associated with improvement in cutaneous sarcoidosis have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16522/abstract/92,93\">",
"     92,93",
"    </a>",
"    ]. In addition, successful treatment with topical psoralen plus UVA (PUVA) therapy has been documented in a case report and small case series [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16522/abstract/94,95\">",
"     94,95",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H323336\">",
"    <span class=\"h2\">",
"     Laser and photodynamic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Improvements in lesions of lupus pernio, nodular sarcoidosis, and scar sarcoidosis have been reported in patients treated with pulsed dye lasers [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16522/abstract/96-100\">",
"     96-100",
"    </a>",
"    ]. Responses to treatment with a 532 nm frequency doubled Nd:YAG laser [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16522/abstract/101\">",
"     101",
"    </a>",
"    ], Q-switched ruby laser [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16522/abstract/102\">",
"     102",
"    </a>",
"    ], and ablative carbon dioxide laser [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16522/abstract/103-105\">",
"     103-105",
"    </a>",
"    ] also have been documented.",
"   </p>",
"   <p>",
"    Photodynamic therapy involves the application of a topical photosensitizer followed by irradiation with laser or visible light. Improvements have been noted in several patients after treatment with this modality [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16522/abstract/106-110\">",
"     106-110",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The avoidance of the serious adverse effects associated with many systemic drugs is a favorable characteristic of these therapies. However, further studies are necessary to evaluate the efficacy and safety of these interventions in sarcoidosis. Of note, the induction of sarcoidal lesions after carbon dioxide laser therapy has occurred [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16522/abstract/111\">",
"     111",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H323526\">",
"    <span class=\"h2\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical excision of cutaneous sarcoidosis lesions is rarely performed due to the potential for sarcoidosis to recur in surgical scars. However, improvement is cosmetic appearance has been reported in patients with severely disfiguring lesions on the nose after reconstructive surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16522/abstract/112,113\">",
"     112,113",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7842325\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cases in which cutaneous sarcoidosis responded to melatonin [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16522/abstract/114,115\">",
"     114,115",
"    </a>",
"    ], leflunomide [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16522/abstract/116\">",
"     116",
"    </a>",
"    ], chlorambucil [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16522/abstract/117\">",
"     117",
"    </a>",
"    ], tranilast [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16522/abstract/118\">",
"     118",
"    </a>",
"    ], fumaric acid esters [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16522/abstract/119\">",
"     119",
"    </a>",
"    ], intralesional chloroquine [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16522/abstract/120\">",
"     120",
"    </a>",
"    ], and phonophoresis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16522/abstract/121\">",
"     121",
"    </a>",
"    ] have been reported.",
"   </p>",
"   <p>",
"    Apremilast is a phosphodiesterase type 4 inhibitor that is being evaluated in clinical trials for the treatment of a variety of inflammatory disorders. In an uncontrolled study of 15 patients with refractory cutaneous sarcoidosis, treatment with 20 mg twice daily of oral apremilast was associated with modest improvements in lesion induration [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16522/abstract/122\">",
"     122",
"    </a>",
"    ]. However, significant differences in erythema, desquamation, and lesion size were not detected. Apremilast has not yet been approved by the US Food and Drug Administration for any clinical indication.",
"   </p>",
"   <p>",
"    Agents such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/28/13765?source=see_link\">",
"     pentoxifylline",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16522/abstract/123\">",
"     123",
"    </a>",
"    ] and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?16/8/16522/abstract/124,125\">",
"     124,125",
"    </a>",
"    ] have been used for systemic disease, but their efficacy for cutaneous lesions is unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H324690\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sarcoidosis is a multisystem granulomatous disorder that can present with skin involvement. Although a variety of therapies have been used for cutaneous sarcoidosis, high quality evidence to support the efficacy of these treatments is limited. (See",
"      <a class=\"local\" href=\"#H16711891\">",
"       'Approach to therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment is not required for all patients with cutaneous sarcoidosis. Spontaneous resolution is possible. In the absence of extracutaneous indications for the treatment of sarcoidosis, treatment should be considered for patients with cosmetically disfiguring, symptomatic, ulcerating, or progressively worsening skin disease. Patients with stable disease that is not bothersome do not require therapy. Treatment is usually required for lupus pernio due to the disfiguring nature of this variant (See",
"      <a class=\"local\" href=\"#H16711891\">",
"       'Approach to therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with a limited number of skin lesions may benefit from local therapies. For patients with localized disease we suggest initiating treatment with superpotent topical corticosteroids or intralesional corticosteroid injections (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H16711898\">",
"       'First line agents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Some patients do not respond sufficiently to local therapy or have widespread disease that makes local therapy impractical. For these patients we suggest treatment with systemic agents, such as glucocorticoids, antimalarial agents, or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/10/3240?source=see_link\">",
"       Minocycline",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      are alternative systemic therapies. (See",
"      <a class=\"local\" href=\"#H8964990\">",
"       'Second line agents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who fail to improve with first- and second-line therapies for cutaneous sarcoidosis, we suggest treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"       thalidomide",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Thalidomide is teratogenic and should not be prescribed in pregnant women.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       Infliximab",
"      </a>",
"      may also be effective for some patients with refractory disease. Additional studies are necessary to determine the efficacy and safety of infliximab for cutaneous sarcoidosis. (See",
"      <a class=\"local\" href=\"#H8965978\">",
"       'Refractory disease'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16522/abstract/1\">",
"      Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med 1999; 160:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16522/abstract/2\">",
"      Hunninghake GW, Costabel U, Ando M, et al. ATS/ERS/WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and other Granulomatous Disorders. Sarcoidosis Vasc Diffuse Lung Dis 1999; 16:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16522/abstract/3\">",
"      Baughman RP, Lower EE. Evidence-based therapy for cutaneous sarcoidosis. Clin Dermatol 2007; 25:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16522/abstract/4\">",
"      Mosam A, Morar N. Recalcitrant cutaneous sarcoidosis: an evidence-based sequential approach. J Dermatolog Treat 2004; 15:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16522/abstract/5\">",
"      Baughman RP, Drent M, Kavuru M, et al. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med 2006; 174:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16522/abstract/6\">",
"      Judson MA, Baughman RP, Costabel U, et al. Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomised trial. Eur Respir J 2008; 31:1189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16522/abstract/7\">",
"      Albertini JG, Tyler W, Miller OF 3rd. Ulcerative sarcoidosis. Case report and review of the literature. Arch Dermatol 1997; 133:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16522/abstract/8\">",
"      Marcoval J, Ma&ntilde;a J, Moreno A, Peyri J. Subcutaneous sarcoidosis--clinicopathological study of 10 cases. Br J Dermatol 2005; 153:790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16522/abstract/9\">",
"      Bachelez H, Senet P, Cadranel J, et al. The use of tetracyclines for the treatment of sarcoidosis. Arch Dermatol 2001; 137:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16522/abstract/10\">",
"      Shigemitsu H, Yarbrough CA, Prakash S, Sharma OP. A 65-year-old woman with subcutaneous nodule and hilar adenopathy. Chest 2008; 134:1080.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16522/abstract/11\">",
"      Katta R, Nelson B, Chen D, Roenigk H. Sarcoidosis of the scalp: a case series and review of the literature. J Am Acad Dermatol 2000; 42:690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16522/abstract/12\">",
"      Wise RD. Clinical resolution of facial cutaneous sarcoidosis with systemic colchicine and a topical corticosteroid ointment. Compr Ther 2008; 34:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16522/abstract/13\">",
"      Chong WS, Tan HH, Tan SH. Cutaneous sarcoidosis in Asians: a report of 25 patients from Singapore. Clin Exp Dermatol 2005; 30:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16522/abstract/14\">",
"      Badgwell C, Rosen T. Cutaneous sarcoidosis therapy updated. J Am Acad Dermatol 2007; 56:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16522/abstract/15\">",
"      Doherty CB, Rosen T. Evidence-based therapy for cutaneous sarcoidosis. Drugs 2008; 68:1361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16522/abstract/16\">",
"      Volden G. Successful treatment of chronic skin diseases with clobetasol propionate and a hydrocolloid occlusive dressing. Acta Derm Venereol 1992; 72:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16522/abstract/17\">",
"      Khatri KA, Chotzen VA, Burrall BA. Lupus pernio: successful treatment with a potent topical corticosteroid. Arch Dermatol 1995; 131:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16522/abstract/18\">",
"      Russo G, Millikan LE. Cutaneous sarcoidosis: diagnosis and treatment. Compr Ther 1994; 20:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16522/abstract/19\">",
"      SULLIVAN RD, MAYOCK RL, JONES R Jr. Local injection of hydrocortisone and cortisone into skin lesions of sarcoidosis. J Am Med Assoc 1953; 152:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16522/abstract/20\">",
"      Verbov J. The place of intralesional steroid therapy in dermatology. Br J Dermatol 1976; 94 suppl 12:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16522/abstract/21\">",
"      Lodha S, Sanchez M, Prystowsky S. Sarcoidosis of the skin: a review for the pulmonologist. Chest 2009; 136:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16522/abstract/22\">",
"      Callen JP. Intralesional corticosteroids. J Am Acad Dermatol 1981; 4:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16522/abstract/23\">",
"      Jarratt MT, Spark RF, Arndt KA. The effects of intradermal steroids on the pituitary-adrenal axis and the skin. J Invest Dermatol 1974; 62:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16522/abstract/24\">",
"      Stagaki E, Mountford WK, Lackland DT, Judson MA. The treatment of lupus pernio: results of 116 treatment courses in 54 patients. Chest 2009; 135:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16522/abstract/25\">",
"      Ahmed I, Harshad SR. Subcutaneous sarcoidosis: is it a specific subset of cutaneous sarcoidosis frequently associated with systemic disease? J Am Acad Dermatol 2006; 54:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16522/abstract/26\">",
"      James DG, Carstairs LS, Trowell J, Sharma OP. Treatment of sarcoidosis. Report of a controlled therapeutic trial. Lancet 1967; 2:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16522/abstract/27\">",
"      Johns CJ, Michele TM. The clinical management of sarcoidosis. A 50-year experience at the Johns Hopkins Hospital. Medicine (Baltimore) 1999; 78:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16522/abstract/28\">",
"      Rose AS, Tielker MA, Knox KS. Hepatic, ocular, and cutaneous sarcoidosis. Clin Chest Med 2008; 29:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16522/abstract/29\">",
"      King CS, Kelly W. Treatment of sarcoidosis. Dis Mon 2009; 55:704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16522/abstract/30\">",
"      Sage RJ, Rao DS, Burke RR, Lim HW. Preventing vitamin D toxicity in patients with sarcoidosis. J Am Acad Dermatol 2011; 64:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16522/abstract/31\">",
"      Kalia S, Dutz JP. New concepts in antimalarial use and mode of action in dermatology. Dermatol Ther 2007; 20:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16522/abstract/32\">",
"      Zic JA, Horowitz DH, Arzubiaga C, King LE Jr. Treatment of cutaneous sarcoidosis with chloroquine. Review of the literature. Arch Dermatol 1991; 127:1034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16522/abstract/33\">",
"      Jones E, Callen JP. Hydroxychloroquine is effective therapy for control of cutaneous sarcoidal granulomas. J Am Acad Dermatol 1990; 23:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16522/abstract/34\">",
"      Siltzbach LE, Teirstein AS. Chloroquine therapy in 43 patients with intrathoracic and cutaneous sarcoidosis. Acta Med Scand Suppl 1964; 425:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16522/abstract/35\">",
"      Lower EE, Baughman RP. Prolonged use of methotrexate for sarcoidosis. Arch Intern Med 1995; 155:846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16522/abstract/36\">",
"      Webster GF, Razsi LK, Sanchez M, Shupack JL. Weekly low-dose methotrexate therapy for cutaneous sarcoidosis. J Am Acad Dermatol 1991; 24:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16522/abstract/37\">",
"      Kaye O, Palazzo E, Grossin M, et al. Low-dose methotrexate: an effective corticosteroid-sparing agent in the musculoskeletal manifestations of sarcoidosis. Br J Rheumatol 1995; 34:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16522/abstract/38\">",
"      Gedalia A, Molina JF, Ellis GS Jr, et al. Low-dose methotrexate therapy for childhood sarcoidosis. J Pediatr 1997; 130:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16522/abstract/39\">",
"      Lacher MJ. Spontaneous remission or response to methotrexate in sarcoidosis. Ann Intern Med 1968; 69:1247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16522/abstract/40\">",
"      Veien NK, Brodthagen H. Cutaneous sarcoidosis treated with methotrexate. Br J Dermatol 1977; 97:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16522/abstract/41\">",
"      Baughman RP, Lynch JP. Difficult treatment issues in sarcoidosis. J Intern Med 2003; 253:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16522/abstract/42\">",
"      Webster GF, Toso SM, Hegemann L. Inhibition of a model of in vitro granuloma formation by tetracyclines and ciprofloxacin. Involvement of protein kinase C. Arch Dermatol 1994; 130:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16522/abstract/43\">",
"      Szeto GL, Brice AK, Yang HC, et al. Minocycline attenuates HIV infection and reactivation by suppressing cellular activation in human CD4+ T cells. J Infect Dis 2010; 201:1132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16522/abstract/44\">",
"      El Sayed F, Dhaybi R, Ammoury A. Subcutaneous nodular sarcoidosis and systemic involvement successfully treated with doxycycline. J Med Liban 2006; 54:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16522/abstract/45\">",
"      Antonovich DD, Callen JP. Development of sarcoidosis in cosmetic tattoos. Arch Dermatol 2005; 141:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16522/abstract/46\">",
"      Antoniu SA. Targeting the TNF-alpha pathway in sarcoidosis. Expert Opin Ther Targets 2010; 14:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16522/abstract/47\">",
"      Ladizinski B, Shannon EJ, Sanchez MR, Levis WR. Thalidomide and analogues: potential for immunomodulation of inflammatory and neoplastic dermatologic disorders. J Drugs Dermatol 2010; 9:814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16522/abstract/48\">",
"      Oliver SJ, Kikuchi T, Krueger JG, Kaplan G. Thalidomide induces granuloma differentiation in sarcoid skin lesions associated with disease improvement. Clin Immunol 2002; 102:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16522/abstract/49\">",
"      Carlesimo M, Giustini S, Rossi A, et al. Treatment of cutaneous and pulmonary sarcoidosis with thalidomide. J Am Acad Dermatol 1995; 32:866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16522/abstract/50\">",
"      Lee JB, Koblenzer PS. Disfiguring cutaneous manifestation of sarcoidosis treated with thalidomide: a case report. J Am Acad Dermatol 1998; 39:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16522/abstract/51\">",
"      Rousseau L, Beylot-Barry M, Doutre MS, Beylot C. Cutaneous sarcoidosis successfully treated with low doses of thalidomide. Arch Dermatol 1998; 134:1045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16522/abstract/52\">",
"      Baughman RP, Judson MA, Teirstein AS, et al. Thalidomide for chronic sarcoidosis. Chest 2002; 122:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16522/abstract/53\">",
"      Nguyen YT, Dupuy A, Cordoliani F, et al. Treatment of cutaneous sarcoidosis with thalidomide. J Am Acad Dermatol 2004; 50:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16522/abstract/54\">",
"      Sweiss NJ, Welsch MJ, Curran JJ, Ellman MH. Tumor necrosis factor inhibition as a novel treatment for refractory sarcoidosis. Arthritis Rheum 2005; 53:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16522/abstract/55\">",
"      Saleh S, Ghodsian S, Yakimova V, et al. Effectiveness of infliximab in treating selected patients with sarcoidosis. Respir Med 2006; 100:2053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16522/abstract/56\">",
"      Mallbris L, Ljungberg A, Hedblad MA, et al. Progressive cutaneous sarcoidosis responding to anti-tumor necrosis factor-alpha therapy. J Am Acad Dermatol 2003; 48:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16522/abstract/57\">",
"      Meyerle JH, Shorr A. The use of infliximab in cutaneous sarcoidosis. J Drugs Dermatol 2003; 2:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16522/abstract/58\">",
"      Baughman RP, Lower EE. Infliximab for refractory sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2001; 18:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16522/abstract/59\">",
"      Doty JD, Mazur JE, Judson MA. Treatment of sarcoidosis with infliximab. Chest 2005; 127:1064.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16522/abstract/60\">",
"      Wanat KA, Rosenbach M. Case series demonstrating improvement in chronic cutaneous sarcoidosis following treatment with TNF inhibitors. Arch Dermatol 2012; 148:1097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16522/abstract/61\">",
"      Sen&eacute; T, Juillard C, Rybojad M, et al. Infliximab as a steroid-sparing agent in refractory cutaneous sarcoidosis: single-center retrospective study of 9 patients. J Am Acad Dermatol 2012; 66:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16522/abstract/62\">",
"      Dhaille F, Viseux V, Caudron A, et al. Cutaneous sarcoidosis occurring during anti-TNF-alpha treatment: report of two cases. Dermatology 2010; 220:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16522/abstract/63\">",
"      Da&iuml;en CI, Monnier A, Claudepierre P, et al. Sarcoid-like granulomatosis in patients treated with tumor necrosis factor blockers: 10 cases. Rheumatology (Oxford) 2009; 48:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16522/abstract/64\">",
"      Sturfelt G, Christensson B, Bynke G, Saxne T. Neurosarcoidosis in a patient with rheumatoid arthritis during treatment with infliximab. J Rheumatol 2007; 34:2313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16522/abstract/65\">",
"      Almod&oacute;var R, Izquierdo M, Zarco P, et al. Pulmonary sarcoidosis in a patient with ankylosing spondylitis treated with infliximab. Clin Exp Rheumatol 2007; 25:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16522/abstract/66\">",
"      Fok KC, Ng WW, Henderson CJ, Connor SJ. Cutaneous sarcoidosis in a patient with ulcerative colitis on infliximab. J Crohns Colitis 2012; 6:708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16522/abstract/67\">",
"      Green CM. Topical tacrolimus for the treatment of cutaneous sarcoidosis. Clin Exp Dermatol 2007; 32:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16522/abstract/68\">",
"      De Francesco V, Cathryn AS, Piccirillo F. Successful topical treatment of cutaneous sarcoidosis with macrolide immunomodulators. Eur J Dermatol 2007; 17:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16522/abstract/69\">",
"      Gutzmer R, V&ouml;lker B, Kapp A, Werfel T. [Successful topical treatment of cutaneous sarcoidosis with tacrolimus]. Hautarzt 2003; 54:1193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16522/abstract/70\">",
"      Katoh N, Mihara H, Yasuno H. Cutaneous sarcoidosis successfully treated with topical tacrolimus. Br J Dermatol 2002; 147:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16522/abstract/71\">",
"      Vano-Galvan S, Fernandez-Guarino M, Carmona LP, et al. Lichenoid type of cutaneous sarcoidosis: great response to topical tacrolimus. Eur J Dermatol 2008; 18:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16522/abstract/72\">",
"      Landers MC, Skokan M, Law S, Storrs FJ. Cutaneous and pulmonary sarcoidosis in association with tattoos. Cutis 2005; 75:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16522/abstract/73\">",
"      Bhat P, Cervantes-Casta&ntilde;eda RA, Doctor PP, et al. Mycophenolate mofetil therapy for sarcoidosis-associated uveitis. Ocul Immunol Inflamm 2009; 17:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16522/abstract/74\">",
"      Kouba DJ, Mimouni D, Rencic A, Nousari HC. Mycophenolate mofetil may serve as a steroid-sparing agent for sarcoidosis. Br J Dermatol 2003; 148:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16522/abstract/75\">",
"      Waldinger TP, Ellis CN, Quint K, Voorhees JJ. Treatment of cutaneous sarcoidosis with isotretinoin. Arch Dermatol 1983; 119:1003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16522/abstract/76\">",
"      Vaillant L, le Marchand D, Bertrand S, et al. [Annular cutaneous sarcoidosis of the forehead: treatment with isotretinoin]. Ann Dermatol Venereol 1986; 113:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16522/abstract/77\">",
"      Georgiou S, Monastirli A, Pasmatzi E, Tsambaos D. Cutaneous sarcoidosis: complete remission after oral isotretinoin therapy. Acta Derm Venereol 1998; 78:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16522/abstract/78\">",
"      Philips MA, Lynch J, Azmi FH. Ulcerative cutaneous sarcoidosis responding to adalimumab. J Am Acad Dermatol 2005; 53:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16522/abstract/79\">",
"      Heffernan MP, Smith DI. Adalimumab for treatment of cutaneous sarcoidosis. Arch Dermatol 2006; 142:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16522/abstract/80\">",
"      Field S, Regan AO, Sheahan K, Collins P. Recalcitrant cutaneous sarcoidosis responding to adalimumab but not to etanercept. Clin Exp Dermatol 2010; 35:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16522/abstract/81\">",
"      Judson MA. Successful treatment of lupus pernio with adalimumab. Arch Dermatol 2011; 147:1332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16522/abstract/82\">",
"      Pariser RJ, Paul J, Hirano S, et al. A double-blind, randomized, placebo-controlled trial of adalimumab in the treatment of cutaneous sarcoidosis. J Am Acad Dermatol 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16522/abstract/83\">",
"      Thielen AM, Barde C, Saurat JH, Laffitte E. Refractory chronic cutaneous sarcoidosis responsive to dose escalation of TNF-alpha antagonists. Dermatology 2009; 219:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16522/abstract/84\">",
"      Rosof BM. Letter: Allopurinol for sarcoid? N Engl J Med 1976; 294:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16522/abstract/85\">",
"      Pollock JL. Sarcoidosis responding to allopurinol. Arch Dermatol 1980; 116:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16522/abstract/86\">",
"      Brechtel B, Haas N, Henz BM, Kolde G. Allopurinol: a therapeutic alternative for disseminated cutaneous sarcoidosis. Br J Dermatol 1996; 135:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16522/abstract/87\">",
"      Antony F, Layton AM. A case of cutaneous acral sarcoidosis with response to allopurinol. Br J Dermatol 2000; 142:1052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16522/abstract/88\">",
"      Pfau A, Stolz W, Karrer S, et al. [Allopurinol in treatment of cutaneous sarcoidosis]. Hautarzt 1998; 49:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16522/abstract/89\">",
"      El-Euch D, Mokni M, Trojjet S, et al. Sarcoidosis in a child treated successfully with allopurinol. Br J Dermatol 1999; 140:1184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16522/abstract/90\">",
"      Voelter-Mahlknecht S, Benez A, Metzger S, Fierlbeck G. Treatment of subcutaneous sarcoidosis with allopurinol. Arch Dermatol 1999; 135:1560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16522/abstract/91\">",
"      Samuel M, Allen GE, McMillan SC, et al. Sarcoidosis: initial results on six patients treated with allopurinol. Br J Dermatol 1984; 111:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16522/abstract/92\">",
"      Mahnke N, Medve-Koenigs K, Megahed M, Neumann NJ. [Medium-dose UV-A1 phototherapy. Successful treatment of cutaneous sarcoidosis]. Hautarzt 2003; 54:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16522/abstract/93\">",
"      Graefe T, Konrad H, Barta U, et al. Successful ultraviolet A1 treatment of cutaneous sarcoidosis. Br J Dermatol 2001; 145:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16522/abstract/94\">",
"      Patterson JW, Fitzwater JE. Treatment of hypopigmented sarcoidosis with 8-methoxypsoralen and long wave ultraviolet light. Int J Dermatol 1982; 21:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16522/abstract/95\">",
"      Gleeson CM, Morar N, Staveley I, Bunker CB. Treatment of cutaneous sarcoid with topical gel psoralen and ultraviolet A. Br J Dermatol 2011; 164:892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16522/abstract/96\">",
"      Goodman MM, Alpern K. Treatment of lupus pernio with the flashlamp pulsed dye laser. Lasers Surg Med 1992; 12:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16522/abstract/97\">",
"      Cliff S, Felix RH, Singh L, Harland CC. The successful treatment of lupus pernio with the flashlamp pulsed dye laser. J Cutan Laser Ther 1999; 1:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16522/abstract/98\">",
"      Ashinoff R, Dosik JS. Treating lupus pernio with the 585 nm pulsed dye laser. Skin and Aging 1999; 7:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16522/abstract/99\">",
"      Roos S, Raulin C, Ockenfels HM, Karsai S. Successful treatment of cutaneous sarcoidosis lesions with the flashlamp pumped pulsed dye laser: a case report. Dermatol Surg 2009; 35:1139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16522/abstract/100\">",
"      Holzmann RD, Astner S, Forschner T, Sterry G. Scar sarcoidosis in a child: case report of successful treatment with the pulsed dye laser. Dermatol Surg 2008; 34:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16522/abstract/101\">",
"      Ekb&auml;ck M, Molin L. Effective laser treatment in a case of lupus pernio. Acta Derm Venereol 2005; 85:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16522/abstract/102\">",
"      Grema H, Greve B, Raulin C. Scar sarcoidosis--treatment with the Q-switched ruby laser. Lasers Surg Med 2002; 30:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16522/abstract/103\">",
"      O'Donoghue NB, Barlow RJ. Laser remodelling of nodular nasal lupus pernio. Clin Exp Dermatol 2006; 31:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16522/abstract/104\">",
"      Young HS, Chalmers RJ, Griffiths CE, August PJ. CO2 laser vaporization for disfiguring lupus pernio. J Cosmet Laser Ther 2002; 4:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16522/abstract/105\">",
"      Stack BC Jr, Hall PJ, Goodman AL, Perez IR. CO2 laser excision of lupus pernio of the face. Am J Otolaryngol 1996; 17:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16522/abstract/106\">",
"      Wilsmann-Theis D, Bieber T, Novak N. Photodynamic therapy as an alternative treatment for cutaneous sarcoidosis. Dermatology 2008; 217:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16522/abstract/107\">",
"      Karrer S, Abels C, Wimmershoff MB, et al. Successful treatment of cutaneous sarcoidosis using topical photodynamic therapy. Arch Dermatol 2002; 138:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16522/abstract/108\">",
"      Kondo C, Watanabe D, Nakaseko H, et al. Photodynamic therapy for recurrent sarcoid flexor tenosynovitis of the finger. J Am Acad Dermatol 2006; 55:S99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16522/abstract/109\">",
"      Patterson C. Successful treatment of cutaneous sarcoid by photodynamic therapy with minimal discomfort using a fractionated dosing regime. Photodermatol Photoimmunol Photomed 2009; 25:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16522/abstract/110\">",
"      Penrose C, Mercer SE, Shim-Chang H. Photodynamic therapy for the treatment of cutaneous sarcoidosis. J Am Acad Dermatol 2011; 65:e12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16522/abstract/111\">",
"      Kormeili T, Neel V, Moy RL. Cutaneous sarcoidosis at sites of previous laser surgery. Cutis 2004; 73:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16522/abstract/112\">",
"      G&uuml;rkov R, Berghaus A. Nasal reconstruction in advanced sinunasal sarcoidosis. Rhinology 2009; 47:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16522/abstract/113\">",
"      Smith R, Haeney J, Gulraiz Rauf Kh. Improving cosmesis of lupus pernio by excision and forehead flap reconstruction. Clin Exp Dermatol 2009; 34:e25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16522/abstract/114\">",
"      Cagnoni ML, Lombardi A, Cerinic MC, et al. Melatonin for treatment of chronic refractory sarcoidosis. Lancet 1995; 346:1229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16522/abstract/115\">",
"      Pignone AM, Rosso AD, Fiori G, et al. Melatonin is a safe and effective treatment for chronic pulmonary and extrapulmonary sarcoidosis. J Pineal Res 2006; 41:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16522/abstract/116\">",
"      Majithia V, Sanders S, Harisdangkul V, Wilson JG. Successful treatment of sarcoidosis with leflunomide. Rheumatology (Oxford) 2003; 42:700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16522/abstract/117\">",
"      Kataria YP. Chlorambucil in sarcoidosis. Chest 1980; 78:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16522/abstract/118\">",
"      Nakahigashi K, Kabashima K, Akiyama H, et al. Refractory cutaneous lichenoid sarcoidosis treated with tranilast. J Am Acad Dermatol 2010; 63:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16522/abstract/119\">",
"      Nowack U, Gambichler T, Hanefeld C, et al. Successful treatment of recalcitrant cutaneous sarcoidosis with fumaric acid esters. BMC Dermatol 2002; 2:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16522/abstract/120\">",
"      Liedtka JE. Intralesional chloroquine for the treatment of cutaneous sarcoidosis. Int J Dermatol 1996; 35:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16522/abstract/121\">",
"      Gogstetter DS, Goldsmith LA. Treatment of cutaneous sarcoidosis using phonophoresis. J Am Acad Dermatol 1999; 40:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16522/abstract/122\">",
"      Baughman RP, Judson MA, Ingledue R, et al. Efficacy and safety of apremilast in chronic cutaneous sarcoidosis. Arch Dermatol 2012; 148:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16522/abstract/123\">",
"      Zabel P, Entzian P, Dalhoff K, Schlaak M. Pentoxifylline in treatment of sarcoidosis. Am J Respir Crit Care Med 1997; 155:1665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16522/abstract/124\">",
"      Rebuck AS, Stiller CR, Braude AC, et al. Cyclosporin for pulmonary sarcoidosis. Lancet 1984; 323:1174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/8/16522/abstract/125\">",
"      O'Callaghan CA, Wells AU, Lalvani A, et al. Effective use of cyclosporin in sarcoidosis: a treatment strategy based on computed tomography scanning. Eur Respir J 1994; 7:2255.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13773 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-00FF42CD0A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_8_16522=[""].join("\n");
var outline_f16_8_16522=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H324690\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H323808\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16711891\">",
"      APPROACH TO THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3545700\">",
"      Choice of therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3545693\">",
"      Specific variants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16711898\">",
"      FIRST LINE AGENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16714853\">",
"      Topical corticosteroids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16711906\">",
"      Intralesional corticosteroids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8964990\">",
"      SECOND LINE AGENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8965336\">",
"      Systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8965351\">",
"      Antimalarials",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8965358\">",
"      Methotrexate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8966978\">",
"      Tetracycline derivatives",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8965978\">",
"      REFRACTORY DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2163944\">",
"      Thalidomide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16711999\">",
"      Infliximab",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8967268\">",
"      OTHER THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3545867\">",
"      Topical tacrolimus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H323844\">",
"      Mycophenolate mofetil",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H323930\">",
"      Oral isotretinoin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7842116\">",
"      Adalimumab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16712048\">",
"      Allopurinol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H323296\">",
"      Ultraviolet light",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H323336\">",
"      Laser and photodynamic therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H323526\">",
"      Surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7842325\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H324690\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/13773\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/13773|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/56/39809\" title=\"table 1\">",
"      Topical corticosteroids",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/9/43161?source=related_link\">",
"      Antimalarial drugs in the treatment of rheumatic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/19/17722?source=related_link\">",
"      Cardiac sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/20/19786?source=related_link\">",
"      Cutaneous manifestations of sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/14/17638?source=related_link\">",
"      Gastrointestinal sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/6/27752?source=related_link\">",
"      General principles of dermatologic therapy and topical corticosteroid use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/37/22103?source=related_link\">",
"      Glucocorticoid withdrawal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/45/40660?source=related_link\">",
"      Intralesional injection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/61/11223?source=related_link\">",
"      Major side effects of low-dose methotrexate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=related_link\">",
"      Major side effects of systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/8/20616?source=related_link\">",
"      Neurologic sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/42/22184?source=related_link\">",
"      Oral isotretinoin therapy for acne vulgaris",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/31/40438?source=related_link\">",
"      Renal disease in sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/12/11463?source=related_link\">",
"      Sarcoid arthropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/28/39370?source=related_link\">",
"      Treatment of acne vulgaris",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/11/38074?source=related_link\">",
"      Treatment of pulmonary sarcoidosis with alternatives to glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/43/11961?source=related_link\">",
"      Treatment of pulmonary sarcoidosis with glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/55/40825?source=related_link\">",
"      Tumor necrosis factor-alpha inhibitors: An overview of adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/49/32538?source=related_link\">",
"      Tumor necrosis factor-alpha inhibitors: Risk of bacterial, viral, and fungal infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/53/33624?source=related_link\">",
"      Tumor necrosis factor-alpha inhibitors: Risk of malignancy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_8_16523="Drugs that potentiate the action of sulfonylureas";
var content_f16_8_16523=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F64887&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F64887&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Drugs that potentiate the action of sulfonylureas",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Displacement from plasma proteins",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Salicylates, phenylbutazone, sulfonamides, warfarin, clofibrate",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Decreased hepatic metabolism",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Warfarin, MAO inhibitors, chloramphenicol, phenylbutazone",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Intrinsic hypoglycemic activity",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Salicylates, fenfluramine, alcohol, MAO inhibitors, beta-blockers, quinine, pentamidine, other antihyperglycemic drugs",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Decreased renal excretion",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Salicylates, probenecid, allopurinol",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Masks autonomic signs of hypoglycemia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Beta-blockers",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Unknown mechanism",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Gatifloxacin",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_8_16523=[""].join("\n");
var outline_f16_8_16523=null;
var title_f16_8_16524="Classify problematic uter sarc";
var content_f16_8_16524=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F78735&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F78735&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Classification of problematic uterine smooth muscle tumors based on pathologic features",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Group",
"      </td>",
"      <td class=\"subtitle1\">",
"       Mitotic Index (MI) (per 10 HPF)",
"      </td>",
"      <td class=\"subtitle1\">",
"       Atypia",
"      </td>",
"      <td class=\"subtitle1\">",
"       Coagulatve tumor cell necrosis",
"      </td>",
"      <td class=\"subtitle1\">",
"       Designation",
"      </td>",
"      <td class=\"subtitle1\">",
"       Metastatic or recurrent disease",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       I",
"      </td>",
"      <td>",
"       &ge;5 to &lt;20",
"      </td>",
"      <td>",
"       None or mild",
"      </td>",
"      <td>",
"       None",
"      </td>",
"      <td>",
"       Leiomyoma with increased MI",
"      </td>",
"      <td>",
"       1/89",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       II A",
"      </td>",
"      <td>",
"       &lt;10",
"      </td>",
"      <td>",
"       Diffuse, moderate or severe",
"      </td>",
"      <td>",
"       None",
"      </td>",
"      <td>",
"       Atypical leiomyoma with low risk percent or recurrence",
"      </td>",
"      <td>",
"       2/46",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       II B",
"      </td>",
"      <td>",
"       &ge;10",
"      </td>",
"      <td>",
"       Diffuse, moderate or severe",
"      </td>",
"      <td>",
"       None",
"      </td>",
"      <td>",
"       Leiomyosarcoma",
"      </td>",
"      <td>",
"       4/10",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       III",
"      </td>",
"      <td>",
"       &le;20",
"      </td>",
"      <td>",
"       Diffuse, moderate to severe",
"      </td>",
"      <td>",
"       Present",
"      </td>",
"      <td>",
"       Leiomyosarcoma",
"      </td>",
"      <td>",
"       19/33",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       IV A",
"      </td>",
"      <td>",
"       &lt;10",
"      </td>",
"      <td>",
"       None to mild",
"      </td>",
"      <td>",
"       Present",
"      </td>",
"      <td>",
"       Smooth muscle tumors of low malignant potential, limited experience",
"      </td>",
"      <td>",
"       1/4",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       IV B",
"      </td>",
"      <td>",
"       &ge;10",
"      </td>",
"      <td>",
"       None to mild",
"      </td>",
"      <td>",
"       Present",
"      </td>",
"      <td>",
"       Leiomyosarcoma",
"      </td>",
"      <td>",
"       3/4",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       V",
"      </td>",
"      <td>",
"       &ge;1 to &le;20",
"      </td>",
"      <td>",
"       Multifocal, moderate to severe",
"      </td>",
"      <td>",
"       None",
"      </td>",
"      <td>",
"       Atypical leiomyoma, limited experience",
"      </td>",
"      <td>",
"       0/5",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     MI: mitotic index; HPF: high-power field.",
"    </div>",
"    <div class=\"reference\">",
"     Data from Bell SW et al. Am J Surg Pathol 1994; 18:535.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_8_16524=[""].join("\n");
var outline_f16_8_16524=null;
var title_f16_8_16525="Types of inferior vena cava filters";
var content_f16_8_16525=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F51423&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F51423&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Types of inferior vena cava filters",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Maximum IVC diameter (mm)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Manufacturer",
"       </td>",
"       <td class=\"subtitle1\">",
"        Required sheath size",
"       </td>",
"       <td class=\"subtitle1\">",
"        Insertion sites",
"       </td>",
"       <td class=\"subtitle1\">",
"        Material",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"6\">",
"        Non-retrievable",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Titanium Greenfield",
"       </td>",
"       <td>",
"        28",
"       </td>",
"       <td>",
"        Boston Scientific",
"       </td>",
"       <td>",
"        12F",
"       </td>",
"       <td>",
"        Jugular, femoral",
"       </td>",
"       <td>",
"        Titanium",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Over the Wire Greenfield&reg;",
"       </td>",
"       <td>",
"        28",
"       </td>",
"       <td>",
"        Boston Scientific",
"       </td>",
"       <td>",
"        12F",
"       </td>",
"       <td>",
"        Jugular, femoral",
"       </td>",
"       <td>",
"        316 stainless steel",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Vena Tech&reg; LP",
"       </td>",
"       <td>",
"        28",
"       </td>",
"       <td>",
"        B. Braun Medical",
"       </td>",
"       <td>",
"        9F",
"       </td>",
"       <td>",
"        Jugular, femoral",
"       </td>",
"       <td>",
"        Phynox&reg;*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Vena Tech&reg; LGM&reg;",
"       </td>",
"       <td>",
"        28",
"       </td>",
"       <td>",
"        B. Braun Medical",
"       </td>",
"       <td>",
"        12F",
"       </td>",
"       <td>",
"        Jugular/femoral single system",
"       </td>",
"       <td>",
"        Phynox&reg;*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Simon Nitinol Filter&reg; (SNF&reg;)",
"       </td>",
"       <td>",
"        28",
"       </td>",
"       <td>",
"        Bard",
"       </td>",
"       <td>",
"        9F",
"       </td>",
"       <td>",
"        Jugular, femoral, subclavian, antecubital",
"       </td>",
"       <td>",
"        Nitinol (Ni-Ti)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        TrapEase&reg;",
"       </td>",
"       <td>",
"        30",
"       </td>",
"       <td>",
"        Cordis (J&amp;J)",
"       </td>",
"       <td>",
"        6F",
"       </td>",
"       <td>",
"        Jugular, femoral, antecubital",
"       </td>",
"       <td>",
"        Elgiloy&reg;*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Gianturco-Roehm Bird's nest&reg;",
"       </td>",
"       <td>",
"        40",
"       </td>",
"       <td>",
"        Cook",
"       </td>",
"       <td>",
"        12F",
"       </td>",
"       <td>",
"        Jugular, femoral",
"       </td>",
"       <td>",
"        304 stainless steel",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"6\">",
"        Retrievable",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        G2&reg;X with RECOVERY Cone&reg;",
"       </td>",
"       <td>",
"        28",
"       </td>",
"       <td>",
"        Bard",
"       </td>",
"       <td>",
"        7F",
"       </td>",
"       <td>",
"        Jugular, subclavian, femoral",
"       </td>",
"       <td>",
"        Nitinol (Ni-Ti)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        OptEase&reg;",
"       </td>",
"       <td>",
"        30",
"       </td>",
"       <td>",
"        Cordis (J&amp;J)",
"       </td>",
"       <td>",
"        6F",
"       </td>",
"       <td>",
"        Jugular, femoral, antecubital",
"       </td>",
"       <td>",
"        Elgiloy&reg;*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Gunther tulip&reg;",
"       </td>",
"       <td>",
"        30",
"       </td>",
"       <td>",
"        Cook",
"       </td>",
"       <td>",
"        8.5F",
"       </td>",
"       <td>",
"        Jugular, femoral",
"       </td>",
"       <td>",
"        Conichrome&reg;*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cook Celect&reg;",
"       </td>",
"       <td>",
"        30",
"       </td>",
"       <td>",
"        Cook",
"       </td>",
"       <td>",
"        7F (IJ), 8.5F (F)",
"       </td>",
"       <td>",
"        Jugular, femoral, UniSet",
"       </td>",
"       <td>",
"        Conichrome&reg;*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Option",
"        <sup>",
"         TM",
"        </sup>",
"       </td>",
"       <td>",
"        30",
"       </td>",
"       <td>",
"        Argon Medical",
"       </td>",
"       <td>",
"        6.5F",
"       </td>",
"       <td>",
"        Jugular, femoral",
"       </td>",
"       <td>",
"        Nitinol (Ni-Ti)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        ALN filter",
"       </td>",
"       <td>",
"        32",
"       </td>",
"       <td>",
"        ALN International&nbsp;",
"       </td>",
"       <td>",
"        7F",
"       </td>",
"       <td>",
"        Jugular, femoral, basilic",
"       </td>",
"       <td>",
"        316 stainless steel",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Trademark names for the cobalt-chromium-nickel-molybdenum-iron alloy specified by ASTM F1058 and ISO 5832-7.",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <br>",
"      <ol>",
"       <li>",
"        file://www.astm.org.",
"       </li>",
"       <li>",
"        file://www.iso.org.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_8_16525=[""].join("\n");
var outline_f16_8_16525=null;
var title_f16_8_16526="Endoscopy in patients who have failed empirical therapy";
var content_f16_8_16526=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F80468&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F80468&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Figure 3. Endoscopy in patients who have failed empirical therapy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 344px; height: 315px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     EGD: esophagogastroduodenoscopy;",
"     <em>",
"      H. pylori",
"     </em>",
"     :",
"     <em>",
"      Helicobacter pylori",
"     </em>",
"     .",
"    </div>",
"    <div class=\"reference\">",
"     Talley NJ. Gastroenterology 2005; 129:1753.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_8_16526=[""].join("\n");
var outline_f16_8_16526=null;
var title_f16_8_16527="Diagnosis esophageal dysphagia";
var content_f16_8_16527=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F81108&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F81108&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 657px\">",
"   <div class=\"ttl\">",
"    Approach to the patient with esophageal dysphagia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 637px; height: 542px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_8_16527=[""].join("\n");
var outline_f16_8_16527=null;
